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Isolierung und Charakterisierung von neuen Genen. die in die 
Tumorprogression involviert sind 
Zusammenfassung 
Der Ausdruck Tumormetastasierung beschreibt die Streuung von Tumorzellen aus einem 
Primärtumor und die Bildung von Tochtertumoren an entfernten Stellen des Körpers. Trotz der 
immensen Bedeutung der Tumormetastasierung in der klinisch-onkologischen Praxis ist die 
molekulare Biologie dieses pathophysiologischen Vorgangs noch immer unverstanden. Hierfür 
gibt es mehrere plausible Gründe: Zum einen unterscheiden sich die möglichen 
Metastasierungswege verschiedener Tumortypen, zum anderen ist der Vorgang der 
Dissemination von Tumorzellen im Körper sehr komplex und erfordert vermutlich Änderungen in 
der Expression einer Vielzahl von Genen. 
Ziel der vorliegenden Arbeit war es, einen möglichst umfassenden Überblick über die mit dem 
metastatischen Phänotyp einer Tumorzellinie verbundenen Änderungen in der Genexpression 
zu gewinnen. Als Modellsystem wurden dabei nicht-metastatische und metastatische Zellinien 
aus dem Ratten-Pankreas-Adenokarzinom Bsp73 gewählt. Durch molekulare Subtraktion der 
exprimierten mRNAs aus der nicht-metastatischen Tumorzellinie Bsp73-1AS von der mRNA 
aus der metastatischen Tumorzellinie Bsp73-ASML wurden solche Gene identifiziert, deren 
Expression in der metastatischen Tumorzelle hochreguliert ist. Die Analyse der subtraktiven 
Genbank ergab, daß sowohl eine Reihe bekannter Gene als auch eine große Zahl 
unbekannter Gene isoliert wurden. Durch Analyse der Expression dieser bislang unbekannten 
Gene in anderen metastatischen Rattentumoren konnten diejenigen Klone identifiziert werden, 
deren Expression nicht nur im Bsp73-Modellsystem, sondern auch in anderen Ratten-
Tumorprogressionsmodellen mit dem metastatischen Phänotyp korreliert. 
Unter den isolierten bekannten Genen befindet sich eine ganze Reihe bekannter 
Tumorprogressionsgene. Ihre Isolierung aus der metastasen-spezifischen, subtraktiven 
Genbank darf daher als Beweis für den Wert des gewählten experimentellen Ansatzes gelten. 
Neben diesen bekannten Genen wurde auch eine Vielzahl bekannter Gene identifiziert, deren 
Assoziation mit dem metastatischen Phänotyp bislang noch unbekannt war, deren funktionelle 
Beteiligung am Metastasierungsprozeß aufgrund der ihnen zugeschriebenen Eigenschaften 
jedoch naheliegt Eines dieser Gene, Ezrin, wurde daher im Detail auf seine Funktion bei der 
Disseminierung von Bsp73-ASML - Zellen hin untersucht. Der Beweis für die funktionelle 
Beteiligung des Ezrin-Proteins am Tumor-Phänotyp von Bsp73-ASML - Zellen wurde durch 
Überexpression einer dominant-negativen Form des Ezrin-Proteins erbracht: ASML-Zellen, die 
dominant-negatives Ezrin überexprimieren, zeichnen sich durch vermindertes Tumorwachstum 
in vivo aus. 
Abstract 
The term tumor metastasis describes the formation and growth of a secondary tumor at a 
distant site from the primary tumor mass. Despite the immense importance of tumor metastasis 
in the context of a clinical setting, the molecular events that drives this pathophysiological 
process remains largely not understood. There are a number of plausible explanations for this 
fact. Firstly, the possible mechanisms by which tumor cells metastasize are different from one 
tumor cell type to another, and secondly, the dissemination of tumor cells in the body is 
extremely complex and probably requires changes in the expression status of many genes. 
The primary goal of this werk was to derive a comprehensive and near total overview of the 
alterations in gene expression that accompanies the metastatic phenotype. As a model 
system a metastatic and non-metastatic cell line originating from a rat pancreatic 
adenocarcinoma Bsp73 were taken. Through molecular subtraction, between expressed 
mRNA transcripts from the non-metastatic Bsp73-1AS line and the metastatic Bsp73-ASML 
cell line genes were isolated that were exclusively expressed in the metastasizing cell line. 
Sequence analysis of the isolated genes revealed that a large proportion were known genes, 
however an equally large proportion were novel. By analysing the expression of these novel 
genes in other metastatic rat cell lines, clones were identified whose expression was not 
restricted to the Bsp73-model system, but whose expression correlated with the metastatic 
phenotype in other tumor progression models. From the known genes isolated many were 
already known tumor progression genes. The isolation of such genes from a subtractive library 
indicates that such an experimental approach is highly valid. Alongside the known genes were 
genes whose association with a metastatic phenotype had not yet been described, however 
for some, their documented function would suggest a putative involvement in the metastatic 
process. The functional role played by one such gene, ezrin in the dissemination of Bsp73-
ASML tumor cells was studied in detail. The proof that ezrin was indeed functionally involved 
in the tumor phenotype of Bsp73-ASML cells, was obtained through the overexpression of a 
dominant-negative mutant form of ezrin. ASML cells overexpressing dominant-negative ezrin 
demonstrated in vivo a dramatic reduction in tumor growth. 
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1.1NTRODUCTION 
The general tendency of the global predisposition of cancer in most forms is on an 
increase as is our knowledge of the underlying genetic dysregulations of cancer cells. lt is also 
apparent that the manifestation of a fully malignant tumor involves the progressive acquisition 
of mutations and epigenetic abnormalities in multiple genes (Liotta & Stetler-Stevenson, 1985). 
Due to the large number and enormaus diversity of function of these genes, it is becoming 
clear that the two classical categories "oncogenes" and "tumor suppressor genes" are not 
adequate because they fail to indicate the specific biochemical functions of the individual 
genes or to consider the cellular contexts in which they function. As a consequence the need to 
dissect the specific molecular function of certain genes in the global frame work of total cellular 
function is of increasing importance. Over one hundred different oncogenic alleles generated 
from cellular proto-oncogenes by point mutation, gene amplification, or chromosomal 
translocation have been identified (Bishop, 1991; Rabbitts, 1994) and more than a dozen 
tumor suppressor genes have been identified and the existence of an ever greater number 
has been suggested through various studies (Weinberg, 1991; Knudson, 1993). For many of 
these genes a causual involvement in tumor progression has been demonstrated and although 
these studies have provided useful insights, they also typify the inadequacy concerning the 
orchestrated action of multiple genes in the instigation of tumor cell development and often the 
poor extrapolation of findings obtained from various rodent models into a clinical setting 
highlights the shortcomings of these models. 
PARTONE 
1.1 The Genetic bases of Cancer Progression 
Although we know intricate details of the molecular genetic dysfunctions that underlie 
cancer, this has not translated into directed therapeutic strategiss that result in substantial 
eures. This is analogaus to sickte cell disease where the defect has been known for many 
years but still today there exists no effective therapy for the disorder. 
Virtually every human cancer can occur in genetically predisposed individuats. The most 
striking form of genetic susceptibility involves mendelian dominant inheritance with high 
penetrance and appearance of cancer at earlier than usual age, as shown for colon cancer in 
persons with familial adenomatous polyposis (FAP). ln this example, the heterozygous state 
of the germ-line mutation imparts a high risk for justoneform of cancer, while in other examples, 
such as the Li-Fraumeni syndrome (LFS), it predisposes to several kinds of cancer, although 
never to all. 
Colorectal and breast cancers account for a significant proportion of deaths due to malignant 
neoplasia in the industrialised world (Wingo et al., 1995). As a result these two forms of cancer 
lntroduction 
will be considered in detail concerning the dysregulation of known proto-oncogenes and tumor 
suppressor genes that have been functionally implicated in the manifestation of these two 
cancers types. 
Oncogenes vs Tumor Suppressor Genes. 
Over 100 oncogenes have to date been identified and the Iist is expanding. Proto-
oncogenes are genes present in normal eucaryotic organisms whose exons are homologaus to 
cancer-causing oncogenes in acutely transforming retroviruses or eucaryotic genes 
demonstrated to induce neoplastic transformation in transfection assays (reviewed by, Garrett 
& Seil, 1995). They participate in normal growth and proliferation, encoding a wide variety of 
proteins and fall primarily into one of five categories: (1) growth factors (e.g., sis, TGF-a); (2) 
growth factor receptors {e.g., fms, c-erbB~1, c-erb-82, c-met, kit, ret, and sea ); (3) mo!ecules 
involved in signal transduction composed of cytoplasmic protein kinases (e.g., src, raf, ab/, 
fes, Iek, and yes); (4) GTP-binding oncogenes (e.g., H-, k-, and N-ras, gip2, and gsp), and 
(5) the transeriptional regulators, whieh makes up the largest group (e.g., erbA-1, erbA-2, 
ets 1/2, fos, jun, myb, re/, ski, c/UN-myc, /yt-1 0, E2A, PBX-1, rhom-2, and Tgt-2 ). 
The alterations that eonverts a proto-oncogene ean take several forms. For example a mutation 
(base substitution) as is in the ease of ras, (reviewed by Barbaeid, 1990), resulting in altered 
GTP-binding or GTPase aetivity, so that there is extended stimulation of effeetor moleeules. 
Gene amplification is frequently observed in N-myc in neuroblastomas and c-erb-2 in breast 
cancers (King et al., 1985). A third mechanism for conversion occurs when the oncogene is 
moved (or translocated) to a different region on the same chromosome, or to an entirely 
different chromosomal site. One of the most thoroughly studied transloeations is the t(9;22) 
(q34;q11) or the Philadelphia ehromosome, whieh oecurs in 95 % of ehrenie myeloeytie 
leukemia (CML; Weinberg, 1997). The cellular ABL gene on ehromosome 9 transloeates to 
ehromosome 22, where it eombines with the BCR genein a head-to tail eonfiguration, resulting 
in a hybrid BCR-c-ABL protein with tyrosine phosphokinase aetivity that can transform 
hematopoietie eells (Melaughin et al., 1985). As oneogenes tend to promote growth b y 
inereasing proliferation, or by allowing the eell to bypass growth inhibitory signals, there exits 
moleeules that appear to have apposing aetions these are the so ealled '1umor suppressor 
genes". 8oth oneogenes and tumor suppressor genes werk in symmetry in that they funetion 
on opposite sides of the road, one promoting, the other stemming, eell proliferation. However 
there also existed a marked asymmetry as germline determinants of human caneer were found 
tobe mutantallelas of tumor suppressor genes. The mutation meehanisms would inaetivation 
tumor suppressor genes (TSG) resulting in loss of gene function. Usually, both allelas of 
TSGs are lost, inaetivated or damaged, resulting in either loss or attenuation of the gene 
produet whieh was neeessary in suppressing the neoplastie phenotype. The two best 
eharaeterised TSGs, are the retinoblastoma (RB1; Mars hall, 1991) gene and p53 (Nigro et al., 
1989; Hollstein, 1991 ). Other identified TSGs inelude Wilms tumor gene (WT1; Franeke et al., 
2 
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1979), deleted in colorectal cancer (DCC; Fearon et al., 1990), adenomatosis polyposis coli 
gene (APC; Groden et al 1991 ), type 1 neurofibromatosis gene (NF1; Latif et al., 1993), 
multiple endocrine neoplasia gene (MEN; Larsson et al., 1988) and the BRCA 1 and 2 breast 
cancer genes (Marshall, 1991 ). Some of these onocgenes and anti-oncogenes will be 
considered further in the pathogenetic mechanisms of two prevailing cancer types in our 
society 
1.2 The Genetic Bases of Colorectal Carcinogenesis 
ln no other form of cancer are the genetic dysregulations that accompanies and 
predisposes to a major cancer of adults so weil understood as that of colorectal cancer. lt 
accounts for around 98 % of all malignant tumors of the large bowel and although most tumors 
are sporadic, several inherited colorectal cancer syndromes are recognised. The most common 
of these are the familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal 
cancer (HNPCC). The peak of incidence is in the seventh decade, with 20 % of cancers 
diagnosed before the age of 50 (HMSO. Mortality Statistics, 1992). The incidence of the 
disaase in the UK is about 30,000 cases per year, resulting in 17,000 deaths per annum. 
Average 5-year survival is about 50%, a figure that has improved only modestly over the 
past 40 years. The genetic features of FAP are discussed below. 
1.2.1 Hereditary Colorectal Cancer 
Following the path demarcated by germline mutations in identified FAP patients and 
somatic alterations in sporadic colorectal tumors, Iead to the identification of the adenomatous 
polyposis coli gene (APC) which was subsequently shown to be the cause of FAP (Groden 
et al., 1991; Nishisho et al., 1991 ). Now there is good evidence that just two mutations are 
required to initiate the growth of a colorectal tumor, and in most cases, these mutations 
probably occur at the APC locus (5q21-q22) (Powell et al., 1992). This was deduced from 
studies in humans with documented FAP, whereby the rate limiting step in tumor initiation is a 
somatic mutation of the wild-type allele inherited from the unaffected parent (Levy et al., 1994; 
Luongo et al., 1994). This provided strong evidence for the "two-hit" hypothesis of Knudson, 
originally proposed to explain the familial and nonfamilial incidences of childhood tumors such 
as retinoblastoma and Wilms' tumor (Knudson, 1993). APC is a 312 kDa protein comprising of 
2850 amino acids and is coded for by a gene spanning several Mb (Groden et al., 1991; 
Kinzieret al., 1991 ). APC mutations, which almost always results in a truncated APC protein 
(Miyoshi et al., 1992) or take the form of allele loss (Solomon et al., 1987), are found in about 
70% of sporadic colorectal cancers (Powell et al., 1992; Miyaki et al., i994) and <i % of FAP 
patients. Additionally, APC mutations appear tobe present in the earlisst neoplastic lesions 
that can be examined (jen et al., 1994). Such lesions, called dysplastic aberrant crypt foci 
(ACF), are believed to be the precursors of adenomas. Are APC mutations always the first 
events in tumorigenesis, or do mutations of other genes suffice? Actually, such mutations do 
3 
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not efficiently initiate the neoplastic phenotype. For example, p53 is altered in >80 % of 
colorectal carcinomas (Baker et al., 1990), yet patients with germline mutations of p53 do not 
develop colorectal cancer (Garber et al., 1991 ). Therefore, though it is apparent that p53 is 
involved in colorectal tumor progression, it is equally apparent that it cannot initiate the process 
in a fashion similar to APC. 
Likewise, the ras protein is also commonly mutated in colonic tumors as they progress 
(Vogelstein et al., 1988; Shibata et al., 1993). However, ras mutations that occur in normal 
epithelial cells do not appear to Iead to colorectal cancers (Jen et al., 1994). Furthermore, cells 
which exhibit ras mutations are amazingly common and form foci of hyperproliferating cells 
(Pretlow et al., 1993). 
Experimental Model for Tumor Progression 
12q 18q 17p 
DNA Hypo- mutation of Lass of Loss of Other 
Sq 
Mutation 
or Loss 
ofFAP 
,...-------,1,...-------, 
Normal 
Epithel 
_.. Hyperprol. 
Epithel 
M:r r:~;; ... I ~.. l::::: .. rt ::~~-
Adenoma Adenoma g:, 
Adenoma g1 
~·, 
Pancreatic 8 8 origin 
Prostatic 8 8 origin Gellfines 
Fig 1. A genetic model for colorectal tumorigenesis. 
Tumorigenesis is believed to proceed through a series of genetic alterations, the most common of which include 
5q, 17p, and 18q are indicated together with the relative timing of the chromosome loss event. The three stages 
of adenomas in general represent tumors of increasing size, and dysplasia. In patients identified with FAP, the 
APC gene locus located on chromosome 5q is mutated and inherited in a dominant fashion. This mutation in 
turn may contribute to the hyperproliferative epithelium present in these patients. Ras gene mutations appears to 
occur in one cell of a pre-existing small adenoma and through clonal expansion produces a larger and more 
dysplastic tumor. Allelic deletions of chromosome 17p and 18q usually occurs at a later stage of tumorigenesis 
than is seen with 5q. However, the order of alterations is not invariant, and accumulation of these changes rather 
than their order with respect to one another, is of greatest significance. Taken from Fearon & Vogelstein, 1996. 
Yet, these hyperplastic cells, unlike their dysplastic counterparts with mutant APC genes, 
have little or no potential to form tumors and may even regress through apoptosis (Shpitz et 
al., 1996). K-ras mutations occur in 50 % of colorectal tumors, mostly in adenomas larger than 1 
cm, and often such adenomas have already altered APC function. ln addition, a specific set of 
K-ras mutations have been identified in colorectal tumors (Burmer et al., 1990) suggesting that 
these may be specific to promoting tumorigenesis. 
4 
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Pointmutation of one allele of the p53 gene coupled with loss of the remaining wild-type allele 
appears to occur frequently in colorectal tumors, although such loss is relatively infrequent in 
adenomas at any stage (Baker et al., 1989; Delattre et al., 1989; Nigro et al., 1989). With the 
accumulating evidence from in vitro transformation systems pointing to a tumor suppressor 
function for the p53 protein, (Eiiyahu et al., 1989; Finlay et al., 1989), a hypothesis arises 
whereby the wild-type p53 gene inhibits colorectal tumor growth, andremoval of the wild-type 
p53 gene is the selective pressure underlying progression in these tumor types. The 
subsequent loss of the wild-type p53 allele is often associated with the progression from 
adenoma to carcinoma, and probably amplifies the growth advantage provided by the 
mutation. 
Another common region of allelic loss is that of 18q, which is lost in more than 70 % of 
carcinomas (Delattre et al. 1989; Vogelstein et al., 1989). The candidate tumor suppressor 
gene in this region has been identified (Fearon et al., 1990) and is termed deleted in colorectal 
cancer (DCC). The gene exhibits high homology to the cell adhesion molecule N-CAM, and its 
expression is reduced or largely absent in the majority of colorectal carcinomas (usually before 
malignancy occurs). Characterised mutations in DCC usually produce truncated, non-
functional proteins, however, no hereditary condition in which DCC is mutant is known. 
Recently, there has been doubt that allele loss of 18q may actually target a genedifferent from 
DCC (Thiagalingam et al., 1996). 
So in light of the above facts, what emerges is a picture that suggest it is not simply the order 
of these alterations, but rather it is the accumulation of mutations, that determines the 
propensity for neoplasia (see figure 1) and that a specific subset of genes can initiate the 
process of tumorigenesis. 
1.3 The Genetic Bases of Breast Cancer Metastasis 
Breast carcinoma is the most common malignancy in women in North America and 
Western Europe and several environmental and epigenetic factors have been demonstrated to 
influence the development of breast cancer. These include exposure to therapeutic and 
contraceptive hormones, age of manarche and menopause, first pregnancy, and even breast 
feeding (Lipmman & Dickinson, 1988). ln addition, the alteration of certain proto-oncogenes and 
tumor suppressor genes has been documented in the pathogenesis of beast cancer 
progression. 
1.3.1 Hereditary Breast Cancer 
The majority of breast cancers are due to the acquision of somatic mutations, with only 
5 to 8 % of breast cancer patients having a streng family history, indicative of inheritance of 
mutations in an autosomal dominant fashion (Hall et al., 1990). Approximately, one half of 
genetically inherited breast cancer cases appear to be linked to a gene on 17q21 named 
BRCA 1 (Miki et al., 1994), which encompassed over 1 00-kb composed of 24 exons encoding 
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a DNA binding zinc-finger protein. A second breast cancer susceptibility gene, designated 
BRCA2 and which is thought to account for much of the remaining genetically linked cases of 
breast cancer, has been localised to chromosome 13q12-13 (Wooster et al., 1995). Unlike 
BRCA 1, the BRCA2 locus does not appear to be linked to ovarian cancer development 
(Hosking et al., 1995). Hogervorst et al. (1995) screened for mutations in exon 11 which 
encodes 61 % of BRCA 1, using a protein truncation test but found no hard evidence that 
BRCA 1 is important in sporadic breast cancers. Additionally, loss of heterozygosity (LOH) of 
BRCA 1 and BRCA2 in sporadic cancers using PCR-based fluorescent DNA technology 
revealed little prognostic value (Beckmann et al., 1996). 
1.3.2 Sporadic Breast Cancer 
(a) Proto-oncogene Activation in Breast Cancer 
Studies on c-myc in breast cancer have generally supported an important role for this 
proto-oncogene in the molecular pathogenesis of breast cancer (Bonilla et al., 1988). 
Tumorigenicity of the breast cancer cellline SW613-S has been reported to directly correlate 
with the degree of c-myc amplification (Lavialle et al., 1988), and overexpression of c-myc in 
primary breast tumors has been associated with increase frequency of lymph node 
involvement (Guerin et al., 1988; Berns et al., 1992). Although these studies suggest that 
overexpression and amplification of c-myc in breast cancer are an adverse finding, evidence 
confirming c-myc as an independent prognostic indicator has not been demonstrated. 
A second proto-oncogene that has been widely evaluated as a prognostic index in breast 
cancer is c-erbB-2. This oncogene was first identified through transfection studies of a rat 
neuroblastoma and encodes a 185 kDa transmembrane glycoprotein with extensive homology 
to the epidermal growth factor receptor (EGFR; Coussens et al., 1985). Amplification of the 
gene is found in 20-30 % in invasive carcinomas (Varley et al., 1987; Barresen et al., 1990), 
and a correlation has been demonstrated between amplification and aggressive features and 
poor short term prognosis, although not by all (Ciark & McGuire, 1991 ). Additionally, many 
investigators have found c-erdB-2 overexpression to be an independent predictor of poorer 
disease free interval and survival (Lovekin et al., 1991; Winstanley, et al., 1991 ). 
Two other proto-oncogenes regarded as potentially important in the molecular pathogenesis of 
human breast cancer are int-1 and int-2, which are located adjacent to each other on 
chromosome 11 q (Lidereau et al., 1988; Tsuda et al., 1990) These genes belang to the family 
of fibroblast growth factor related genes and evidence has been presented that amplified 
expression of int-21FGF3 is seen in 10-20 % of breast cancers. An association was also 
found with the cestrogen receptor (Fanti et ai., 1 990) although others found that amplification 
was concomitant with poor prognosis (Borg et al., 1991; Henry, et al., 1993). More recently, 
another oncogene CCND1 was located at 11 q13 and encodes cyclin 01 (Xiong et al., 1993). 
This, when complexed with its associated cyclin-dependent kinase, controls cell cycle 
progression in G1 by phosphorylating the retinoblastoma (RB) protein (Sherr, 1994). Over-
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expression of cyclin 01 has been found in breast cancer cell lines in both the presence and 
absence of amplification and dysregulation of cyclin 01 could hold promise as a factor in the 
manifestation of breast cancer (Buckley et al., 1993). Gillet et al. (1996) could later show, using 
immunohistochemical detection of 01 and the cestrogen receptor, that cyclin 01 was a very 
good indicator of likely response to endocrine therapy. 
(b) Tumor Suppressor Genes in Breast Cancer 
Studies to identify specific tumor suppressor genes associated with breast cancer has 
not advanced to the degree achieved in colon cancer. The retinoblastoma gene (RB1) is the 
classical example of a tumor suppressor gene, and has been located on 13q14 (Friend et al., 
1986) and encodes for a 105 kOa protein. This gene product in its under-phosphorylated state 
restricts cell cycie progression in G1, by direct interaction with transcriptional factor-2 (E2F; 
Chellappan et al., 1991 ). Alterations to chromosome 13q have been found at several loci in 
breast carcinomas (Lundberg et al., 1987) as have structural alterations in the RB gene (T'Ang 
et al., 1988). Of significance was that alterations were found either in advanced cases ( Varley 
et al., 1989) or in aneuploid, high S phase cancers (Borg et al., 1992), suggesting that 
alterations to RB are not an initiating event in breast cancer but is an event occurring in an 
unstable genome. 
Evidence for the involvement of p53 in the pathogenesis of breast cancer arises from several 
lines of evidence. Kindred's with the Li-Fraumeni syndrome (Malkin et al., 1990), in which a 
germ-line mutation occurs in one of the p53 alleles, are characterised by young onset sarcoma 
associated with breast cancer, primary brain tumor or leukaemia in a first degree relative under 
the age of 45 years. lnteresting is the fact that only about half the Li-Fraumeni families have 
p53 mutations (Santibanez-Koref et al., 1991 ), and germ-line mutations are rarely found in 
cases of early onset breast cancer and those with strong family history (Sidransky et al., 
1992; Warren et al., 1992). There is however an association between the presence of 
mutations and aggressive features within breast carcinomas e.g., Iack of cestrogen receptor 
(Anderson et al., 1993b), and a high S-phase index (Merlo et al., 1993). Allred and colleagues 
examined tissue from 700 breast cancers of auxiliary lymph node-negative patients and found 
a significant association between overexpression of p53 and early death in node-negative 
breast cancer cases (AIIred et al., 1993). Besides being of value for the prediction of 
prognosis, p53 can aid in the selection of therapy. Bergh et al. (1995) found adjuvant 
tamoxifen therapy to be of less value in p53 mutation lymph node positive cases. Moreover, 
response to chemotherapy and radiotherapy can be affected by altered p53 function, due to 
its role in regulating DI'JA darnage response (Lowe et al., 1993). 
ln addition to the dysregulation of known oncogenes and tumor suppressor genesthat have 
been documented in the manifestation of breast cancer, other molecules such as the cestrogen 
receptor (ER), epidermal growth factor receptor (EGFR; Klijn et al., 1992; Nieholsan et al., 
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1994) and certain growth factors (TGF-ß; Dalal et al., 1993; Walker et al., 1994) have all been 
implicated in breast cancer. 
(c) The Destrogen Receptor 
The evaluation of the cestrogen receptor (ER) status of a breast cancer has been 
used for over 20 years to aid the determination of likely response to hormonal therapy. The 
receptor can be detected in 60-70% of breast cancers, of whom a half (i.e. a third overall) will 
respond to hormonal manipulation (Barnes & Millis, 1995). While the main stream of research 
has focused on the role of (ER) in the clinical management of breast cancer, some very 
intriguing observations have arisen. For example, (i) why are a proportion of carcinomas ER 
negative? (ii) why do some ER positive cancers fail to respond to endocrine therapy? and (iii) 
why do a small number of ER negative tumors respond to endocrins therapy? A number of 
alterations in ER have been identified that may contribute to explaining some of the above 
questions. For example, ER gene methylation of CpG islands in ER negative breast cancers 
Ieads to transcriptional block of the gene (Lapidus et al., 1996) and therefore Iack of ER 
protein. Fuqua et al. (1992) identified in ER positive tumors a truncated ER lacking exon 7, 
which was unable to induce transcription and which functioned in a dominant negative manner 
with respect to normal ER function. These Observations might offer insight into ER positive 
tumors that fail to react to hormonal manipulation. 
1.4 Cancer: Mechanisms of Invasion and Metastasis 
Metastasis, which is the spread of tumors throughout the body, is a pathophysiological 
process of profound clinical significance. The relentless and often intractable nature of 
metastatic spread can have a servere psychological impact on cancer patients (Hersh, 1985) 
and the overt manifestation and initial presentation of cancer usually occurs at a late stage in 
the disease process when the capacity for invasion has already been unleashed. By the time 
of diagnosis, a high proportion of patients have occult or clinically detectable metastasis and 
this often Ieads to treatment failure despite successful control of the primary tumor. From a 
clinical perspective, how metastasis develops, while of scientific interest, is not a critical issue. 
Most patients (50-75 %), depending on which tumors are included, have either regional or 
distant metastasis (Uotta & Stettler-Stevenson, 1985). Patients who do not have evidence of 
metastasis on presentation, generally undergo what is, presumptively, curative surgery. 
Although indications of how widespread a malignancy is at the time of presentation is directly 
relevant to the clinician's choice of strategy, knowledge of how the metastases developed 
offers little insight about control. 
The difficult challenge remains the treatment of metastases and one might say that cancer is a 
disease that pushes out the Iimits of conventional methodology and thought. What is clear is 
that the propensity for metastasis formation varies significantly within different tumor entities 
and that a !arge multitude of widely varying gene products, whose expression status changes 
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on a temporal and spatial basis, forms the bases of a series of remarkably complex 
interactions between the cancer cell and its microenvironment. However, despite this apparent 
complexity, the process of metastasis from a solid primary tumor can be segregated to some 
degree into a number of discrete stages some of which, under an appropriate experimental 
setting and be separately investigated. 
1.4.1 The Metastatic Cascade 
1t is an old truism that metastasis accounts for the majority of cancer deaths in 
industrialised countries. ln these societies, the mostfrequent cancers are derived from epithelia 
of the gastrointestinal and urogenitary tract, as weil as of mammary ducts and bronchi. Yet 
despite improved methods of diagnostics, mortality has not substantially decreased 
essentially because patients continue to succumb to metastatic disease. This cieariy points to 
dissemination of tumor cells at an early stage of tumor growth, and implies that the acquisition 
of at least some characteristics of metastatic behaviour can occur prior to attainment of 
unrestrained growth observed in fully developed tumors. ln this context, it is important to 
consider that tumorigenesis and metastasis development are not necessarily the result of the 
same genetic changes (Fidler & Radinsky, 1990; Liotta et al., 1991 ). ln fact, defined mutations 
in proto-oncogenes often confer tumorigenic characteristics to cells while their metastatic 
potential is not activated (Price et al., 1989). This is not surprising in light of the fact that the 
characteristics of these two processes can, at least in part, be separated. Development of 
unrestricted growth is focused on the acquisition of growth factor independence and loss of 
contact inhibition while development of metastasis is focused on enhanced cell motility, 
expression of certain proteases and alterations in the expression of cell and matrix adhesion 
molecules (Hart et al., 1989). 
Neoplastic transformation is now recognised to occur because of the progressive accumulation 
of mutations in genomic DNA within clones of cells. These mutations may enhance expression 
of genes that either increase cellular growth, mobility and angiogenesis, or suppress 
expression of genes that depress cellular replication or promote cell differentiation (Fearon et 
al., 1990). To equate cancer with uncontrolled growth, however, is a gross oversimplification. 
Cancer may be succinctly defined as the loss of growth and spatial control (Schwartz, 1993). 
tn the etassie descriptions the initial carcinogenic events give rise to benign (non-invasive and 
non-metastatic) tumors that then "progress" to more malignant phenotypes. This view was 
first described by Foulds, 1953, and was based on histological examination of tumor 
specimens. He reasoned that if the same lymph-node metastasis contained a group of weil, 
poorly and undifferentiated ce!ls, then the latter populations had to derive from the we!!-
differentiated cells. Some 24 years later, Nowell, (1976) proposed that the carcinogenic event 
induces a "genetic liability" that "permits stepwise selection of variant sublines and underlies 
tumor progression". Progression means selection of variants with increasing genomic and 
phenotypic abnormalities that in turn Iead to tumor heterogeneity. The implication has been 
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that "genomic instability" (a tenn whose precise meaning is difficult to define) produces 
heterogeneity and progressively selects for the more malignant and diverse cells whose 
inherent heterogeneity enhances their malignant potential. Now, it is generally accepted that 
tumors arise from clonal expansion of a single or few transformed cells (Fialkow, 1976; 
lnnaccone et al., 1987) and that this monotonaus cell population eventually gives rise to 
multiple subpopulations. By the time a tumor is clinically detectable, it most likely consists of 
diverse subpopulations that differ in characteristics, such as response to growth factors 
(Poste & Greig 1982). For example, the response of most epithelial cells to transforming 
growth factor-ß (TGF-ß) is decreased proliferation and/or a more differentiated phenotype. 
Escape from the growth inhibitory effects of TGF-ß is a hallmark of many transformed cells 
(Huggett et al., 1991; Steigerwalt et al., 1992). Additionally, tumor heterogeneity facilitates 
tumor survival because it minimises the likelihood that a single insult will eradicate all 
Subpopulations (Heppner, 1989). 
Although the precise mechanisms that regulate phenotypic diversity are unknown, it has been 
proposed that interactions of tumor cell populations maintain phenotypic diversity at an 
"equilibrium" Ievei (Poste et al., 1981 ). Thus the concept that evolves is one of a highly 
integrated "tumor ecosystem" in which a heterogeneity "set-point" maintains a certain degree of 
heterogeneity among tumor cell populations in each patient. The tumor heterogeneity is so 
dynamic, that at the moment of definition (whether a tumor is invasive or metastatic), the tumor 
contains an undefined number of cells capable of expressing invasive and metastatic 
phenotypes. 
1.4.2 Molecular Processes lnvolved in Metastasis 
As noted before, the metastatic cascade encompasses a sequence of events that 
requires the production of different groups of molecules for each step. These molecules may 
be synthesised either by the metastatic cell or by hast cells collaborating with the 
metastasising cells. Most generally (see figure 2) the process involves, after the initial 
transforming event, either unicellular or multicellular neoplastic cells grow progressively (if a 
tumor mass is to exceed 2 mm in diameter, extensive vascularisation must occur). Several 
angiogenic factors play key roles in establishing a neocapillary network from the surrounding 
hast tissue. 
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Seguential Steps of the Metastatic cascade 
Dissemination of neoplastic cells from the primary tumor 
I Local invasion of extracellular matrix 
Intravasalion of tumor cells into lymphatics or vasculture 
Avoidance of immunologica! detection/destruction 
Extravasalion from vasculature into secondary organ tissue 
Fig 2. The individual steps that make up the metastatic cascade. 
After an initial transforming event there are a total of eight separate steps recognized that must be successfully 
completed such that a secondary neoplasms results. Failure at any stage will prohibit metastasis and further 
more, metastatic cells that display low efficiency to carry out one particular step are not compensated by their 
high efficiency to carry out other downstream steps in the cascade. Details are provided in the text. 
Once vascularisation occurs, local invasion of the host stroma by some tumor cells 
could occur by several mechanisms that are not mutually exclusive: thin walled venules, like 
lymphatic channels, offer very little resistance to penetration by tumor cells and provide the 
most common pathways for tumor cell entry into the circulation. Detachment and embolization 
of small tumor cell aggregates occur next; those that survive the circulation must then arrest in 
the capillary beds of organs. Extravasation then occurs, probably by the same mechanisms 
that influence initial invasion. Finally, proliferation within the organ parenchyma completes the 
metastatic process. To produce detectable lesions, these metastases must develop their own 
vascular network, evade the host immune system, and respond to organ-specific factors that 
influence their growth. Once they do so, the cells can invade host stroma, penetrate blood 
vessets, and enter the circulation to produce secondary metastases, the so-called metastasis 
of metastases (Fidler, 1995). Most of these stages that orchestrate a network of co-operative 
interactions will be considered separately and in the context in which they take place. 
1.4.3 Angiogenesis in Tumor Formation 
Although tumors 1-2 mm in diameter can receive all nutrients by diffusion, further growth 
is strictly dependent on the development of an adequate blood supply through angiogenesis 
(Folkman, 1987, 1989). Angiogenesis describes the process of new blood vessel formation 
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from parent micro vessels. Under physiological circumstances, angiogenesis is observed 
during embryonie development and growth (O'Rehilly, & Müller, 1992), and almest never 
occurs in adulthood except under strictly controlled conditions and cyclically in the ovarian 
follicle, corpus luteum and post-menstrual endometrium (Christenson et al., 1996; Modiich et al., 
1996; Risau, 1995). Pathological situations accompanied by this process are wound healing 
and inflammation (Kovacs & DiPietro, 1994), ischemia (Harada et al., 1994), diabetic 
retinopathy (Frater-Schroder et al., 1987) and of course tumor growth (Folkman, 1995). 
Most tumors in humans persist for months to years without neovascularization until a 
subset of tumor cells acquires an angiogenic phenotype. The switch is a deliberate change in 
the regulation of angiogenesis and many angiogenic signals have been identified that activate 
endothelial cells. Both stromal cells and tumor cells produce an enormaus and complex 
assortment of angiogenic factors such as VEGF and TGF-ß, both of which allow the tumor to 
recruit macrophages through their potent chemotractant properties. Macraphages themselves 
induce angiogenesis by secreting TNF-a (Leibovich et al., 1987). Additionally tumors secret 
proteases and heparanases which mobilize and activate angiogenic molecules stored in the 
ECM, such as bFGF, aFGF, SF/HGF and VEGF. Substances such as prostaglandins PEG1 
and PEG2 (From et al., 1983) and degradation products of hyaluronic acid (West et al., 1985) 
are also capable of stimulating angiogenesis. PD-ECGF (platelet derived endothelial cell 
growth factor) induces angiogenesis but not by direct action on endothelial cells but via its 
thymidine phosphorylase (dThdPase) activity ( Finnis et al., 1993). PD-ECGF is produced 
mainly by tumor infiltrating macrophages (Takahashi et al., 1996) whereas, dThdPase activity 
is up-regulated in tumor cells (Haraguchi et al., 1994). 
Up-regulation of angiogenic factors, however is not sufficient in itself for a tumor cell to 
become angiogenic, and it is becoming evident that there are different classes of endogenaus 
inhibitors of endothelial growth and motility that work in concert with inducer molecules to control 
angiogenesis. Reducing the concentration of inhibitor or increasing that of inducer results in an 
angiogenic switch. The tumor suppressor protein p53 depresses VEGF-A production and 
supports the secretion of thrombospondin-1 (TSP-1 ), a multi functional 450kDa glycoprotein 
which is a major constituent of platelet alpha granules. lt functions as a angiogenesis inhibitor 
that modulates endothelial cell adhesiveness, motility and proteolytic activity, by sequestering 
angiogenic inducers. (Dameron et al., 1994; V an Meir et al., 1994). Thus, p53 mutations induce 
angiogenesis, which is a pivotal component of tumor progression. 
ln 1995 Folkman and co-workers published the first findings of an endogenaus peptide 
that displayed antiangiogenic properties. Angiostatin (as it is now known ) is a 38 kDa internal 
fragment of plasminogen and contains the first four "kringle domains" of plasminogen. lt has a 
half life of 2.5 days in the blood and accumulates in the circulation in the presence of certain 
growing primary mause tumors but disappears upon excision of the tumor mass. (O'Reilly, et 
al1995). Laterit was demonstrated in certain animal tumor models to suppress primary tumor 
growth and consequently metastasis ( Holmgren, 1996) by inducing a state of "dormancy". lts 
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mode of action remains unclear but it is imagined that it acts as a decoy molecule and occupies 
the catalytic site of enzymes that proteolytically cleave plasminogen, thus preventing matrix 
remodelling required for angiogenesis. 
The same group in 1997 described another member, endostatin, a 20 kDa carboxy-terminal 
fragment of collagen XVIII, that elicited even more potent antiangiogenic effects in vivo 
(O'Reilly, 1997). To date other peptide fragments have been shown to possess intrinsic 
antiangiogenic properties including a 6 kDa fragment of platelet factor 4 (PF4), and peptides 
from laminin, epidermal growth factor and TSP-1 (reviewed in Hanahan & Folkman, 1996). 
Based on these findings, the principal target for antiangiogenic therapy is represented b y 
proliferating endothelial cells. However it is important to distinguish between antiangiogenesis 
and vascular targeting. The former interferes with a wide range of biological processes 
involved in growth, migration and differentiation of blood vessels. The latter provides rapid 
destruction and cell death of the vessels, infarcting !arge areas of the tumor (reviewed in Fan et 
al., 1995). 
1.4.4 Adhesion, Invasion and Motility of Tumor Cells 
The molecular characterisation of diminished adhesive properties, invasiveness and 
sensitisation to motility factors of primary tumor cells has led to the identification of checkpoints 
that constitute intervention targets. As a consequence all three points will be considered in 
more detail. 
A simplistic tale of sequences of events Isading to dissemination of tumor cells would begin 
with the escape of cells from their local environment. For this to occur, homotypic and 
heterotypic adhesion bonds of tumor cells in their immediate surrounding must be actively 
modified. Gell adhesion molecules (GAMS) represents a very !arge group of cell surface 
structures that are involved in cell-cell and cell-matrix interactions. They can be divided 
structurally into four superfamilies, namely the cadherins, intergrins, immunoglobulins and other 
adhesion molecules. 
1.4.5 lntegrins in Tumor Progression 
lntegrins are a growing class of heterodimeric receptors composed of a common ß 
subunit noncovalently associated with a variety of a subunits that confer Iigand specificity, 
although there is redundancy at both the Ievei of receptor and Iigand. ln total 16 a and 8 ß 
subunits have been identified, which can result in over 20 different receptor types (reviewed 
by Hynes, 1992), and alternative splicing adds further complexity. These integral plasma 
membrane ceii surface receptors are responsible for ceii-ECM and cell-cell intemctions, but 
above this they are also implicators or complex signal transduction events, including 
modulation of intercellular pH, activation of specific tyrosine kinases and alterations in inositol 
Iipid metabolism (reviewed by Hynes, 1992; Schwartz, 1992). More recent evidence 
demonstrates that the integrins provide key survival signals for endothelial and epithelial cells 
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(Meredith et al., 1993; Frisch & Francis, 1994). Detachment from the ECM results in anoikis, 
however this can be reverted by transformation of the cells with v-Src or treatment with 
hepatocyte growth factorlscatter factor (HGFISF) (Frisch & Francis, 1994). These 
observations support the notion that resistance to apoptosis correlates with acquisition of an 
anchorage independent state and I or increased motility. 
Exhaustive studies have implicated the role of ß1 subclass of intergrin in tumorigenesis. 
Through transfection of Chinese hamster ovary (CHO) cells with cDNA coding for the aaß1 
fibronectin receptor inhibits their ability to grow in soft agar, to establish tumors in nude mice 
and to migrate (Giancolti & Rouslahti, 1990). ln counter distinction, clonal sublines of 
erythroleukemia cells (Symington, 1990), or CHO cells expressing decreased Ievels of 
fibronectin receptor (Schreiner et al., 1991 ), are characterised by increased tumorigenicity. ln 
human melanomas, up regulation of the expression of certain integrins, including ~ß1 , aaß1 and, 
a6ß1 has been shown to correlate with metastatic potential (Danen et al., 1993), or progression 
of the disease (Natali et al., 1993). For several integrin receptors whose functions can be 
competed by synthetic Arg-Giy-Asp (RGD) peptides, the addition of such peptides inhibits 
both in vitro and in vivo melanoma cell invasion ( Gehlsen et al, 1988; Yamada, 1991 ). 
Experiments with the human melanoma cell line A375M have revealed that stimulation of the 
avß3 vitronectin receptor resulted in increased expression of the 72 kDa type IV collagenase 
(gelatinase A) (Seftor et al., 1992) and that this integrin is elevated in melanoma cells ( Gehlsen 
et al., 1992). More recently, a highly metastatic melanoma cellline C8161 with little avß3 surface 
expression was found to increase expression of type IV collagenase in response to 
stimulation of a5ß1 but not avß1 (Seftor, 1993). Changes in integrin profiles also have been 
documented for both breast cancinoma and prostate carcinoma which show a down-regulation 
of asß1 (Zutter et al., 1993) and ß4 subunit (Knox et al., 1994), respectively. Consequently, it 
would appear that alterations in adhesive properties by changing of integrin expression 
profiles of tumorigenic cells in their immediate vercinity, could reflect a higher propensity for 
invasion as they are more motile. 
ln normal cells focal adhesion kinase (FAK) is the major tyrosine phosphorylated protein 
present in cells upon integrin activation (Kornberg et al., 1992; Guan & Shalloway, 1992). 
Phosphorylation of FAK creates a high affinity binding site for the SH2 domain of the Src family 
kinases and the recruitment of Src and I or Fyn to the FAK complex. The formation of this 
bipartite kinase complex is important in the tyrosine phosphorylation of other downstream 
substrates in intergrin signaHing (Jewell et al., 1995). Successful phosphorylation of FAK and 
activation of MAP kinases requires the existence of an organised actin cytoskeleton (Guan, 
1991; Chen, 1994). The small GTP binding protein rho regulates ECM cytoskeletal 
organisation (Ridley & Hall, 1992), and inactivation of rho by ADP-ribosyiation, aiso 
inactivates FAK activity (Kumagai et al., 1993), indicating that rho is in the pathway of FAK 
activation by external stimuli (Ridley & Hall, 1994). These perturbations in rho activation could 
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be envisaged to be involved in malignant transformation due to uncoupling of the integrin-rho 
pathway (McGiade et al., 1993). 
1.4.6 Cadherins in Tumor Progression 
These constitute a family of cell surface molecules that generally mediate cell-cell and 
cell-matrix calcium dependent homophilic adhesions, although E-cadherin can also interact with 
an intergrin (aEß7) expressed on a subset of lymphocytes (Cepek et al., 1990). Thus, 
cadherins may function outside of the narrow range of interactions previously assigned to 
them. Structurally, cadherins are transmembrane gylcoproteins with an extracellular region 
composed of four repeat domains, a transmembrane portion and a long cytoplasmic domain. 
The cytoplasmic domain of functional cadherins require association with accessory cytoplasmic 
proteins (Ozawa et al., 1989), namely the catenins, of which exists four types being a, ß, y 
and more recently, p120cas (Reynolds et al., 1994; Shibamoto et al., 1995), and this 
association is required for full adhesion activity (Takeichi, 1991; Kawanishi et al., 1995). 
Although there are numerous different cadherins, E (epithelial)-cadherin, P (placental)-cadherin 
and N (neural)-cadherin are the best characterised ( reviewed by Gumbiner, 1988; Grunwald, 
1993). E-cadherin, also known as uvomorulin, L-Cam, celi-CAM120/180 or Arc-1 is the best 
characterised in the context of neoplasia and metastasis. 
The initial observation that a monoclonal antibody directed against E-cadherin altered 
the morphology of Madin-Darby Canine Kidney (MDCK) epithelial cells so as to acquire an 
invasive phenotype, was the first evidence that this molecule could be important in tumor 
invasion (Vestweber & Kemler, 1985; Behrens et al., 1985; Behrens et al., 1989) Concomitant 
with this acquisition of invasive capacity was a loss of E-cadherin expression seen in a 
variety of epithelial carcinoma celllines (reviewed by Behrens, 1993). Although in some tumor 
cells E-cadherin may be normally expressed, the dysfunction or mutation of ß-catenin may 
result in a cell-cell disengagement with consequent invasiveness ( Kawanishi et al., 1995). 
There are however few in vitro studies showing the relationship between E-cadherin, 
catenins and tumor cell motility and invasiveness. Manipulations of E-cadherin (VIeminckx et 
al., 1991; Navarra et al., 1991; Doki et al., 1993), a catenin (Shimoyama et al., 1992), ß-catenin 
(Kawanishi et al., 1995) and y catenin by means of antibodies, gene deletion or mutation, 
genetic engineering, microinjection and antisense provides evidence that abnormalities of these 
proteins facilitate tumor cell dissociation and increase motility and invasiveness. lndeed, 
studies on human cancers ranging from liver tumors (Siagle et al., 1993), ovarian tumors 
(Veatch et al., 1994), invasive breast carcinomas (Giukhova et al., 1995), pancreatic cancer 
(Pignate!li et al., 1994) and renal cancers (Katagiri et al., 1995) confirm the relationship between 
these molecules and metastasis. Most recently, Guilford et al. 1998, could show that germ-line 
mutations in the gene coding for E-cadherin, leading to a truncated gene product, probably 
contributes to the molecular basis for familial gastric cancer. The adenomatous polyposis coli 
(APC) tumor suppressor gene codes for a protein that normally associates with catenins and 
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E-cadherin (Rubinfeld et al., 1993; Su et al., 1993). Mutations in APC occur in the germline of 
patients with familial adenomatous polyposis (FAP) and as a somatic event in more than two 
thirds of sporadic colorectal carcinomas. Despite being an early event in colorectal 
carcinogenesis, APC abnormalities may Iead disruption of normal cell-to-cell adhesion, thereby 
contributing to the malignant phenotype. 
1.4.7 Acquisition of lnvasive Characteristics Mediated by the 
Secretion of Proteases 
Invasion and metastasis largely determine the clinical course of tumors. As a rule, cell 
proliferation in most normal sedentary tissues is under strict control; cells respect specific 
boundaries and do not spread to distant sites. Malignant tumors also grow locally but they 
invade tissues other than their tissue of origin. Nevertheless, most tumor cells do not 
metastasise but remain within the primary tumor, held in place by their inability to overcome 
cell-cell interactions or interactions between cell surface receptors and basement membrane 
structures (Bresalier, 1994). 
lt should be noted that invasion is not metastasis but represents a crucial prerequisite for 
metastasis to occur. Ratherinvasion is the active translocation of neoplastic cells across tissue 
boundaries and through host cellular and extracellular matrix barriers (Duffy, 1992; Tryggvason 
et al., 1987). Invasion is not due to growth pressure but involves additional genetic 
deregulation over and above those molecular events that cause uncontrolled proliferation. That 
is, it is the tendency of malignant cells to cross tissue boundaries which distinguishes 
proliferative disorders and carcinomas in situ from true malignancy. 
lf one assumes that the malignant tumor cell is inappropriately expressing a pre-existing 
normal cell program of physiological invasion, then the fundamental difference between normal 
and malignant cells is regulation. The difference must lie in the proteins that start, stop, or 
maintain the invasion program at times and places that are totally inappropriate for non-
malignant cells (Nicolson, 1991 ). However proteolysis of tissue barriers is not restricted to 
malignant processes and numerous examples of physiological invasion exist including, 
amongst others, smooth muscle cell migration from the media to the intima (Bendeck et al., 
1994), nerve growth cone extension and homing (Wu & Goldberg, 1993), and traphoblast 
implantation (Lola & Graham, 1990). 
(a) Metalloproteinases 
For invasion to take place, subsequent release of a large cohort of proteolytic enzymes 
of differing substrate specificity must occur in a direct and controlled manner. Degradation of 
basement membrane and interstitial stroma followed by tumor cell traversal must be completed 
on three separate occasions during the transition from in situ to invasive carcinoma (Duffy, 
1992): escape of tumor cells from the primary site and both intravasation to and extravasation 
from the vasculature. As the ECM is a highly complex and specialised, semielastic, continuous 
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structure composed of mainly various collagens, glycoproteins and proteoglycans (Timpl, 
1989), by logical inference, metastatic cells require sufficient degradative enzymatic capacity to 
break down these proteinaceous structural barriers (Barsky et al., 1983). lmplicated 
repeatedly, are the matrix metalloproteinases (MMPs) of which currently 16 members have 
been identified and have been associated with the malignant phenotype for several decades 
(DeCierk et al., 1997; Stack et al., 1998). However, from both rodent model systems and 
histopathologic assessment of patient material, correlations between protease Ieveis and 
metastatic competence are not universal (Duffy, 1987. and 1990). ldentified degrading 
enzymes include MMPs, plasmin, heparanases, urokinase plasminogen activator (uPA), 
cathepsins and tumor associated trypsinogen (TAT) 2, but only MMPs and the uPA/PAI 
system will be considered. 
MMPs are a family of secreted or transmembrane proteins in a latent form (proenzymes) that 
require extracellular proteolytic cleavage for activation. They share a catalytic domain with the 
HEXGH motif responsible for complexing zinc required for catalytic function (Windsor et al., 
1994) in addition to a PRCGVPD sequence in the pro-domain, which maintains latency of the 
zymogen (reviewed by Birkedal et al., 1993; Powell et al., 1996). There are three main 
subgroups of MMPs, identified by their substrate preferences: (1) the collagenases degrade 
fibrillar collagens, (2) the gelatinases are particularly potent in degrading denatured and 
basement membrane collagens (gelatin), and (3) the Stromelysins degrade proteoglycans and 
glycoproteins. Activation of proforms of MMPs or serine proteases can occur through 
proteolytic cleavage by other pre-activated MMPs. For example, plasmin activates most 
MMPs by making one cleavage in the prodomain which initiates the autoactivation of the MMP. 
(Eeckhout & Vaes, 1997; Santibanez & Martinez, 1993). The MMP matrilysin can act on 
urokinase to liberate the NH2-terminal fragment containing the receptor binding domain 
(Marcotte et al., 1992), which could effect subsequent cell surface activation of urokinase. 
These activations although documented in in vitro have not been suitably demonstrated in 
vivo (He et al., 1989; Marcotte et al., 1992). 
Once MMPs are activated they are susceptible to inhibition by the general serum proteinase 
inhibitor a2-macroglobulin and by a family of naturally occurring specific tissue inhibitors of 
metalloproteinases (TIMPs; Woesner, 1991). There are currently four members of the TIMP 
family, each capable of inhibiting MMPs by forming tight stoichiometric, noncovalent complexes 
with either proenzyme or the activated enzyme (DeCierck & lmren, 1994), or by controlling 
their autocatalytic activation (DeCierck et al., 1991; Howard et al., 1991 ). The first member of 
the MMP family to be cloned was transin, the rat homologue of stromelysin-1, which was 
identified as an oncogene and growth factor inducible gene (Matrisian et al., 1985). Later it 
became clear that many oncogenes can regulate MMP Ieveis, and to date all but one MMP 
family member has been shown to contain an AP-1 transcription element in their promotor 
(Gaire et al. 1994) which has been implemented in many cases tobe involved in mediating the 
response (Gutmann & Wasylyk, 1990). 
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Evidence that MMPs play a functional role in metastasis came originally from experiments with 
recombinant or genetically manipulated Ieveis of TIMP-1. Schultz et al, 1988, first showed that 
an intraperitoneal injection of recombinant TIMP-1 reduced lung colonisation of intravenously 
injected B16F10 melanoma cells. A reduction in TIMP-1 Ieveis by antisense RNA in mouse 
fibroblasts resulted in formation of metastatic tumors in nude mice (Khokha et al., 1989), and 
targeted disruption of the TIMP-1 gene resulted in an increase in in vitro invasion (Aiexander et 
al., 1992). Conversely, overexpression of TIMP-2 in c-Ha-Ras transfected rat embryo cells 
inhibited tumor growth (DeCierck et al., 1992). Transfeetion of TIMP-2 in the highly metastatic 
melanoma cellline M24met, that expresses both MMP2 (gelatinase A) and MMP9 (gelatinase 
8), results in reduced growth potential in vivo and in in vitro collagen gels, but their metastatic 
ability remains unaffected (Montgomery et al., 1994}. Other transfection studies have 
demonstrated that forced expression of gelatinase A in a bladder cancer cell line increased the 
area of lung metastasis (Kawamata et al., 1996), and a transmembrane domain MMP, MT1-
MMP (also known as MMP14) when overexpressed enhanced the survival of mouse lung 
carcinoma cells in the lungs of intravenously injected mice (Tsunezuka et al., 1996}. 
However the most definitive evidence for a role for MMPs in tumor cell establishment comes 
from studies in which Ieveis of a specific MMP were manipulated. Stromelysin-3, originally 
isolated from the surrounding malignant breast carcinomas (Basset et al., 1990}, when 
overexpressed in human breast carcinoma cells or ablated by anti sense RNA in mouse 
fibroblasts, demonstrated altered tumorigenicity in nude mice. However, growth of established 
tumors, their invasive capacity or their metastatic competence was completely unchanged 
(Noel et al., 1996}. Collagenase expression in the skin of transgenic mice resulted in earlier 
onset and increased numbers of papillomas arising after chemical initiation and promotion 
(D'Armiento et al., 1995) and expression of stromelysin-1 in mammary glands of transgenic 
mice resulted in the development of aggressive malignant mammary tumors (Sympson et al., 
1995). Most recently, mice in which the gene for gelatinase A (MMP-2) had been inactivated 
through targeted disruption, show a dramatic reduction of tumor progression and angiogenesis 
when B16-BL6 or Lewis lung carcinoma cells were implanted intradermally (ltoh et al., 1998}. 
How MMPs and their inhibitors contribute functionally to metastasis is very difficult to address 
experimentally, and many initial conclusions have been derived by inference rather than direct 
experimentation. Nevertheless, in light of the above facts, MMPs expression can promote 
tumor take and that certain MMPs may favour cancer cell survival in a tissue environment 
initially not permissive for tumor growth. Yet ultimately it is the subtle balance of MMPs verses 
their inhibitors that will dictate the outcome. 
(b) Urokinase P/asminogen activator 
The plasminogen activator (PA)/plasmin system has been significantly characterised at 
the biochemical Ievei in the context of tissue remodelling and particularly in malignancy (for · 
reviews see Dan0 et al., 1985; Kwaan, 1992). There exists two known mammalian PAs, 
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tissue type PA (tPA) and urokinase type PA (uPA), both of which are serine proteases with 
narrow specificity cleaving the ubiquitous zymogen plasminogen and thereby generating the 
broad acting serine protease plasmin. This in turn can degrade fibrin, fibronectin and laminin 
and is also able to contribute to matrix degradation by activating some latent MMPs. Like 
MMPs, the PA/plasmin system is tightly controlled by specific inhibitors, including the PA 
inhibitors, PAI-1 and -2 and a2 antiplasmin, all of which beleng to the serpin superfamily. 
Studies with in vitro assays provide substantial evidence for an important role of the u-PA 
system in cell migration and invasion at the Ievei of individual cells. The situation in tumors is 
more complex as non-malignant cells also may be migratory and invasive during processes of 
cancer cell-directed tissue remodeHing (Dvorak et al., 1995). Using the model of dissemination 
of human tumors in nude mice, Ossowski et al. (1991) reported that antibodies against human 
uPA prevented local invasion of cancer cells, while lung metastasiswas not inhibited. Quax et 
al. (1991) using the same approach, reported a correlation between cancer cell u-PA 
expression and lung metastasis with a series of human melanoma cell lines. Transfeetion of rat 
PC3 prostate carcinoma cells with uPA cDNA enhanced their metastatic potential in vivo when 
inoculated into ventricles of rats (Achbarou et al., 1994). Gene targeting of u-PA demonstrated 
that u-PA-t mice exhibited a drastically reduced progression to malignant melanomas when 
challenged (Shapiro et al., 1996). 
Early studies established that the Ievei of u-PA in malignant tumors is significantly higher than 
in the corresponding normal tissue or in benign tumors of the same tissue type (reviewed b y 
Duffy, 1996). lndeed, u-PA was the first proteinase shown tobe a prognostic markerinhuman 
malignancies (Duffy et al., 1988). He showed that patients with breast tumors containing high 
Ieveis of u-PA enzyme activity had a significantly shorter disease-free interval than patients 
with tumors with low Ieveis of activity. Later, high u-PA antigen Ieveis were found to correlate 
with a shortened overall survival (Duffy et al., 1990). These results have been substantiated 
by many groups (Jänicke et al., 1990; Spyratos et al., 1993; Fern0 et al., 1996). u-PA antigen 
Ieveis appear to be among the strengest prognostic factors so far described for breast cancer. 
Using both univariate and multivariate analysis, u-PA is at least as streng a markeras nodal 
status and better than other prognostic indices such as tumor size, cestrogen receptor status 
and cathepsin D Ievels (Duffy et al., 1990; Schmitt et al., 1990; Jänicke et al1993). 
Apart from breast cancer, u-PA has been shown to be of prognostic value in other 
malignancies, including cancers of the lung (Oka et al., 1991 ), stomach (Nekarda et al., 1994), 
colorectum (Mulcahy et al., 1994), cervix (Kobayashi et al., 1994), ovary (Kuhn et al., 1994) 
and brain (Bindahl et al., 1994). As with u-PA, its molecular inhibitor PAI-1 was demonstrated 
to be also a prognostic marker in breast cancers (Jänicke et al., 1993). ln node-negative 
women, PAI-1 was almest as streng a prognostic markeras u-PA. Combining u-PA and PAI-1, 
patients with tumors containing low Ieveis of both molecules had a very small risk of relapse 
(93 % disease-free survival at 3 years) in centrast to those patients with high amounts of 
both (55% disease-free survival at 3 years). The cellular receptor for u-PA, u-PAR also holds 
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prognostic value in certain cancers, but constitutes an independent marker (Ganesh et al., 
1994), and again, high Ieveis are indicative of poor outcome. lnterestingly, u-PAR on the 
surface of cells is mainly localised in caveolae (Stahl & Mueller, 1995), flask-shaped micro-
invaginations of the plasma membrane that clusters cell surface receptors and signal 
transduction molecules in a characteristic Iipid environment (Anderson, 1993a; Lisanti et al., 
1994). The function of caveolae is currently not weil understood, but the structural integrity of 
caveolae appears to be required for efficient plasmin generation on the cell surface. Evidence 
has been presented that uPA has other substrates, for example, hepatocyte growth 
factor/scatter factor (HGF/SF) and macrophage-stimulating protein (MSP) are secreted from 
cells as inactive single-chain pro-forms. They become active as growth factors after 
conversion to 2-chain forms by limited proteolysis (Donate et al., 1994}. uPA is able to 
catalyse this conversion, at least in the case of HGF/SF (Naldini et al., 1992; Mars et al., 
1993). This rises the possibility of tumorigenic cells being capable of activating their own 
HGF/SF and thereby increase their propensity to migrate. Additionally, HGF/SF-MET 
signalling has been shown to significantly increase the protein Ieveis of both uPA and its 
receptor uPAR in certain cell types (Jeffers et al., 1996), through the induction of the ETS1 
transcription factor (Fafeur et al., 1997}. These data couples HGF/SF-MET signalling to the 
activation of proteases that mediate dissolution of the ECM, a critical step in the metastatic 
cascade (Vande-Woude et al., 1997). 
The overall picture that is painted concerning in vitro data generally implicates u-PA as being 
able to enhance cell migration and invasion. However a growing body of evidence suggests 
that the function of the system does not rely on the unbridled enzyme activity of u-PA. Rather, 
the dynamic state of the system at the cell surface allows temporal and spatial re-
arrangements of its components during migration and invasion. Results obtained from animal 
model systems, collectively and almest unanimously, point to the enzyme activity of u-PAR-
bound u-PA at the surface of the cancer cells being causally involved in the metastatic 
process. ln humans, the correlation between u-PA and u-PAR concentrations and poor 
prognosis is in agreement with the basic notion of u-PAR-bound u-PA at the surface of the 
cancer cells being necessary for cancer-cell invasion and metastasis .. 
1.4.8 Motility Factars lnvolved in Tumor Cell Migration 
Active locomotion by invading tumor cells is a prerequisite step in the establishment of 
secondary tumors. The repeated observation of non-random patterns of metastatic 
dissemination suggested the existence of specific parameters governing cell migration 
(Nico!son, 1988a; Raz & Ben-Ze'Ev, 1987), and recent studies have now identified a group of 
secreted cytokines that have been described as cell motility factors termed autocrine motility 
factors (AMFs). 
Secretion of AMF is largely confined to transformed or immortalized cells thus far and in addition 
to regulating the induction of both random and directional cell migration in self-producing cells, it 
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has been demonstrated they also act in a paracrine fashion (Watanabe et al., 1991 ). A tumor 
specific autocrine factor of less than 30 kDa was characterised from the Dunning R-3327 rat 
prostatic adenocarcinoma AT -2.1 subline which was shown to induce motility through the 
cyclic adenosine monophosphate (cAMP) pathway (Evens et al., 1991). Another AMF was 
purified to homogeneity from the A2058 human melanoma cellline (Liotta et al., 1986) This 125 
kDa protein induces migration of the producer cells via a pertussis toxin-sensitive G protein 
and was termed autotaxin (Stracke et al., 1992). Stimulation of producer cells with AMF at 
concentrations as low as 15 pg/ml causes them to consistently clear an area two to three fold 
larger than controls when plated on a gold particle-coated substrate (Silletti et al., 1991 ). This 
nondirectional motility induction (chemokinesis) was described previously in addition to the 
chemotatic effect observed in a modified Boyden chamber assay (Liotta et al, 1986). lt is 
however not known at present which of these activities, chemokinesis or chemotaxis is 
exploited in vivo during cancer cell dissemination. The receptor for AMF has been identified as 
a 78 kDa cell surface glycoprotein designated gp78 (Watanabe et al., 1991) and nucleotide 
sequence analysis revealed significant homology to the tumor suppressor gene p53 implying 
a common ancestral gene. lt is now thought that the motility response of AMF on target cells 
functions through rearrangement of focal adhesion plaque proteins into thin filamentaus 
structures orientated perpendicular to the cells edges, often showing a preponderance of 
accumulation within the advancing edges of pseudopodia (Silletti et al., 1995). ln addition an 
anti-gp78 mAb was able to mirnie the motility stimulating effect of the natural Iigand but only in 
high-metastatic sublines of a series of melanoma cell lines as indicated by an increase lung 
colonization (Silletti et al., 1994) 
ln the course of more thorough investigations addressing motility factors, it became evident 
that motility factors often functioned as growth factors and vice versa. For example scatter 
factor (SF) was later shown tobe identical to hepatocyte growth factor (HGF) (Weidner et al., 
1991) and vascular permeability factor (VPF) identical to vascular endothelial growth factor 
(VEGF; Leung et al., 1989). Now there exists a large repertoire of growth factors such as 
PDGF, FGF, EGF, IL-6, NGF, or IGF-1 that also affect cell motility (see review by Stoker & 
Gherardi, 1991). 
Hepatocyte growth factor (HGF) and scatter factor (SF) were independently identified by their 
abilities to induce the proliferation of primary hepatocytes and dissociation/motility of epithelial 
cells ("scattering"), respectively (Nakamura et al, 1986; Stoker et al., 1987; Zarnegar & 
Michalopoulos, 1989; Weidner et al., 1990). The soluble pleiotropic mesenchymal cytokine 
HGF, is capable of promoting a highly integrated biological program leading to and including 
proliferation, dissociation and migration, cell polarization and tubule formation, prevention of 
apoptosis and invasive growth in epithelial cells (Medico et al., 1996; Bardelli et al., 1996). 
This phenotype results from the integration of many distinct HGF responses that are initiated 
upon binding to its receptor. The large (1 00 kDa) single chain heterodimeric HGF protein 
requires proteolytic cleavage for activation, resulting in the generation of two subunits (a and 
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ß), being 60 kDa and 30 kDa respectively (Hartmann et al., 1992; Lokker et al., 1992). The cell 
membrane receptor for HGF (c-Met) belongs to the tyrosine kinase receptor superfamily and is 
the product of the c-Met proto-oncogene (Bottaro et al., 1991; Naldini et al., 1991 ). This 190 
kDa heterodimeric receptor, like the Iigand, undergoss proteolytic eisavage to yield two mature 
subunits, a and ß of 50 kDa and 145 kDa respectively, both of which are required for biological 
activity (Giordano et al., 1989}. lnactivation of either HGF or c-Met in the mouse causes 
embryonallethality (Schmidt et al., 1995; Maina et al., 1996}, as a functional HGF/c-Met pair is 
essential for morphogenic migration of epithelial cells to the surrounding mesenchyme and 
migration of myoblasts from the somites into the limb buds (Biadt et al., 1995}. 
Constitutive overexpression of the c-Met receptor has been demonstrated in several tumors 
of epithelial origin and even amplified in the derived metastatic cells (Liu et al., 1992; Rong et 
al., 1993}. The ability to grow independently from a substrate attachment and to invade the 
ECM is considered a hallmark of tumorigenic cells, and these properties can be conferred to 
normal cells by transfection of the activated HGF receptor (Giordano et al., 1993; Rong et al., 
1994}. ln addition, HGF/SF stimulates the ras-guanine nucleotide exchanger (Graziani et al., 
1993}, which is required for the scattering activity of SF (Hartmann et al., 1994). ln agreement 
with these results, ras activity is continuously required throughout the process of endothelial 
cell motility (Fox et al., 1994). These data would suggest that ras activity, stimulated by either 
growth factor binding or integrin engagement, might be a central regulator of cell motility. 
lnterestingly, other small GTP-binding proteins rho and rac have been implicated in growth 
factor-induced actin reorganization (Ridley & Hall, 1992; Nobes & Hall 1995), in that ras and 
rac function downstream of c-Met to mediate cell spreading but not scattering. When full-length 
c-Met cDNA was transfected into NIH 3T3 fibroblast, stable transfectants responded to 
HGF/SF factor Stimulation as determined by c-Met receptor phosphorylation, changes in cell 
shape, migration in Boyden chambers, and invasion of collagen matrices in vitro. The motile 
and invasive phenotype was strictly dependent on the presence of HGF/SF. The factor did 
not stimulate either cell growth or thymidine incorporation in transfected cells. These data 
conclude that the c-Met receptor induces cells to pursue a motogenic-invasive rather than a 
proliferative program (Giordano et al., 1993). Later Matsumoto et al. (1994) could show that the 
migratory response of fibroblasts to HGF/SF proceeded through the initial recruitment of certain 
intergrins, cytoskeletal proteins and p125 FAK into focal adhesions that are dependent on 
tyrosine kinase activity (Matsumoto et al., 1994). The recent identification of a number of 
germline and somatic mutations in the tyrosine kinase domain of c-Met in cells from patients 
affected by papillary renal carcinomas, represented a milestone in the field of research 
involving this oncogene (Schmidt et al., 1997). ln addition, c-Met overexpression had been 
observed in carcinomas derived from follicular epithelium (Di Renzo et al., 1992) of the thyroid. 
ln ovarian carcinomas, an increased expression of c-Met correlated with a particular 
aggressive phenotype. ln colorectal cancers, the c-Met oncogene is overexpressed from 5- to 
50-fold in about 50 % of primary lesions, and in 70 % of liver metastasis (Di Renzo et al., 
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1995). Moreover, is has been shown that HGF/SF is expressed in breast carcinomas, and 
that the Ievei of expression correlated with the state of tumor progression (Yamashita et al., 
1994). All of the above observations strongly implicates that the c-Met oncogene can and 
does play a relevant role in the ability of tumorigenic cells to invade and cause distant 
metastasis. 
1.4.9 Patterns of Metastatic Spread of Tumorigenic Cells 
Lymphatic and vascular drainage at the primary site initially determine tumor cell access 
to secondary sites, and much of the organ distribution can be explained solely by anatomical 
location of the primary tumor (Weiss, 1985). This explanation, while sufficient for the majority of 
early metastatic patterns, fails to account for the observations made in late-stage disease or in 
instances of marked aggression where widespread dissemination occurs early in tumor 
development. lt is a weil established observation that a malignant tumor of specific histological 
type often metastasize preferentially to specific ergans (Pauli & Lee, 1988). This surprisingly, 
was already proposed in 1889 by Paget. He questioned whether the distribution of 
metastases was due to chance and thereby analysed the autopsies of a large number of 
patients with metastatic breast cancers (Paget, 1889). The non-random pattern of visceral 
metastasis suggested that metastasis to a particular site was not due to chance, but rather 
that certain tumor cells (the seed) had a specific affinity for a certain organ (the soil). ln the last 
few years, Paget's hypothesis has received considerable experimental and clinical support 
(Price, 1994, Fidler, 1995). Studies with B 16 melanoma cells injected intravenously into 
syngeneic mice produced metastases in the lungs and ovarian tissues but not in kidneys 
even when implanted intramuscularly (Hart & Fidler, 1981 ). The introduction of peritoeovenous 
shunts for palliation of malignant ascites provided similar data in humans. The autopsy findings 
in 15 of these patients substantiated the clinical observation that the shunts did not increase 
the incidence of visceral organ metastasis. ln fact, despite continuous entry of billions of tumor 
cells into the circulation, metastases in the lung (the first capillary bed encountered) were rare 
(Tarin et al., 1984). 
lt is therefore evident that that development of distant metastases in a particular target organ 
depends on characteristics of the tumor cells and the target organ (Zetter, 1990). Tumor cell 
characteristics responsible for organ preferential metastasis likely include cell adhesion 
molecules and the ability to respond to tissue-specific factors (chemotaxis and proliferation) 
(Cavanaugh et al., 1991; Doerr et al., 1989; Rossi et al., 1992; Zetter, 1990). Target organ 
factors that influence tumor cell population include microvascular endothelial cell adhesion 
molecules (Auerbach et al., 1987; Pauli et al., 1992) and local growth factor production b y 
target organ stromal cells (Nicolson, 1993). For example, Sierra et al. (1997) could show that 
astrocyte-derived cytokines, namely IL-6 enhanced the growth and adhesion of the 435-Br1 
cell line (derived from a brain metastases in a nude mouse previously inoculated 
subcutaneously (s.c) with the breast cancer cell line MDA-MB-435) relative to the parental 
23 
lntroduction 
MDA-MB-435 line, when seeded onto primary astrocytes in culture. These results hint to a 
plausible scenario whereby metastatic cells respond to exogenaus cytokines in a paracrine 
fashion such that their growth is favoured in certain organs where these factors are present. 
When two sublines of the Lewis lung carcinoma, H-59 and M-27, which are both highly and 
preferentially metastatic to the liver and lung respectively, were grown in serum-free 
conditioned medium from primary mouse hepatocytes, the medium proved highly and 
specifically mitogenic for H-59, but had no effect on M-27. Furthermore, this mitogenic activity 
could be blocked with a monoclonal antibody to the insulin-like growth factor 1 (IGF-1). This 
would indicate that hepatocyte-derived IGF-1 is a potential mechanism of selection in the 
process of liver colonization by these carcinoma cells (Long et al., 1994). More recently, 
transfection of full length insulin-like growth factor receptor (IGF-1 R) cDNA into the M-27 
subline (which normally has low Ievels of the receptor) resulted in multiple tumors of the liver 
when inoculated via the splenic/portal route in vivo (Long et al., 1998). 
Knowledge of the expected metastatic pattern of a particular tumor type is of clinical importance 
as the pattern data may contribute to the development of innovative strategies aimed at 
inhibiting metastasis. For example, breast cancer in women has a predilection for metastasis to 
regionallymph nodes, skeleton and lung. Paracrine Stimulation of cell proliferation by insulin-like 
growth factor-1 (IGF-1) is a feature of many mammary carcinoma cell lines (Cullen et al., 1992), 
and recently tamoxifen, a partial antagonist to the cestrogen receptor now widely used in the 
treatment of breast cancer, was demonstrated to decrease IGF-1 production by lung stromal 
cells (Huynh et al., 1993). Because IGF-1 is a potent mitogen for breast cancer cells (Doerr & 
Jones, 1996), reducing the expression of IGF-1 in common target organs for breast cancer 
metastasis may contribute to its antineoplastic properties. Thus, suppression of organ specific 
local growth factors opens up a new avenue of potential therapeutics because it recognizes 
the role and importance of target organ microenvironment in the development of metastatic 
disease. 
1.5 Genetic Aspects of Invasion and Metastasis 
The term tumor progression encompasses a range of incremental biological changes 
that typically occur in tumors over time (Mareel et al., 1990). lt is proposed instead that the 
genomic instability inherent in the tumor cell Ieads to disruption of only a relatively small 
number of critical regulatory genes common to several cellular processes (Egan et al., 1991 ). 
This view is supported by the demonstration that metastasis may be controlled in 
experimental systems by altering the expression of oncogenes which are known to have 
critic.al regulatory roles in cellular growth. Two genes that have recently been reported to be 
associated with metastasis, namely nm23 and MTS1 will be considered further. 
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1.5.1 NM23 in Metastasis and Oncogenic Development 
A central hypothesis in metastasis research proposes that some of the phenotypic 
changes noted are mediated, at least in part, by increased or decreased tumor cell expression 
Ieveis of specific genes. A number of techniques have been used with success to identify 
differentially expressed genes that accompanies a metastatic phenotype and are all founded 
on the analysis of mRNA from usually highly versus non-or low metastatically competent 
rodent celllines. Using differential colony hybridization between a low and high metastatic K-
1735 murine melanoma cellline, one clone was identified that exhibited a pattern of expression 
that was consistent with the tumor metastatic potential of all seven cell lines in the K-1735 
system. This Iead to the isolation of clone nm23, whose mRNA Ieveis were ten-fold higher in 
the two low metastatic cell lines (Steeg et al., 1988a/b) that is there was an inverse 
relationship of gene expression verses metastatic capacity. 
Subsequent cloning revealed that nm23 encodes a 17 kDa cytoplasmic metabolic enzyme, 
nucleoside diphosphate kinase (NDPK), whose principal function is to provide nucleoside 
triphosphate precursors for DNA and RNA synthesis (Lascu, 1996). There exists two 
isoforms denoted nm23-H1 and nm23-H2, the later being identical to the previously described 
c-myc transcription factor PuF (purine-binding factor; Postel et al., 1993). Both the murine 
genes nm23-M1 and -M2 (Urano et al., 1992) and the rat ndpk-ß and -a (Shimada et al., 1993) 
are 80 % and 90 % homologous, respectively, to human nm23-H1 and -H2. Validation of 
nm23-H1 has proceeded by examination of its expression in other metastatic model systems. 
Reduced expression, either at the protein or RNA Ievei, was correlated mouse mammary tumor 
virus induced mammary tumors (Caligo et al., 1992), ras or ras plus adenovirus E1a 
transfected rat embryo fibroblasts (Steeg et al., 1988b) and B 16 murine melanomas (Lakshimi 
et al., 1993). ln other systems, no correlation was found. Transfeetion studies of nm23 cDNAs 
into a paneal of murine, rat and human celllines resulted, in each case, in a reduction of in vivo 
metastatic potential using experimental (tail vein) or spontaneaus (fat pad) injection routes. 
(Leone et al., 1991, 1993; Baba et al., 1995; Parhar et al., 1995). These data confirm nm23 as 
a metastatic suppressor gene in a variety of model systems. The potential relevance of nm23 
to human cancer metastasis has been investigated by examining nm23 expression in tumor 
cohorts. A decreased expression has been significantly correlated with either decreased 
patient survival or the presence of lymph node metastases in women with breast carcinomas 
(Tokunaga et al., 1993; Cropp et al., 1994; Noguchi et al 1994). ln other tumor cohorts, such 
as lung, colon, prostate and kidney, no trend of nm23 expression and tumor metastatic 
potential has been evident (reviewed by Oe La Rosa et al., 1995). Perhaps these systems 
indicate that the role of nm23 in tumor progression is rather restricted to tumor types or that 
nm23 is itself victim to deregulation. Of interest is the fact that the kinase activity of nm23 
appears not to be required for its metastasis-repressing ability (MacDonald et al., 1993), but 
rather serine phosphorylation of the protein was correlated with its repressing function. This 
may suggest that particular facets of intracellular signalling may be involved in nm23 function. 
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The possibility of nm23 functioning as a transcription factor concerns the nm23-H2 isoform. 
whereby Postel could show that nm23-H2 is indeed a DNA-binding protein capable of 
stimulating transcription of, amongst others, the human c-myc gene in vitro (Postel et al., 1993), 
and that it can transactivate c-myc in a cell transfection assay (Berberich & Postel, 1995). The 
role of nm23-H2 in c-myc activation was recently confirmed by Ji et al. (1995). They observed 
that nm23-H2 is involved in the deregulation of the c-myc gene in Burkitrs Iymphoma, and 
thus, in the pathogenesis of this tumor. A possible nm23/PAI-1 connection is intriguing, since 
PAI-1 is elevated in breast tumors (Schmitt et al., 1992). A model whereby nm23-H2 is 
responsible for the activation of PAI-1 expression, by blocking the proteolytic pathway that 
results in matrix degradation and metastasis, is proposed. PAI-1 requires a PuF-Iike sequence 
element (TGGGTGGGGC) at -78 to -69 for promotor activity in cell transfection assays 
(Descheemaeker et al., 1992; Amarosa, 1993). Since urokinase (uPA) inhibitors such as PAI-1 
are implicated in tumor progression, it is possible that nm23-H2, PAI-1 and c-myc (which also 
regulates PAI-1; Prendergast et al., 1990) may all be involved in a common regulatory 
pathway. 
1.5.2 Metastasis-Related mts-1 Gene 
As with nm23, transcriptional comparison between two murine mammary carcinoma cell 
lines one of high metastatic capacity, CSML-1 00 and its non-metastatic counterpart CSML-0 
was performed to generate a subtracted library. Upon differential screening of the library, one 
clone designated mts-1 hybridized only with cDNA probes derived from the highly metastatic 
CSML-100 cell line (Ebralidze et al., 1989). Sequence analysis revealed mts-1 to be the 
murine homologue to p9Ka (Barraclough et al., 1987), and CAPL (Engelkamp et al., 1993) 
which represent the rat and human homologues respectively. The mts-1 gene encodes a 101-
amino acid cytosolic protein belanging to the 8100 subfamily of Ca2+-binding proteins, which 
are reported to be involved in the regulation of cell growth and differentiation by conversion of 
Ca2+message signals into intracellular responses (Kretsinger et al., 1991; Heizmann & 
Hunziker, 1991). 
Demonstration of a role for mts-1 in metastasis was obtained through transfection studies 
whereby mts-1 cDNA in antisense orientation was transfected into the CSML-100 cell line, 
resulting in a marked reduction of metastatic ability (Grigorian et al., 1993). Conversely, forced 
expression in CSML-0 cells gave rise to clones of increased metastatic capacity although not 
all clones metastasized, suggesting clonal variation. Davies and co-workers, transfected the 
nonmetastatic rat mammary epithelial Rama 37 cell line with p9Ka (Davies et al., 1993) which 
upon subsequent inocu!ation into rats produced tumors which metastasized to the lung and 
lymph nodes. ln light of the above, it would appear that mts-1 has the capacity to modulate 
the metastatic phenotype of several tumor cell lines. Several attempts were made to find 
proteins that interact with mts-1, one of which was tropomyosin (TM; Takenaga et al., 1994). 
The bindingwas specific and dependent on the presence of Ca2+. Although the function of 
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S 1 00 proteins remains still unanswered, it is tempting to speculate that mts-1 might b e 
involved in the Ca2+-dependent regulation of the cytoskeleton (Bianchi et al., 1993) and 
thereby influence cell motility as a result. 
The human connection has come from a different angle. lt has been appreciated for some time 
that the long arm of chromosome 1 is characterized by a high degree of anomaly in human 
hematological and solid tumors. For instance, duplication of the chromosomal segments 1q11 
and 1 q32 corresponded to increased proliferation and metastasis formation in human leukemia 
B cell clones (Ghose et al., 1990). Human gastric adenocarcinomas frequently undergo a loss 
of heterozygosity on chromosome 1 q (Sano et al., 1991) and genetic alterations in breast 
cancer are often associated with locus 1 q21 (Devilee et al., 1991 ), 1 q23-32 (Chen et al., 1989) 
and 1 q42-43 (Gendler et al., 1990). When Pedrocchi et al. (1994) examined expression of four 
members of the 8100 family, all of which are clustered on chromosome 1q21, in a battery of 
different human breast cancer cell lines and human breast cancer tissues, only expression of 
CAPUmts-1 was specifically correlated with the tumorigenesis of human mammary cells. 
The biology of cancer extends far beyond the physiology of cell growth control and while we 
are just beginning to unravel the intricate complexities that predisposes normal cells to shift 
their phenotypic behaviour to one capable of uncontrolled growth and insensitivity to 
surrounding growth promotinglinhibiting signals, this shortfall in understanding represents the 
major drawback in current cancer genetics. The last two decades has seen the rapid increase 
in number of genes thought to be functionally involved in tumor progression, and beyond this 
may lie yet other genes about which we know little or nothing at present. New cloning 
techniques for example subtractive suppression hybridization (SSH) may have a role here as 
they hold promise concerning the isolation of these novel genes whose deduced function may 
open up new avenues that can be exploited for the prevention of cancer. 
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1.6 Current Strategies and Methodologies that Allow 
ldentification of Differentially Expressed Genes 
/ntroduction 
There exists a !arge repertoire of techniques that aim at producing an inventory of 
differential transcripts based between two populations of mRNAs. The isolation and 
identification of differentially expressed transcripts is generally achieved by one of the 
following methods: Differential Display and related techniques (Liang & Pardee, 1992; Sokolov 
& Prockop, 1994), Representational Difference Analysis (cDNA-RDA; Lisitsyn et al., 1993), 
Enzymatic Degradation Subtraction (EDS; Zeng et al., 1994), Linker Capture Subtraction 
(Yang & Sytkowski, 1996), and techniques involving physical removal of common sequences 
(Akopian & Wood, 1995; Deleersnijder et al., 1996). Despite the fact that all these methods 
have proven successful in the isolation of differentially expressed genes they all possess 
some specific intrinsic drawbacks. For instance, differential display restricts the analysis to 
differences of the 3'end of cDNAs, so that differences in the 5'portion of cDNAs (e.g. variants 
of alternatively spliced genes) are often not detected. Additionally, variable reproducibility of 
the differential band patterns and the significant incidence of false-positives makes it difficult to 
isolate rare transcripts that are truly differentially expressed. Another common feature of the 
methods mentioned above and represents also an obstacle in the isolation of rare transcripts, 
is the disproportion of concentrations of differentially expressed genes which is maintained in 
the subtraction. For this reason, RDA requires multiple rounds of subtraction as the method 
fails to take into account the !arge differences in relative abundance of individual mRNA 
transcripts. The ideal system for subtractive cloning would generate an equalized 
representation of differentially expressed genes irrespective of their initial relative abundance, 
would permit the monitaring of subtraction efficiency prior to the time consuming screening 
work, and would minimize if not completely exclude the isolation of false positive clones. 
Recently, a novel technique called Subtraction Suppression Hybridization, (SSH; 
Diatchenko et al., 1996) has been described that combines a high subtraction efficiency with 
an equalized representation of differentially expressed sequences: The method is based on a 
specific form of PCR that permits exponential amplification of cDNAs which differ in 
abundance, whereas amplification of sequences of identical abundance in two populations are 
suppressed. The tabulation of this technique became a central piece of the work in this Ph.D 
project 
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1. 7 Project Outline and Specific Aims 
The principal aim of this thesis was to address the question "What are all the global 
changes in gene expression that accompanies the transition from a benign to a 
metastatic phenotype in a defined cellular system"? Although simplistic enough, the 
question is of great importance as it recognizes the fact that metastasis is not the result of 
dysregulation of a single gene, whether it be loss or overexpression, but rather the result of a 
cohort of genesthat have pivotal roles in cell regulation. To date there exists no such study, 
as to answer such a question is of some technical challenge and was not previously possible 
up until a few years due to technical limitations. Most reports have instead focused on one 
particular gene whose expression coincided with the metastatic phenotype. This in itself is of 
limited use as it fails completely to consider the functional actions of such a gene in the context 
of other dysreguiated genes. 
The model system which I chose was the Bsp73-AS pancreatic adenocarcinoma cell line 
system that comprises of two subclones of increasing metastatic capacity (Bsp 73-1 OAS and 
Bsp73-ASML respectively) that originate from the non-metastatic parental line Bsp73-1AS. 
The ASML cell line was reported to be highly metastatic in vivo (Matzku et al., 1983) when 
compared to 1 AS. Previous studies on these two cell lines demonstrated that there were 
intrinsic differences between ASML and 1 AS at the molecular Ievei by using a monoclonal 
antibody (MAb1.1 ASML) raised against a surface glycoprotein of the metastasizing rat 
pancreatic carcinoma cellline BSp73-ASML. With the help of this antibody, one clone was 
isolated that encode an additional extracellular domain inserted into the rat CD44. This new 
variant was only expressed in the metastasizing cell lines of two rat tumors, and further more, 
overexpression of this variant in the non-metastasizing BSp73-AS cells sufficed to establish 
full metastatic behaviour (Günthert et al., 1991 ). This variant form of CD44 was then 
subsequently shown to be also expressed in human tumors (Hofmann et al., 1991 ). As a 
result CD44 became the focus of intense study in relation to human tumors. So while there 
existed documented evidence that a variant form of CD44 is necessary and indeed sufficient 
to endow metastatic properties to recipient cells, it was clear that a complex phenotype such 
as metastasis cannot be the product of genetic dysregulation of a single gene. Hence it seem 
appropriate that the Bsp73-AS system would offer a suitable platform from which other 
genetic alterations could be identified by subtraction at the nucleic acid Ievei. 
Specific aims of the project where as follows:-
1) Isolation and subsequent identification of the majority of genetic dysregulations in the 
form of upregulation that accompanies the transition from a non-metastatic to a 
metastatic phenotype. 
2) Selective screening of all identified differentially expressed genes against a large 
paneal of rodent and human cell lines of varying tumorigenicity. This would identify 
29 
lntroduction 
those clones that appeared to have a more significant role in tumor progression and 
exclude those that were specific to the pancreatic system from which they were 
obtained. 
3) Screening of human tumor material against all individual differentially expressed 
clones in order to identify those clones that not only cross hybridize and therefore may 
possess high homology, but to identify clones specific to the tumor and therefore 
absent in normal matched tissue. 
4) Selective full length cloning of potential genes involved in tumor progression as 
defined from the two screening procedures. 
5) Functional analysis of the full length clones in vivo through overexpression and /or 
interference with normal function by ectopic expression of a dominant negative mutant 
in non-metastasizing and metastasizing celllines respectively. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
All general chemieals were of the highest purity grade, the majority of which were supplied 
from Merck, Darmstadt, Gar/ Roth GmbH & Co Karlsruhe and Sigma Chemie GmbH, 
Deisenhofen. Aqueous solutions where made with water previously purified (bi-dest) using a 
Milli-Q water purification system. 
Oligos 
All oligos were obtained from either MWG Biotech GmbH or from Birsner & Grob-Biotech 
GmbH and were all of a HPLC purified grade. 
Sequencing 
5'- TCAGCGATGAGATCTACTGCC-3' 
5'- AACGCGGAGGCACGGAGGAGGTCG-3' 
5'- TTGGCCTCCGTGCCTCCTCCAGC-3' 
5'- GTTTTCCCAGTCACGAC-3' 
5'- CAGGAAACAGCTATGAC-3' 
5'- TAATACGACTCACTATAGGG-3' 
5'- A TT AACCCTCACT AAAG-3' 
Colony PCR (SSH nested primers) 
5'- TCGAGCGGCCGCCCGGGCAGGT -3' 
5'- AGGGCGTGGTGCGGAGGGCGGT-3' 
uPAR 
5'- TGTATTGAAGTGGTGACGCTCC-3' 
5'- AGGCAATGAGGATAAGATGAGC-3' 
Full length cloning of Ezrin (rat) 
5'- CTCGGAAGCTTAGCCACCAACCAGCCA 
AGATGCC-3' 
5'- GCCATGAATTCCTAGCCCGCATAGTCAG 
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For (Ezrin)-Texas red 
Rev (Ezrin)-Texas red 
3'-Ezrin-Texas red 
PUC/M13 For(-40)-Texas red 
PUC/M13 Rev-Texas red 
T7-Texas red 
T3-Texas red 
PN1 
PN2 
Rat uPAR (457s) 
Rat uPAR (958as) 
5'- Ezrin (Hind 111) 
3'- Ezrin (HA/EcoRI) 
GAACATCGTATGGGTACATGGCCTCAAA 
CTCGTCGATGCG-3 
Materials & Methods 
5'- GCCATGAA TTCCTAGCCCGCATAGTCAG 
GAACATCGTATGGGTACTGGGCCTTCAT 
CTGCTGCACCTC-3' 
3 '-Ezrin (HA/EcoRI)N 
Antibodies 
Anti-Ezrin (mouse lgG1 cross-reacts to rat, human and dog. Also reported to cross-react to two 
related proteins, moesin and radixin. Peptide corresponds to positions 575-585. 
(Transduction Labs. Kentucky. USA) 
Anti-HA (mouse monoclonal to an epitope derived from hemagglutinin protein of human 
influenza virus (HA-tag). Recognizes peptide sequence YPYDVPDY A. Boehringer 
Mannheim) 
Anti Erk (K-23, a goat polyclonal to an epitope corresponding to amino acids 305-327. 
Reactivity to human, mouse and chicken. Santa Cruz Biotech) 
2.2 General Methods 
A number of protocols and receipts for commonly used buffers used in this project were taken 
from the Iabaratory manual of Maniatis et al (1989) and Current protocols in Molecular Biology 
(Ausubel F.M.,et al1989) unless otherwise stated. 
Phenol/Chloroform extraction of nucleic acids 
To remove unwanted protein contaminants from nucleic acids, an equal volume of Tris-
buffered phenol, chloreform and isoamylalcohol (2-propanol) at a ratio of 25:24:1 was added 
and the mixture vortexed until the solution had a milky appearance. The two phases were 
separated by centrifugation at 13000 x g for five minutes after which the upper aqueous 
nucleic acid containing phase was transferred to a new reaction tube and subjected to a further 
round of extraction with chloroform/isoamylalcohol (24:1). 
lsolation/Purification of DNA from agarase gels 
A number of methods were employed to isolate DNA (e.g.,Oiigos, PCR fragments, vectors, 
plasmid clones or ds cDNA) from agarose gels once eletrophoresis was complete. 
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(a) Electrophoretic isolation of DNA 
Once the DNA had migrated the desired distance, as determined by visualising the gel 
under UV light, a slit was cut into the gel with a scalpel just below the chosen DNA band. A 
strip of DE81 DEAE-cellulose membrane (Schleicher & Schuell, Dassel) was inserted into the 
slit and electrophoresis continued until the DNA fragment had run into the membrane. At this 
point the membrane was removed, rinsed briefly with distilled H20 and the DNA eluted b y 
incubation in 400 ~-tl1.5 M NaCI, 10 mM Tris-HCI pH 7.5 and 1 mM EDTA for 30 minutes at 65 
oc with shaking. After two extractions with phenol/chloroform, the DNA was precipitated with 
ethanol, air dried and dissolved in an appropriate volume of water. 
(b) Direct isolation from agarase ge/s 
The DNA band of choice was cut out from the gel, under long wave UV light with the 
aid of a scalpel. After trimming excess agarose the DNA containing gel strip was placed inside 
a pierced 0.5 ml reaction tube containing glass wool which in turn was placed inside a 1.5 ni 
reaction tube and centrifuged at high speed for 5 minutes. The DNA would be collected in the 
reaction tube, leaving the agarase caught in the glass wool. The DNA was then extracted with 
phenol/choloroform and precipitated with ethanol. 
(c) DNAeasy kit (Biozyme) DNA iso/ation from agarase gels. 
As above with the exception that the gel strip containing the DNA is added to 3 x it's 
weight to volume of "satt buffer'' (all reagents provided in the kit). The gel piece is melted in the 
buffer by incubation at 65 °C before the binding resin is added. After two subsequent 
washing steps the resin with bound DNA was air dried and the DNA eluted by addition of bi-
dest H20. 
Precipitation of nucleic acids 
The precipitation of both RNA or DNA was performed by adjusting the final satt 
concentration of the reaction mixture to 300 mM with 3M Na-acetate (pH 4.8-5.2) and adding 
2.5 volumes of 100% ethanol or 1 volume of 2-propanol (lsopropanol) followed by a 30 
minute incubation at -20 °C. The precipitate was pelleted by centrifugation at 13000 x g, at 12 
oc for 30 minutes after which the aqueous phase was discarded. The pellet was washed 
twice with 80 % ethanol to remove excess satt and allowed to air dry for 1 0 minutes. 
Determination of nucleic acid concentration 
The concentration of nucleic acids in aqueous solution was determined b y 
spectroscopic measurement of their extinction coefficient at 260nm and 280nm. An optical 
density (OD) of 1 at 260 nm is equivalent to 50 mg/ml of double stranded DNA, 40 mg/ml of 
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RNA or 20 mg/ml single stranded oligonucleotide. The 00280 is used as an indication of purity 
and should be approximately 50% of the 00260 value. Pure RNA and ONA should have a 
002sof00280 ratio of 1.8-2.0 and 1.6-1.8 respectively in bi-dest water. 
Restrietion endonuclease digestion of DNA 
Oepending on the restriction enzyme used, 2-5 units (U) of the enzyme was added for 
each 11g of ONA taken. The digestion was performed using the appropriate buffer and 
incubation temperature as indicated by the supplier. Reactions were incubated for ;::: 2 hours at 
a final ONA concentration of 1-5 mg/ml after which the reaction was terminated by either heat 
inactivation of the enzyme (65 oc for 10 minutes) or by phenol/chloroform extraction. 
DNA Ligation 
Allligation reactions were performed in a total volume of 1 0 111 and incubated overnight 
at 14 °C, followed by heat inactivation of the ligase at 70 °C for 5 minutes before storing at -20 
oc 
(a) Ligation of linkers I adaptors 
Approximately 100-200 ng of ds cONA was Iigated to a 3-4 molar excess of linkers or 
adaptors using the supplied ligation bufter 1-3 units of ligase. 
(b) Ugation of PCR fragments 
After purification of the PCR fragment, the ONA was directly cloned via the T/A overhangs into 
the T/A cloning vector pCR2.1 kit (Ciontech Laboratories, lnc. USA) according to the suppliers 
protocol and using the kit' s components. 
(c) Sub-cloning 
The cloned fragment of ONA was released from the vector using appropriate restriction 
endonucleases, purified by agarose gel electrophoresis and subsequently cloned into the 
new vector using compatible sites or through blunt end ligation. 
Polymerase Chain Reaction (PCR) 
All PCR reactions were performed in a total volume of 25-100 111, in the presence of 250 
11M dNTPs, 1-2 pmol of primer(s), 0.25U to 1 U of Taq and 1 X suppliers buffer and 1.5-2.0 rrM 
f.c MgCI2 (EuroBio Taq buffer is Mg2+ free). The reactions were carried out in a number of 
commercially available PCR machines (e.g., Perkin Eimer 9600/2400 and ONA Engine MJ 
Research), using specific cycling parameters depending on the application. All individual 
parameters are noted for each PCR reaction in the results section. Analysis of the PCR 
reaction was performed using gel electrophoresis. 
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Reverse Transcription Polymerase Chain Reaction (RT -PCR) 
All reactions were performed as described for standard PCR with the exception that 5 
Jll of a previously diluted (1: 1 0) first-strand cDNA reaction was taken as template DNA and 
the primers used were specific for the gene of interest only (as determine through BLAST). 
Again, specific cycling parameters were dependent on the primers chosen and size of the 
expected product. Evaluation of the RT-PCR reaction was performed by gel eletrophoresis, 
and were cloning was concerned, the product was sequenced. 
Radioactive labelling of DNA/cDNA probes 
Approximately 25 ng of ds cDNA in a volume of 45 Jll was denatured by heating to 
1 00 oc for 1-2 minutes then rapidly cooled on ice. The entire solution was then added to a 
ReadyPrime reaction vial (redi Prime kit, Amersham Life Science) to which was added 5 Jll of 
[a32P]-dCTP (Amersham Buchler GmbH, Braunschweig, 370 Mßq/ml, 10 mCi/ml). After 
incubation for 15-30 minutes at 37 °C, or one hour at room temperature, unincorporated 
nucleotides were remove from the Iabeiied DNA using Elutips (Schleicher & Schuell, Dassel) 
according to the manufactures guidelines. The Iabeiied DNA was eluted in a volume of 600 Jll 
and denatured at 1 00 oc for 2-3 minutes immediately before use. 
Isolation of total RNA from tissue or human tumor material 
Approximately 200-500 mg of frozen tumor material was placed in a pre-chilled stone 
pestor and ground to a fine powder under liquid nitrogen. The powdery contents were then 
immediately poured with the nitrogen into a falcon 50 ml tube and allowed to stand briefly until 
all the nitrogen had dissipated upon which 5 ml of a mono-phasic solution (peqGOLD RNA 
Pure™, peqlab GmbH) was added. For fresh wet tissue, the above step was omitted and 
instead the tissue was homoginized directly in 5 ml of the solution. The entire contents were 
then homoginized at 20000 rpm using an ultra-Turrax T25(1KA®-Labortechnik) for 5-10 minutes 
followed by an incubation period of 3-10 minutes at RT to allow the nucleic acids to dissolve 
into the solution. Following this, 1 ml of pure chloreform (0.2 ml of chloreform per 1 ml of 
peqGOLD used) was added to the homogenised mix and vortexed vigorously until the 
solution took on a milky white appearance. Again following a brief incubation at RT, the mixture 
was transferred to a 14 ml polypropylene tube and subsequently centrifuged for 15 minutes at 
10000 x g in a cooled 4 oc swing-out rotor. Once completed, the tubes were carefully 
removed and the top aqueous RNA containing phase was removed and transferred to a clean 
polypropylene tube containing 3 ml of pure choloroform before vortexing the contents. Again 
the tubes were centrifuged as before and the top phase removed for a further round of 
choloroform extraction. Lastly, the top phase was precipitated with an equal volume of 
isopropanol and the nucleic acid pellet was washed twice with 75 % ethanol before 
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resuspending in 150 ml of bi-dest water. The integrity of the isolated total RNA was monitared 
by size fractionation over a 1 % formaldehyde/MOPS agarase gel. 
Isolation of Poly (A)+ RNA 
Cells were grown to a confluency of approx 70-80% in 15 cm petri dishes (Greiner) 
after which the medium was removed and the cells washed briefly in PBS. The cells were 
then immediately lysed in 20 ml of STE-SOS (20 mM Tris-HCL pH 7.4, 100 mM NaCI. 10 rrM 
EOTA and 0.5% SOS) containing 300 mg/ml proteinase K (Sigma, München). Using an Ultra-
Turax™ homogenizer, the high molecular weight ONA was sheared followed by incubation at 
50 oc for 30 minutes in order to degrade cellular proteins by the action of proteinase K. After 
adjusting the final concentration of Na Cl to 0.5M, 100-200 mg of oligo-dT cellulose (type VII, 
Pharmacia Biotech or NEB) was added and the resulting mixture rotated over night (o/n) to 
allow binding of the poly A + RNA to the oligo-dT cellulose. The oligo dT cellulose was then 
washed by pouring the contents into a 20 ml Biorad column, allowing the liquid to drain out 
while retaining the oligo-dT cellulose, then applying 20 ml washing solution (1 00 mM Na Cl, 20 
mM Tris-HCI pH 7.4, 10 mM EOTA and 0.2% SOS). The poly A+ RNA was eluted from the 
oligo-dT cellulose by addition of 4 ml of elution solution(1 mM Tris-HCI pH 7.4, 1 mM EOTA 
and 0.2% SOS) and the contents collected in a 14 ml polypropylene tube on an ice bed. The 
RNA concentration was estimated from 400 J.ll of the eluent, the remainder precipitated b y 
adding 350 J.ll of 3 M Na-Acetate and 0.8-1 vols of isopropanol (2-propanol) followed b y 
centrifugation at 12000 x g for 30 minutes at 4 °C. Once the centrifugation was completed, the 
aqueous phase was decanted off and the RNA pellet washed twice with 70 % ethanol, 
before being air dried for 10 minutes. The pellet was then resuspended in bi-dest H20, 
usually at a concentration of 0.5-2.0 mgtml before being transferred to a 1.5 ml reaction tube 
and stored at -80 oc. 
First and second strand cDNA synthesis 
(a) First strand synthesis using SuperScript™ II for RT-PCR 
For most applications, 2 J.Lg of high quality poly (A)+ RNA tagether with 500 ng of oligo 
( dT) 12-18 primer in a total volume 11 J.tl was heated to 70 oc for 1 0 minutes in a thermal cycler 
(Perkin Elmar 9600/2400) before placing the reactions rapidly on ice. The reaction mixturewas 
then subsequently made up to 20 J.ll by adding 4 J.ll of 5 x first strand reaction buffer (provided 
with the reverse transcriptase), 2 J.ll of 0.1 M OTI and 1 Jll dNTP mix (10 mM each dATP, 
dCTP, dGTP and dTIP). Reverse transcription was started by addition of 2 J.tl of 
SuperScript™ reverse transcriptase (Gibco BRL) to each reaction before incubation for 1-1.5 
hours in an air incubator previously equilibrated at 42 °C. After which the reverse transcriptase 
was inactivated by rapidly heating the contents to 94 oc for 3 minutes then placing the tubes 
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on ice. The firststrand reactions were stored at -20 oc once their volume had been adjusted to 
200 Jll by the addition of 180 Jll bi-dest H20. 
ln order to monitor the efficiency of the first strand reaction, 1 Jll was removed directly after the 
addition of the reverse transcriptase and added to ~ Jll of a labeHing mixture containing 0.3 
J.LI[32P]dCTP and likewise incubated at 42 °C. This so called tracer reaction was stopped b y 
the addition of EDTA to a f.c. of 20 mM. Specific incorporation of dCTP into high molecular 
weight nucleic acidwas determined by the TCA precipitation procedure (Ausubel et al., 1987). 
Typically, -28% of all poly(Af RNA transcripts were converted into firststrand cDNA. Note: 
first strand cDNA synthesis performed for the generation of a subtracted library was done 
exactly as described above with one exception. The oligo ( dT) primer used for cDNA 
synthesis contained an Rsa I restriction site and a 'dT' tail of 30 nucleotides in length. This 
primer was provided in the PCR-Select™ cDNA subtraction kit (Ciontech Laboratories, lnc. 
USA). 
ln the case of performing second strand synthesis, the heat inactivation and dilution steps 
were omitted and instead the reaction vials were placed on ice after incubation at 42°C. 
(b) One-tube second strand synthesis 
Following first strand synthesis, secend strand synthesis was performed by adding 92 
Jll of sterile, bi-dest water, 32 Jll of 5x secend strand buffer [94 mM Tris-HCI, pH 6.9, 453 mM 
KCI, 23 mM MgCI2, 750 J.LM ß-NAD and 50 mM (NH4)2S04], 3 Jll of Escherichia coli DNA 
ligase (7.5U/J.LI), 4!ll E.coli DNA polymerase I (10U/J.LI) and 0.7 Jll of E.co/i RNase H (2U/J.LI). 
The contents were mixed and 5 Jll removed for the radioactive incorporation assay (as 
above). Both reactions were incubated at 16 oc for 2.5 h. The double stranded cDNA in the 
unlabelled reaction was blunted by the addition of 2 Jll of T4 polymerase (10UIJ.1I, using 10U 
per J.Lg of mRNA taken in the reaction), followed by further incubation at 16 oc for 20 minutes 
before both reactions were stopped by addition of EDT A. As before, Iabeiied second strand 
cDNA synthesis was monitared by TCA precipitated and resolved on an alkaline agarose gel 
as described by Maniatis (1989). The unlabelled fraction was P/C/1 extracted and precipitated 
in the presence of 1 0 J.Lg of glycogen before resuspending the ds cDNA in bi-dest to a 
concentration of 0.1-0.5 mglml. 
Mini-prep plasmid preparation from bacteria 
( a) Standard method. 
Individual colanies were picked from a LB agar piate and used to inoculate 3 ml of LB 
medium (10 g/lt tryptone, 5 g/lt yeast extract, 5 gilt NaCI), containing 100 mg/ml ampicillin. The 
inoculated bacteria were then incubated with shaking (220 RPM) o/n at 37 oc until a stationary 
phase had been reached upon which 1.5 ml was removed and the bacteria pelleted b y 
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centrifugation at 4000 x g for 5 minutes. The pellet was resuspended in 100 111 of solution I (50 
mM Glucose, 25 mM Tris-HCI pH 8.0, 10 mM EOTA and 300 mglml RNase A) and left at RT 
for 5 minutes before addition of 200 111 of solution II (0.2 M NaOH and 1.0 % SOS). Once the 
resulting mixture appeared clear, it was neutralised with 150 111 of solution 111 (3 M Na-Acetate 
pH 5.2) and mixed by gentle inversion of the reaction tube. Following 15 minutes incubation 
on ice, the precipitated protein and chromosomal ONA was pelleted by centrifugation at 1 0000 
x g for 1 0 minutes before the aqueous supernatant was removed. Extraction of the 
supernatant with P/C/1 was followed by precipitated of the plasmid ONA with ethanol and the 
resulting ONA pellet resuspended in 50 111 of bi-dest H20. 
(b) Wizard Mini-prep kit (Promega) 
Resuspension, lyses and neutralising of the bacteriai peilet was carried out according 
to and using the manufacturer' s provided buffers. The plasmid ONA in the retained 
supernatant was isolated using the supplier' s ONA-binding resin and suction manifold. The 
resulting plasmid ONA was then eluted in 50 111 of bi-dest H20. This method was primarily 
used for the production of sequencing-grade plasmid ONA. 
Large scale plasmid preparation from bacteria 
Usually, a volume of 200-250 ml of LB or 2TY (16 gilt tryptone, 5 gilt yeast extract, 
and 5 gilt NaCI) medium supplemented with the relevant antibiotic was inoculated with a 
single bacterial colony and incubated with shaking (220 rpm) at 37 oc overnight until the 
bacteria had reached a stationary growth phase. The bacteria were pelleted by centrifugation 
in a fixed angle rotor at 4000 x g for 1 0 minutes and the pellet resuspended in 1 0 ml of solution 
I (10 mM EOTA, 50 mM Tris-HCI pH 8.0 and 400 mglml of RNase A). Following 5-10 minutes 
incubation at RT, the cells were lysed by the addition of 10 ml of solution II (200 mM NaOH 
and 1% SOS). Once the solution had taken an opaque appearance, the mixture was 
neutralised with 10 ml solution 111 (3 M potassium acetate pH 4.8) the entire contents gently 
inverted to aid mixing of the solutions. After an additional 1 0-20 minutes on ice, the cell wall 
fragments and the bacterial chromosomal ONA were sedimented by centrifugation at 13000 x g 
for 20 minutes at 4 oc in a fixed angle rotor. The retained supernatant was then added directly 
to a pre-equilibrated Qiagen-tip 500 column (Qiagen lnc.) and the plasmid ONA was 
recovered according to and using the manufacturer's supplied buffers. The purified ONA was 
precipitated using 0.8-1.0 vols of isopropanol, washed twice in 70 % ethanol before 
resu.spending the ONA to a final concentration of 1-3 mglml in bi-dest H20 and stored at -20 
oc. 
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Preparation of competent bacteria (E.Coli) 
( a) Chemical competent E. Co/i ( calcium chloride method) 
A single colony of E.coli DH5a was taken. to inoculate 5 ml of LB medium (1 Og/lt 
tryptone, 5 g/lt yeast extract, 5 g/lt Na Cl) and allowed to grow o/n at 37 °C with shaking (220 
rpm) before 4 ml was removed and added directly to 400 ml of LB medium. The bacteria were 
grown to an 00590 of 0.375 before incubating the bacteria on ice for 10 minutes. The bacteria 
were sedimented by centrifugation without brake at 3600 x g for 7 minutes at 4 oc and the 
pellet carefully resuspended in 20 ml of ice cold 0.1 M CaCI2 and allowed to stand on ice for a 
further 1 0-15 minutes. The cells were centrifuged again under the same conditions and 
resuspended in a further 20 ml of ice cold CaCI2 • This process was repeated once more and 
the final pellet resuspended in 2 ml of ice cold CaCI2.with 10 % glycerol After a short period on 
ice, the bacteria were dispensed in 100 111 aliquots in pre-chilled reaction tubes and snap-
frozen in liquid nitrogen before storing at -80 oc. 
(b) Electrocompetent E. Co/i 
As above, a single colony of E.co/i DH5a was taken to inoculate 1 ml of SOB medium 
and the culture grown o/n at 37 oc with shaking. This in turn was used to further inoculate 300 
ml of SOB medium and the bacteria grown at 18-20 oc until and 00600 of 0.4-0.5 had be 
reached. At this point the entire culture was heat-shocked at 37 oc for 5 minutes before 
subjecting the bacteria to a further 20 minutes at 18-20 °C. The bacteria were then gently 
sedimented by centrifugation at 3600 x g for 10 minutes before the pellet was resuspended in 
50 ml of ice cold bi-dest H20. The process of pelleting and resuspending was repeated 4-5 
times in order to remove trace amounts of salt from the original medium. Finally, the cells were 
taken up in 800 111 of ice cold H20 containing 7 % DMSO. Aliquots of 40 111 were then snap-
frozen and stored at -80 oc until use. 
Transformation of bacteria 
(a) Chemical/y 
Depending on the application, 5 ng of super coiled plasmid DNA or 1 111 of a ligation mix 
(usually a 1/10 of the ligation) was added to 200 111 of competent cells and left on ice for a 
period of 30 minutes. Following this, the cells were heat-shocked at 42 oc for 90 seconds 
before rapidly returning the tube to ice for a few minutes. After addition of 1 ml of SOG medium 
(2.0% tryptone, 0.5% yeast extract, 10 mM NaCI, 2.5 mM KCi, iO mM MgS04 , and 20 mM 
glucose) the bacteria were transferred to a shaker and incubated for 45 minutes at 37 °C. The 
cells were then pelleted lightly by a short centrifugation (3 min at 1 000 x g) and 1 ml of the 
supernatant was removed before resuspending the cells in the remaining 200 111. A volume of 
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50-200 111 was plated out on LB-agar plates supplemented with the correct antibiotic and the 
plates incubated 18-24 hours at 37 °C. 
(b) Electroporation 
Usually, 1-2 111 of a ligation mixture was added to 40 111 of electrocompetent cells 
previously aliquoted in pre-chilled reaction tubes. The cells were then immediately transferred 
to a pre-cooled electroporation cuvette (0.1 cm gap, BioRad) and pulsed at 1.8 Kv (Gene 
pulser, BioRad). Once completed, 1 ml of SOC medium was immediately added to the cuvette 
and retrieved with the cells and placed in a 15 ml falcon tube before incubation at 37 oc for 45 
minutes. Again the cells were lightly pelleted before plating out on appropriate LB-agar plates. 
Sequencing of double-stranded template DNA 
(a) [a-33Pj-ddNTP method 
The Thermo Sequenase radiolabelad terminator cycle sequencing kit (Amersham) was 
used for the sequencing of cloned templates. The kit combines two revolutionary innovations 
for sequencing DNA. First, the Iabel is incorporated into the DNA reaction products by the use 
of four [a32P)-ddNTP terminators and secondly, the use of a engineered Thermo Sequenase 
DNA polymerase which allows for efficient incorporation in cycling sequencing protocols. 
Sequencing of desired templates was carried out according to the manufacturer's guidelines. 
Approximately, 0.5 119 of plasmid DNA was taken together with 1-2.5 pmol of an appropriate 
primer (usually M13 Forward or Reverse universal primers) with 8 U of the Thermo 
Sequenase polymerase in a total volume of 20 111. From this mixture 4.5 111 was aliquoted into 
each termination vial ('G', 'A', 'T and 'C') and cycled in a Perkin Elmar 9600 PCR machine 
using the following cycle parameters: 95 oc, 30 sec, 55 °C, 30 sec and 72 °C, 1 minute for a 
total of 35 cycles. Upon completion, 3 111 was loaded in each lane and resolved over a 6% 
polyacrylmide 6 M urea TBE gel. Once the run had reached the desired length, the gel was 
removed, dried on Whatman 3MM paper at 80 oc for 2 hours on a vacuum gel dryer before 
autoradiography. Films were developed after 18-36 hours exposure. 
(b) ™Vistra DNA sequencer 725 
For the use of automated fluorescent sequencing of template DNA, a commercially 
available kit was used (Thermo Sequenase pre-mixed cycle sequencing kit, Amersham) 
together INith the appropriate Texas Red Iabeiied primers. All reagents were taken from and 
used following the supplier's protocol. The thermocycling conditions for the sequencing 
reactions were set at: 94 oc 1 minute, then 22 cycles of 94 °C, 30 sec; 50 °C, 15 sec; and 72 
oc for 30 sec. Following completion, 3 111 of loading dye was added to each reaction vial and 
mixed before placing the reactions in a vacuum centrifuge until the desired volume had been 
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reached (usually 3-4 f.ll). After the gel had been pre-run for 30 minutes 3 fll of each reaction 
sample was loaded onto the gel and allowed to run over night. Sequences were base called 
from the gel using the provided software. 
Generation of a subtracted library by SSH 
Suppression Subtractive Hybridisation was performed between Bsp73-1 AS 
("Driver'') and Bsp73-ASML ("Tester") using the PCR-Select™ cDNA Subtraction Kit 
(Ciontech Laboratories, lnc. USA) according to the manufacturers' recommendations, except 
for modifications of the PCR and hybridisation conditions. All PCR and hybridisation steps 
were performed on a Perkin-Eimer 2400 thermal cycler. Approximately 6-8 f.l9 of high quality 
poly(At RNA from both celllines was converted to firststrand cDNA as described previously 
using the oligo (dT) 30 primer in 3-4 separate reactions. Upon completion, the first strand 
reactions were converted directly to double strand and blunted with T 4 DNA polymerase as 
previously described. Like samples were pooled and both batches of ds cDNA were then 
restricted as described in the original protocol. All further manipulations were performed in 
accordance to the original protocol. 
For the first hybridisation the mixture of driver and tester cDNAs was denatured at 1 00 oc for 
20 seconds and then cooled over one minute to 68 °C and maintained at that temperature for 
approximately 8 hours. For the second hybridisation, driver cDNA was denatured at 100 oc for 
20 seconds then added directly to the pooled mix of the two previous hybridisation's and 
allowed to incubate at 68 oc for 20 hours. lt was necessary to alter the PCR conditions (see 
below) such that amplification of unwanted sequences was kept to a minimum. All other 
procedures for the generation of the subtracted library were done according to the manual 
provided with the cDNA subtraction kit (Ciontech). 
Evaluation of subtraction efficiency 
Double stranded cDNA from the tester (Bsp73-ASML) and the Driver (Bsp73-1AS) 
were separately digested with Rsa I (a four base cutter-as used for the construction of the 
initial subtracted library). Hind 111 linkers were added to the tester cDNA and EcoRI linkers to 
the Driver cDNA [Hind II! linker 5'-ATCGTCAAGCTTCAAGTTACATCG-3', 5'-GCTAACTT 
GAAGCTTGACGAT-3'. EcoRI linker 5'-TAGTCCGAATTCAAGCAAGAGCACA-3', 5'-
CTCTTGCTTGAA TTCGGACT A-3']. Free linkers were removed by preparative agarose gel 
electrophoresis and the cDNA mixture was amplified as follows. 1 fll of adaptor-ligated cDNA 
was diiuted into 1 ml of H20 and amplified in a 50 Jll reaction using the appropriate primers 
(Hind 111 and EcoRI primers), a standard PCR buffer (Pharmacia), 200 f!M dNTPs and 2 units 
of Taq-Polymerase (Pharmacia). Cycling parameters were as follows: 30 cycles of 94 oc 20 
seconds, 52 oc for 20 seconds and 72 oc for 2 minutes. For the subtracted cDNA, PCR 
conditions were as follows: 27 cycles each of 94 oc for 30 seconds, 68 oc for 30 seconds and 
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72 oc for 2 minutes. Only the subtracted cDNA was subjected to a second round of PCR 
(nested) using the same PCR conditions with the exception that 12 cycles were performed. 
Equal amounts of amplified cDNA from the Driver, the Tester and of the subtracted library 
cDNA were resolved on a 1.5 % agarose gel, blotted and transferred onto nylon membrane. 
This was performed in order to monitor the degree of subtraction efficiency as determined b y 
the removal of genes common to both population (e.g., GAPDH) and the subsequent 
enrichment of genes specific to the tester population (e.g., uPA). This is discussed further 
under the results section. Hybridisation's were carried out under stringent conditions in 0.5M 
Na2P04 pH7.2, 7% SOS at 65 oc (Church & Gilbert, 1984). Filters were washed twice in 2 x 
SSC, 0.5 % SOS at 68 °C, then once in 0.1 x SSC, 0.1 % SOS at 68 °C. 
Cloning into TA vector 
After evaluation of the subtraction efficiency the subtracted library cDNA was cloned 
directly into pCRII.1 vector (TA cloning kit, lnvitrogen). Prior to ligation, the subtracted PCR 
cDNA mixwas incubated forafurther 15 minutes at 72 oc with additional dATP and Taq DNA 
polymerase (Pharmacia) to ensure that most of the cDNA fragments contained 'A-overhangs' 
(known as forced 'A' tagging). Approximately 100 ng of PCR-amplified cDNA was Iigated 
without further purification into 50 ng of vector and the ligation mixture was introduced into 
ELECTROMAX bacteria strain DH1 OB (Gibco/BRL) by electroporation (1 ,8 kV) using an 
E.coli pulser (BioRad). The library was plated onto 22 x 22 cm ampicillin containing agar plates 
and bacteria were grown until colonies were visible. Bacteria were then washed oft in LB 
medium, aliquoted and frozen in 1 0% DMSO. For library screening the titer was determined 
and bacteria were plated onto 22 x 22 cm agar plates containing 100 11g/ml ampicillin, 100 11M 
IPTG and 50 11g/ml X-Gal. Plates were incubated at 37 oc until small colonies were visible 
then incubated further at 4 oc until blue/white staining could be clearly distinguished. 
Reverse-northern high density blots and screening 
A total of 5000 individual recombinant clones were picked from the subtracted library 
and used to inoculate 52 sterile 96-well microtiter plates containing LB medium and ampicillin at 
100 f.lg/ml. After incubation of bacteria on a gyratory shaker for 4 hours at room temperature, 5 
f.ll of bacterial culture were transferred into 15 f.ll of sterile water in PCR tubes. [This part of the 
protocol was done in 96 tube format using a Perkin-Eimer 9600 thermal cycler. Pipetting of 
PCR mixes was done using a multi-channel pipette.] The bacteria were lysed by heating to 
1 00 oc for 5 minutes. 5 Jll of the bacterial lysate was used to PCR-amplify cloned inserts in 50 
J.ll reactions using standard PCR buffer (Pharmacia), 200 f!M dNTPs, 2 units Taq-Polymerase 
(Pharmacia), and 10 J.lmol of M13 rev and M13( -20) primers (which flank the multiple cloning 
site of pCRII.1) under the following conditions: 30 cycles each of 94 oc for 20 seconds, 48 oc 
for 20 seconds and 72 oc for 45 seconds. 
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After amplification, 12 f.LI were loaded onto high density gels (Centipede™ gel electrophoresis 
chambers, Owl Scientific, Woburn, USA). PCR products were denatured and alkaline blotted 
onto nylon membranes. The filters were hybridised under stringent conditions (7% SOS in 0.5 
M NaP04 pH 7.2) with equivalent amounts (20-30 ng) of 32P-Iabelled double stranded cDNA 
of approximately equal specific activity derived from driver and tester mRNA, respectively. 
Filters were washed under stringent conditions (see above), and exposed to phosphoimager 
plates overnight (equivalent to 8 days exposure to conventional film). ln addition, the filters 
were exposed to conventional film up to 12 days at -80 oc and the signals of like clones 
compared. 
Subtracted clone amplification and reverse northern screening 
From the subtracted library all differentially expressed genes identified, were screened 
via reverse northerns against Rsa I restricted ds cDNAs obtained from a large paneal of both 
rat and human tumorigenic celllines as mentioned above. 
Cloned inserts were amplified using the nested primer sequences from the original subtraction 
protocol in a total volume of 1 00 f.LI. Approximately 1 0 ng of plasmid template harbouring the 
insertwas taken tagether with the standard PCR components (see PCR conditions) and 1 f.LI 
of a 10 pmole stock of the nested primers. Cycling parameter were set at 94 oc for 40 sec, 
then 30 cycles of:. 94 oc 20 sec, 68 oc 12 sec and 72 oc 30 sec. Using a multichannel pipette, 
12 f.LI of PCR product was loaded onto the high-density gels and once electrophoresis was 
complete, the gels were blotted over onto Hybond membrane as described below (see 
protocol for southern blotting). ln this manor, 40-50 membranes each containing the predefined 
complete set of differentially expressed genes as identified from the original library could be 
hybridised to ds cDNA from differing sources. 
Coupled transcription/ translation in vitro (TNT} 
The TN~ (Promega) coupled rabbit reticulocyte lysate system was used to determine 
the authenticity of the cloned full length rat ezrin and the dominant negative mutant generated 
by PCR. All reagents used were supplied in the kit and performed according to the 
accompanying outlines provided. Briefly, 1 Jlg of clean plasmid DNA was taken and added to 
a reaction vial containing: 25 f.LI of TNT lysate, 2 j1l TNT reaction buffer, 1 f.LI of an amino acid 
mix (minus methionine), 1f.LI RNasin (40U/f.LI), 4 f.LI of [35S]-methionine, 1 f.LI T7 RNA Poly (10 
U/f.LI), in a total vol of 50 f.LI. For cold protein products, the Iabeiied methionine was omitted and 
replaced with normal methionine. All reactions were incubated at 30 oc for 1 hour before the 
product was heat denatured and loaded on a 12 % polyacrylamide gel. The gel was dried and 
exposed to autoradiography. 
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Cell Culture and Transfeetions 
Cell lines. 
The rat BD 10 pancreatic celllines Bsp73-1AS, Bsp73-10AS and Bsp73-ASML were 
cultured as described. (Matzk et al., 1983). Fisher rat F344 prostatic tumor cell lines (Dunnings 
celllines. lsaacs et al., 1986) AT1, AT3, Mat-Lu and Mat-Lylu were cultured according to the 
conditions originally described. Rat 13762NF mammary carcinoma lines MtPa, MTC, MTLy, 
MTLN-2 and MTLN-3 were cultured according to the authors recommendations (Steck & 
Nicolson, 1983). All human pancreatic adenocarcinoma and carcinoma cell lines were obtained 
from the German collection of micro-organisms and cell cultures (Braunschweig, Germany) and 
maintained according to their recommendations. AR42J a rat pancreatic carcinoma cell line was 
maintained in RPMI1640 medium supplemented with 10 % Fetal calf serum and antibiotics. 
MTW9B and MT 450, a non-metastasising and metastasising rat mammary carcinoma cell lines 
respectively, were both maintained in DMEM medium supplemented with 10 % fetal calf 
serum and antibiotics. 
Cell culture 
All cells were maintained at 37 oc in an incubator (Forma Scientific, Labotect GmbH, 
Göttingen) in 5% C02 and 95 % air humidity. All cells were grown in petri dishes (Greiner 
Labortechnik, Flikenhausen) of varying sizes depending on the application. The cells were 
allowed to grow until a confluency of 80-90 % had been reached, whereupon, the cells were 
subsequently split by trypsinization and reseeded at a lower density. 
Tyrpsin treatment of cells was performed by removal of the culture medium from the cells, 
followed by one wash with 20 ml of Ca2+ I Mg2+ free PBS (137 mM NaCI, 2.7 mM KCI, 6.5 mM 
Na2HP04 x 2 H20, 1.5 mM KH2P04). After removal of the PBS, 1.5-2.0 ml of 0.25 % trypsin 
was applied to the cells (amount depending on petri dish size) and the cells incubated at 37 
oc until cells had become detached as seen under a low-powered microscope. Fresh medium 
was then directly applied and the cells replated at the desired density in new petri dishes. 
Storage of cells was done by trypsinizing logarithmically growing cells followed by addition of 
10 ml of medium before the cells were pelleted with light centrifugation at 300 x g. The medium 
was removed and the cells resuspended in 1 ml of modified medium containing 20 % FCS, 
without antibiotics and 10% DMSO (Fiuka Chemie AG. Switzerland) and placed in a cryo-
vial. After incubation on ice for 1 hour, the cells were transferred to -80 oc for several hours 
before finally to liquid nitrogen. To re-propagate cells, the vials were removed form nitrogen 
placed at 37 oc until most of the cells had thawed. The cells were then removed and mixed 
with 10 ml of fresh medium (to remove DMSO) followed by light centrifugation, before being 
replated on petri dishes in fresh medium. 
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Stable transfection of cells 
(a) DOTAP /iposomal transfection protoco/ 
Cells used for transfection were split and reseeded 24 hours before transfection 
commenced. Usually, transfections were performed in 10 cm petri dishes containing 
approximately 2 x 106 cells, giving a confluency of 60-80 %. Transfeetion was performed 
using the liposomal transfection reagent DOTAP (Boehringer Mannheim) exactly as described 
in the protocol provided, using 8-10 11g of maxi-prep plasmid DNA per transfection. The cells 
were reseeded 24-36 hours post-transfection and placed under appropriate antibiotic selection 
to generate stable clones. After a period of 1-2 weeks, visible clones were picked and placed 
in 24 weil petri dishes and propagated further under selection until sufficient cell number had 
been reached, whereupon, the clones were expanded further in 10 cm dishes. 
ln vivo inoculation of eucaryotic cells 
Before cells were taken for in vivo experiments, they were monitared for the presence 
of mycoplasma in the medium of the growing cells. Detection was carried out according to and 
using the reagents provided in a commercial mycoplasma detection kit (Boehringer Mannheim). 
Once cells had been confirmed as negative, they were grown to about 70 % confluency, 
before being lightly trypsinized, washed once in fresh medium (to inactivate the tyrpsin) and 
twice in sterile PBS. Cells were resuspended at a density of 5 x 106 cells/ml. Male BDX-10 
rats (9-16 weeks of age) were then inoculated subcutaneously (s.c.) with 5 x 105 cells in the 
left flank before the hind leg. Measurement of tumor growth began at the point were the tumor 
was easily palatable and continued, twice weekly until the animals were sacrificed (before the 
tumor had reach a size of 5 cm in one dimension). Tumor samples and metastases of the 
lymph and lung were removed and immediately snapped-frozen in liquid nitrogen. 
Human tumor samples 
All human tumor samples and corresponding matched normal tissue were obtained with 
consent from Dr Kurt Zatloukal, Institute for Pathologie, Graz University Austria Foreach tumor 
specimen received exists a record describing the pathological staging of the sample as judged 
by histological means, sex and age of the poor barstard. 
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2.3 Analytical Methods 
Northern blot hybridisation 
Usually between 2-4 J.Lg of poly (A)+ RNA was mixed with DEPC treated bi-dest H20 
to give a final volume of 15J.LI. Tothis was added 7.5J.LI of formaldehyde denaturing buffer (50 
% crystallised formamide, 1 x MOPS, 3j.tg/ml ethidium bromide and 6.5 % formaldehyde) and 
the samples denatured at 65 oc for 10 minutes before snap-cooling the tubes on ice. To the 
denature mRNA was added 3 J.LI of 10 x RNA loading buffer (50% glycerol, 1nM EDTA and 
0.1 % bromophenol blue). The mRNA samples were then size fractionated on a 1-1.4 % 
formaldehyde/MOPS agarose gel (1-1.4 g of agarose dissolved in 79 ml of bi-dest H20 and 
allowed to cool to 60 oc before addition of 16 m! of 37 % formaldehyde and 5 ml of 20 x 
MOPS) in 1 x MOPS running buffer. Once the migration of the bromophenol blue band had 
reached the desired distance the gel was removed and the integrity of the mRNA visualised 
under 302 nm UV light source. Providing the mRNA was of sufficient quality and that no signs 
of degradation were seen, the mRNA was blotted onto Hybond W membrane (Amersham). 
For this purpese it was first necessary to incubate the gel in 5 x SSC for 30 minutes before 
the mRNA was transferred to Hybond W membrane as described by Maniatis et al. (1989) 
using 10 x SSC as the transfer buffer. Following transfer , the mRNA was covalently cross-
linked to the active OH groups in the membrane using a UV stratalinker 2400 (Stratagene, La 
Jolla, CA) 
Southern blotting of ds cDNA and PCR products 
The desired ds cDNA was loaded onto an agarose gel and run in 1 x TBE buffer until 
the DNA had migrated sufficiently as determined by visualisation under UV-Iight. The gel was 
then removed and allowed to incubate for 30 minutes in a solution of 0,4 M NaOH at RT with 
mild rocking. During this time, a blotting chamber was set up in a manor identical to that for a 
northern blot. The gel was removed and carefully laid down on 3-4 pieces of 3MM Whatman 
paper soaked in 0,4 M NaOH After ensuring no air bubbles under the gel were visible, a 
piece of Hybond N+ membrane (Amersham) was placed on top of the gel followed by one 
piece of pre-wetted (in NaOH) Whatmann. A stack of Kimwipes was placed on top and 
weighted down with a suitable weight. Blotting was allowed to continue o/n upon which the 
membrane was removed, the position of the wells marked clearly before washing the 
membrane for 5-10 minutes in 5 X SSC. Membranes were stored dry until use. 
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lmmunoblot analysis of proteins (Western blot) 
(a) Separation of profeins by polyacrylamide gel elecfrophoresis (PAGE) 
For most applications a polyacrylamide separating gel of 1 0-12 % was made and a 5 
% stacking gel. Reagents for the stacking gel were 8.3 ml of acrylamide/bis -acrylamide 
(30:0.8, Carl Roth GmbH & Co, Karlsruhe) 6.25 ot 1.5 M Tris-HCI pH 8.8, 0.125 ml of 20% 
SOS, and 10.05 ml ot H20 (for a 12 % separating gel, the amount of acrylamide/bis -
acrylamide added was 10mland the H20 reduced accordingly to give the sameend volume) 
To the mixture was added 250 111 of 10 % ammonium persulphate (APS) and the reaction 
initiated with 20 111 of TEMEO. The gel mix is poured between two glass plates with spacers 
between and allowed to polymerize. Upon completion, a stacking gel is poured on top. This 
was made up of 1.7 ml of acrylamide/bis -acrylamide, 2.5 ml of 0.5 M Tris-HCI pH 6.8, 50 111 of 
20% SOS, 5.65 ml of H20, 100111 of 10% APS and 7.51J.I of TEMEO. The gelwas then run in 
1 x Laemmli-running buffer (25 mM Tris-HCI pH 8.3, 0.2 M glycine and 0.1 % SOS) until the 
desired distance had been reached. 
(b) Preparation of profein probes 
Cells of confluency between 60-80 % in 10 cm petri dishes were washed twice in 20 
ml of fresh PBS before 0.75 ml ot Iysis-butter was added (160 mM Tris-HCI pH 6.8, 4 % 
SOS, 16% glycerol, 0.57 M ß-mercaptoethanol, and 0.005% bromophenol blue). The slurry 
was transferred to a 2 ml reaction vial and the genomic ONA sonified (Branson cell disruptor 
815. output 6) to reduce the viscosity. Before loading the samples, the proteins were 
denatured by heating for 3 minutes at 95 °C. 
(c) Coomassie blue sfaining of resolved profeins 
That part of gel that was not used for transfer was cut away and incubated with mild 
shaking for 1-2 hours in Coomassie staining solution (0.25 % Serva Blue G250, 46 % 
methanol, and 8 % acetic acid). After this the gel was destained in two steps. Firstly in 50 % 
methanol and 8 % acetic acid and then incubated in 1 0 % methanol with 7 % acetic acid until 
blue clear bands were visible. At this point, the gelwas removed, placed on whatmann paper 
and vacuum dried. 
( d) Elecfrophorefic fransfer of resolved profeins onfo membrane and 
subsequent antibody detection 
The section of gel containing proteins ot interest was isolated and a piece of pre-
soaked (in methanol) Immobilenmembrane (Millipore, type PVOF) placed on top of the gel and 
the proteins transferred in 25 mM Tris-HCI pH 8.3, 250 mM glycine, 20 % methanol using a 
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BioRad Trans-Blot Cell transfer chamber. Transfer was usually carried out at 350 mA for 4- 16 
hours. Once complete, the membrane was incubated for 30 minutes with in blocking buffer (1 0 
% low-fat milk in PBS with 0.3 % Tween 20) to reduce unspecific binding of the antibodies to 
the membrane. For detection, the membrane was further incubated in fresh blocking buffer 
containing the appropriate primary antibody (usually, at a dilution of 1:500 to 1 :10,000) for one 
hour. After extensive washing in PBS/0.3 % Tween 20, the membrane was incubated again 
in blocking buffer containing a 1 :3000 dilution of a peroxidase-coupled secondary antibody 
(anti-rabbit or anti mouse depending on the primary Ab used). Once the membrane had been 
washed in PBS/0.3 % Tween 20, detection of specific proteins was achieved by enhanced 
chemifluoresence using Amersham ECL westarn blotting detection reagents following the 
manufactures recommended guidelines. 
lmmunoprecipitation of proteins 
For the immunoprecipitation of cytosolic proteins, cells were grown to 60-80 % 
confluency in 10 cm dishes, washed once in ice-cold PBS before lysing the cells on ice with 1 
ml of lyses buffer ( Na Cl 150 mM, Tris-HCI pH 7.4 30 mM, EDTA 1.0 mM, Triton X1 00 0.5 %, 
Na-deoxycholate 0.5 %, PMSF 1 mM, Aproptinin 1 11Vml (1 0 mg/ml), Leupeptin 1 f.ll/ml (1 0 
mg/ml). After a 10 minute incubation cells were scraped together. To the lysed cell mix was 
added either 30 111 of protein A-sepharose ( if a rabbit antisera is used) or 30 111 of protein-G 
agarose (if a murine monclonal antibody is used). The entire mix was rotated at room 
temperature for 2 hours before being washed 3 times with 600 111 of Iysis buffer. The 
immunoprecipitation reaction was the washed once with 50 mM Tris-HCI, pH 7.4, 10 mM 
EDTA, briefly centrifuged and the supernatant removed and kept for analysis. To the pelleted 
product 50 111 of sample buffer was added, heated to 1 00 oc followed by a short centrifugation 
and reheating to 100 °C. The reaction is then loaded on a SOS-PAGE gel of appropriate 
percentage. 
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3.RESULTS 
PART ONE 
3.1 The Model System 
The rational for using a cellline system as compared to a direct subtraction between a 
specific human tumortype and its matched normal tissue rests on the fact that tumor material is 
limited and the quality of RNA transcripts cannot be guaranteed. Moreover, a tumor represents 
an additional Ievei of complexity due to the presence of other cell types in the tumor mass 
(e.g., infiltrating leucocytes). Furthermore, tumor cell population is composed of multiple 
heterogeneaus cells. When subtracted against normal tissue, there is considerable risk that 
many potential differentially expressed clones are not derived from the tumor cells, but 
represent transcripts originating from other cell types. 
As described in the introduction, the model system chosen for the generation of a subtracted 
library and the subsequent isolation of differentially expressed genes, was a pancreatic 
adenocarcinoma cell line system (Bsp73) composed of a parental line and two sub-lines of 
increasing metastatic potencies. Bsp73 arose spontaneously in 1979 (Matzku et al., 1983) as 
intraperitoneal nodules tagether with ascites. Histologically, the nodules were classified as 
adenocarcinoma of the pancreas and through serial transplantation of ascites cells to a s.c. site, 
two variants appeared being Bsp73 (AS) non-metastasizing and Bsp73 (ASML) 
metastasizing. The AS cell line form solid tumors when inoculated subcutaneously (s.c) the 
cells actively invade neighbouring normal tissue, but do not form metastases in distant organs. 
The ASML line when inoculated only form rather loose accumulation of tumor cells but rapidly 
start to colonize in the ipsilateral region lymph nodes, spreading then through the lymphatic 
system to finally form numerous metastases in the lung. When inoculated intravenously, both 
tumor cell types develop nodules in the lung which in turn results in metastases to other 
organs (Knierim et al., 1986b; Paweletz et al., 1986). Other than their metastatic potencies, the 
two cell lines also differ in other respects such as morphology, adherence characteristics, 
sensitivity to trypsinization amongst others (Weling. et al., 1985; Knierim et al., 1986a; Paku et 
al., 1986; Raz et al., 1986). As mentioned in the introduction, Günthert et al. (1991) could show 
that a specific variant form of the cell surface glycoprotein CD44 was necessary and sufficient 
to promote metastases upon transfection into non-metastatic Bsp73-AS recipient cells. Further-
mors the in vivo effects of transfected variant CD44 could be abolished by antibodies directed 
against the variant. What is also evidently clear is that the requirement of CD44 in metastasis 
is not absolute. That is, the functional relevance of CD44 for metastasis is apparent for some 
tumor ceU types such as Bsp73-ASML (Günthert et al., 1991) but not for other cancer types, 
such as endometrial cancer (Tokumo et al., 1998). lt is therefore likely many other genetic 
dysregulations in ASML cells that predispose them to a metastatic phenotype. The isolation 
and identification of these "other'' genetic alterations in respect to the metastatic cellline Bsp73-
ASML became the primary aim of my work. 
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3.2 Confirmation of the Metastatic Potential of the Bsp73 Cell 
Lines 
As a !arge part of the project centred in the systematic isolation of genes whose up-
regulation coincided with a metastatic phenotype, it was foremost that the cell system chosen 
responded in vivo as previously described (Matzku et al., 1983). Forthis purpese all celllines 
used were passaged in male BD 1 0 rats. 
The rat pancreatic adenocarcinoma cell lines Bsp73-1AS (1AS), Bsp73-10AS (10AS) and 
Bsp73-ASML (ASML) were reported to form local tumors at the site of injection when 
inoculated subcutaneously (s.c.) in syngeneic rats (Paweletz et al., 1982). ln this series, the 
1 AS represented the non-metastatic parental cell line from which the other two are derived 
subclones of differing metastatic competence. They are therefore isogenic in origin. The 1 OAS 
gives rise to a low number of lung and lymph metastases, whereas the ASML is highly 
metastatic, producing secondary neoplasms in lymph and lung tissue. All cell lines were 
inoculated s.c. into male BD 10 rats (eight animals per line) and their growth rates recorded 
based on relative tumor volume. Figura 3, indicates the growth rates of the cell lines plotted as 
tumor volume against time. What is evident from the graph is that the relative growth rates of 
the primary tumor shows an inverse correlation to metastatic capacity of the cell line. 
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Figure 3. Relative in vivo growth rates of three isogenic pancreatic adenocarcinoma cell 
lines. The lAS cellline is non-metastatic in syngeneic rats. lOAS is of low metastatic capacity, and the ASML 
line is highly metastatic. 5 x 105 cells in sterile PBS were injected s.c. in BD 10 male rats and measurements 
taken twice weekly until sacrificed. Tumor volumes were calculated and have been plotted as a function of time. 
This is in accordance with original observations made (Matzku et al., 1983), describing the in 
vivo characterisation of these celllines, namely the non-metastatic being the fastest growing. 
The 1 AS produced tumors of comparable volume to ASML, however in half the time period 
required for ASML. Measurements are depicted after day 14 post-injection (point at which 
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tumorwas measurable). Upon dissection of the animals, the Bsp73-1ASML cell line gives rise 
to multiple metastases (through the lymphatic and venous routes) in both lymph and lung 
tissues. These in vivo data demonstrates that the metastatic properties of the Bsp73 cell 
system are as expected in that they have not altered their intrinsic metastatic capacity and 
confirm the original Observationsmade with these celllines (Matzku et al., 1983). 
3.3 Subtractive Suppression Hybridization (SSH) 
The art of obtaining differentially expressed clones from a cell or tissue system has 
been a much pursued avenue of research. This is reflected by the large number of 
documented methods that now exists enabling such aims to be achieved. However, no 
method is infallible as they all have some intrinsic Iimitation that must be taken into 
consideration. One particular method (Diatchenko et al, 1996) seemed to offer a high degree of 
sensitivity over other existing methods, and is composed of a normalisation step coupled with 
a PCR enrichment step that would enable the isolation of the majority of differentially 
expressed transcripts, irrespective of their initial relative abundance in a given system. The 
method is known as Subtractive Suppression Hybridization (SSH) and functions in the 
following manner. 
lt starts with the two populations of mRNAs that are to be subtracted (see figure 4). The 
"Driver'' is defined as the population of mRNAs that will be eliminated during subtraction 
whereas the "Tester'' population of mRNAs contains, in addition, the differentially expressed 
genes of interest. Both mRNA populations are reversely transcribed, producing double-
stranded (ds) cDNA that are then restricted with a four-base recognition endonuclease Rsal 
(cuts theoretically every 256 bp). This ensures that the majority of cDNAs have an average 
length of 200-800 bp which in turn aids hybridization of compatible strands as the complexity 
has been reduced via the restriction. At this point, the "Driver'' cDNA population requires no 
further modification. 
The cDNA originating from the "Tester'' population is split into two equal aliquots, and Iigated to 
two different linkers to produce two sub-populations that differ only in their respective linkers. 
These two sub-populations are subsequently denatured and each separately hybridized in 
the presence of a 30-fold excess of "Driver cDNA". This step is critical as it normalizes the 
cDNA populations originating from the driver and the tester mRNA, and thereby prevents over-
representation in a library. That is, a transcript whose initial abundance is high in relation to the 
driver, has a high probability of hybridizing to compatible driver sequences such that the 
concentration of single stranded cDNA ofthat gene is reduced. Conversely, a transcript of low 
initial abundance will not readily hybridize to compatible driver sequences (as the probabi!ity 
is proportional to the initial concentration) thereby the concentration of single-stranded cDNA 
will remain largely unchanged. So in effect the high abundant differentially expressed cDNAs 
are reduced in concentration, and those of low abundant differentially expressed cDNAs are 
unchanged.After the normalization, both hybridizations are pooled and hybridized again to a 
51 
Results 
30-fold excess of denatured driver (note: only the driver is denatured). From the first 
hybridization only the remaining single-stranded cDNA can form hybrids with complementary 
sequences derived from the driver. Those cDNAs that do not have complementary sequences 
in the driverwill anneal to complementary tester sequences instead. lt is exactly these hybrids 
( one strand from the tester sub-population with one type of adaptor annealed to a 
complementary strand from the other tester sub-population with the other adaptor) that form 
the bases of subtraction as they are the only form of hybrid capable of exponential 
amplification with two different primers that are complementary to the two different linkers used. 
Figure 4. Schematic 
diagrame of SSH and how 
it functions Upon isolation of 
poly (At RNA from the non-
metastatic and metastatic cell 
lines, cDNA is made and restricted 
such that the average length of 
cDNAs is reduced. For the non-
metastatic cDNAs no further steps 
are required. cDNAs derived from 
the metastatic line are split into 
two pools, each of which receives 
a specific but different adaptor 
(depicted as black and green ends 
of cDNA molecules). The red bars 
indicate sequences that are specific 
to the metastatic cellline whereas, 
the blue bars indicate unspecific 
sequences present in both cell 
lines (e.g., GAPDH). Upon 
hybridization with an excess of 
driver cDNAs, unspecific 
sequences from the metastatic line 
anneal to complementary 
unspecific sequences derived from 
the non-metastatic cell line 
(indicated by the double-stranded 
blue cDNA molecules). Specific 
sequences find no complementary 
partner and remain single-stranded 
(shown by the two red bars). 
During the last hybridization step 
these two red cDNAs will anneal 
together (providing they represent 
complementary strands of the 
same cDNA) to produce a double-
stranded cDNA molecule, having 
having a different adaptor sequenced on 
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either end (shown as double red bars). These molecules are subsequently exponentially amplified through PCR 
using a primer pair that anneals to the two adaptor sequences. 
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Suppression of PCR amplification occurs with those hybrids that have the same linker on 
either end of the single-stranded cDNA molecule due to the internal sequence complementarity 
(inverted terminal repeats). During each primer annealing step, the hybridization kinetics 
strongly favour (due in part to the fact that the adaptor is twice the nucleotide length as that of 
the primer) the formation of a pan-like structure (see figure 5) that prevents successful primer 
annealing and thereby, the template is not amplified. Should a primer anneal the newly 
amplified template will contain again the inverted tandem repeats so a pan-structure is again 
possible. Thus, during the course of PCR, non-specific amplification is efficiently suppressed 
while amplification of specific sequences having different adaptors at both ends precedes as 
normal. 
The net out come is selective amplification and enrichment of cDNAs that originate from the 
tester population only. The differentially expressed cDNAs are then be subsequently cloned 
into a suitable vector cloning system such that a library is constructed that now contains an 
enriched proportion of cDNAs derived from the tester population. 
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Figure 5. Suppression PCR. (Siebert et al., 1995). 
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(A) If primer anneals to one of the complementary sequences (adaptor) present on each end of the ss cDNA 
molecule, and is extended through the action of the Taq polymerase, such that the resulting double stranded cDNA 
molecule (B) has now also inverted terminal repeats (as in the case for the original template (A)). Upon the 
denaturing cycle of a PCR protocol, the two strands dissociate and during the annealing step form a pan-like 
structure (C) thereby preventing the successful annealing of a much shorter primer sequence. In this fashion such 
template amplification is suppressed, Consequently, only the amplification of single-stranded DNA templates, 
having two different adaptors on their ends is possible as no inverted repeats are present to form the pan structure. 
In the SSH protocol, these can only originate from the tester population. 
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Despite the low number or reports that have utilized this method (due in part to the technical 
demands) it has nevertheless, when coupled with a sensitive screening protocol, proven to 
be extremely versatile and powerful were identification of differentially expressed genes is 
required (von Stein et al., 1997). 
3.4 Generation and subtraction efficiency monitaring of the 
Bsp73-1 AS/ASML subtractive library 
The construction of the subtractive library was performed as outlined in the methods 
section. Prior to screening the library it was of utmost importance to monitor the Ievei of 
efficiency of subtraction between the two celllines. This is done by monitaring the depletion of 
a transcript (negative control) that displays no differential expression pattern between the two 
cell lines (e.g., usually the common housekeeping gene, GAPDH). The retention and 
subsequent enrichment of a gene whose expression is exclusive to the metastasizing cell line 
(positive control) can be determined assuming prior knowledge of such a gene. ln the Bsp73 
system it had been previously shown that the urokinase type plasminogen activator gene 
(uPA) was expressed in the ASML cell line (Hofmann, Ph.D thesis 1991 ), showing no 
detectable expression in the 1 AS cell line 
Library Control 
Un-sub Sub Un-sub Sub Kbp 
1.1 
0.9 
0.6 
0.3 
0.27 
0.2 
Figure 6. Efficiency monitoring of subtraction ("experimental test with deliberate 
contamination of plasmid specific sequences"). 
Lanes denoted as "un-sub" depict PCR amplified cDNAs before subtraction and those marked "sub" indicate PCR 
amplified cDNAs after subtraction. In the case of the control, a mock subtraction was performed between human 
skeletal muscle cDNA against human skeletal muscle cDNA that had been previously contaminated with 100 pg 
of Hae III-digested bacteriophage 0X174 DNA. For the library, Bsp73-ASML was subtracted against Bsp73-1AS. 
The appearance of bands in the sub-lane of the control lane corresponds to the plasmid fragments used to 
contaminate the tester. Likewise, bands seen in the sub-lane of the library indicate enrichment of specific 
transcripts that are derived from the tester only. 
ln the case were no positive control is known, the appearance after subtraction of specific 
contaminating plasmid sequences can be determined. ln this respect, the contaminating 
plasmid sequences function as an internal subtraction control. ln figure 6, there is no visible 
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banding pattern in the unsubtracted lane of the control, however, after subtraction bands 
become clearly visible and represent the correct fragment sizes seen with a pure 0X174 DNA 
Hae 111 digest. lt is therefore obvious that through subtraction, there is a selective amplification 
of these plasmid sequences (as they do not exist in the driver population), with a concomitant 
reduction of background sequences. The appearance of bands seen after subtraction in the 
library is typical, the banding pattern being different to that seen in the control, and indicates 
again selective enrichment of certain sequences derived from the tester cDNA population. 
Figure 7 
GAPDH uPA 
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Figure 7. Efficiency monitoring of the lAS/ASML subtraction (using positive and 
negative controls, see Materials & Methods) 
(A) Following the nested PCR amplification (using primers complementary to the adaptors used in the initial 
subtraction) as outlined in the subtraction protocol, 200 ng of amplified ds cDNA from the tester (Bsp73-
ASML), driver (Bsp73-1AS) and subtracted cDNA (tester minus driver) was loaded in duplicate on a 1.4 % TAB 
agarose gel and transferred to Hybond-N+ membraneunder alkaline conditions. Both membranes were probed with 
32P-dCTP labelled GAPDH (mouse probe, nucleotide positions 489-723) and rat uPA, (B) and (C) respectively. 
(D) 2 !lg of poly(At RNA was size fractionated on a 1.2 % forrnaldehyde agarose gel and transferred to 
membrane. The membranewas probed with uPA as in panel (C). 
Figure 7 again demonstrates the efficiency of subtraction in the context of two specific genes. 
The negative control (panel B) indicates the presence of GAPDH in both cell populations prior 
to subtraction. However it is no Ionger detectable after subtraction indicating a very efficient 
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removal of the gene, and thereby one can assume that other sequences that also exhibit no 
differential status between the two celllines will be also efficiently removed. For the positive 
control (panel C), the uPa gene is present exclusively in the tester cDNA population, reflecting 
its true differential status as seen in direct northern analysis, (panel D). This gene and others 
of similar differential status becomes successfully enriched during the subtraction procedure. 
Consequently, there is a specific amplification for sequences originating from the tester (uPA) 
with a concomitant suppression of sequences common in both cDNA populations (GAPDH). 
After positive evaluation of subtraction efficiency, the subtracted cDNAs were cloned and 
screened as described in Materials & Methods (see also; von Stein et al. (1997). 
3.4.1 Reverse Northern Screening of the Bsp73-1 AS/ASML 
Subtracted Library 
A total of 5000 clones were picked under blue/white selection and amplified by colony 
PCR in 96 well-format before loading the amplicons via the use of a multi-channel pipette onto 
high-density gels in parallel. lt is of great importance that each gel is loaded equally such that 
potential differences identified through differential screening reflect true differences and not 
variations as a result of unequal loading. The gels were run in parallel (see figure 8) then 
transferred onto membranes under alkaline conditions. This resulted in the generation of two 
membranes each containing an identical set of clones that are subsequently used for 
differential screening. Screening takes place in the form of 32P-dCTP radiolabeled cDNAs 
derived from the tester and driver cell lines. Again, it is of importance that the ds cDNAs are 
restricted with Rsa I prior to labelling such that the fragments produced match those as cloned 
inserts. Results obtained with unrestricted probes are vastly less sensitive than those seen 
with resticted probes (data not shown). For screening, two identical membranes were 
hybridized under stringent conditions with Iabeiied ds cDNA from both tester and driver 
respectively. The membranes were then exposed and the two films superimposed to allow for 
direct comparison of like clones. Signals specific for the tester probe represent potential cDNA 
clones originating from the metastatic cell line. Conversely, like signals seen with both probes 
are obviously not differentially expressed and are ignored. ln figure 9 two identical membranes 
have been hybridized with tester and driver ds cDNAs respectively. What is immediately 
obvious is the increase in signal number seen on the filter hybridized with cDNAs derived from 
the metastatic cell line (ASML blot 2). Signals present on both membranes act as internal 
positive controls with respect to labelling efficiency, hybridization and amount of insert cDNA; 
in other words, like signals of equal intensity indicate equal conditions. All clones that are 
potential differentially expressed are marked with a straight bar and in addition, not a!l 
differential signals are of equal intensity. This may be indicative of the initialrelative abundance 
of these cDNAs within the tester population. Those clones which fail to hybridize to either 
probes may represent cDNAs whose abundance is too low and thereby falls outside the Iimit 
of sensitivity of reverse northerns. 
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Figure 8. Simultaneous 
analysis of 200 clones o n 
duplicate high-density gels. 
The above figure displays the 
appearance of the gel format used to 
screen the subtractive library. Bach 
gel has a total capacity of 200 
individual clones that can be run in 
one setting. The clones were PCR 
arnplified in 96 well-format in a total 
volume of 100 111 under the 
following cycle pararneters ( 94 °C, 
1 min, then 30 cycles of 94 °C, 20 
sec; 68 °C, 12 sec; 72 °C, 30 sec) 
using a Perkin Eimer 9600 PCR 
machine. 12 111 of arnplified product 
was loaded into each weil of a 1.2 % 
T AE agarose gel and run until the 
cDNA had rnigrated roughly half-way 
between the rows of slots. The gels 
were then alkaline blotted and probed 
as outline in Materials & Methods. 
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Equally, not all clones contain inserts (approximately 10% of clones harbour no insert as 
determined by restriction analysis of plasmid mini-prep DNA). However, reverse northern 
screening allows for the rapid high-throughput and easy detection of cDNAs that are specific to 
the metastasizing ASML cellline. lt does not, however, allow for the detection of polymorphism 
of mRNA, or indeed splice variants, or size of transcripts and it is not as sensitive as direct 
northern analysis These facts highlight the Iimitation of reverse northern screening. Reverse 
northern screening is, however, very much more reliable and has a higher sensitivity when 
compared to standard colony-lifts. Considerable time was invested in attempts to screen the 
subtracted library via colony Iifts, but due to the unacceptable high background (caused in part 
by the presence of bacterial proteins, chromosomal DNA that had adhered to the membrane) 
was not pursued further. Additionally, if the criteria for a positive signal is just signal intensity 
difference between the two probes, colanies of unequal size can often Iead to mass isolation 
of false positives. This in turn necessitates additional rounds of screening. With reverse 
northerns this is not the case. The amount of DNA can easily be monitared (see figure 8) and 
due to ist reliability, rescreening is completely unnecessary. 
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Figure 9 
Figure 9. Differential screening of amplified cDNA clones. 
Blot 1 and 2 represent identical clones probed with 32P-dCTP Iabelied cDNAs derived from Bsp73-1AS (Driver) 
and Bsp73-ASML (tester) respectively. Hybridizations were performed in Church buffer at 64 °C and the 
membranes subsequently washed once in 2 x SSC, 0.1 % SDS and twice in 0.1 x SSC, 0.1 % SDS at 65 °C. 
Exposure to film at -80 °C was up to 12 days to allow detection of those clones of lower expression status. Bars 
indicate position of clones harbouring potential differentially expressed cDNAs with respect to the rnetastasizing 
cell line. Signals common to both function as an internal control insofar as like signals of equal intensities 
indicates identical conditions. 
3.4.2 Confirmation of Differential Status by Northern Analysis 
Through reverse northern screening a total of 625 differentially expressed signals were 
identified that demonstrated expression intensities from very streng to very week (seen only 
after 10-12 days exposure to film). All positive clones were grouped and the inserts re-
amplified by colony PCR and gel purified before being Iabeiied with 32P-dCTP. Inserts were 
hybridized against poly(AtRNA derived from the non-metastatic (Bsp73-1AS), low metastatic 
(Bsp73-10AS) and the highly metastatic (Bsp73-ASML) cell lines. A selective panel of 19 
clones and a loading control (GAPDH) are shown in figure 10. 
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Figure 10. Northern analysis of a number of positively identified clones. 
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The above figure represents a selection of known and novel cDNAs identified through the subtracted library 
(panels B-U). For each blot, 4 J.Lg of poly (At RNA isolated from lAS, lOAS and ASML cell lines were loaded 
and size fractionated on a 1.2 % formaldehyde agarose gel before transfer to Hybond N+ membrane. Each blot was 
hybridized under stringent conditions with a different clone (B-U) and exposed to film (between a few hours up 
to 4 days at -80 °C). Putative clone identities are given in parenthesis. The blot indicated with an (A) represents 
GAPDH and is used as a loading control. All other probes were as follows: (B) clone# 75 (melanoma growth 
stimulatory activity); (C) clone #128 (transcript differentially expressed after nerve growth factor treatment); (D) 
clone#135 novel; (E) clone #29 novel; (F) clone #94 rat testin; (G) clone #86 novel; (H) clone #72 novel; (I) 
clone #115 (CDK4/6 inhibitor p16ink4"); (J) clone #43 HMG-1; (K) clone #18 (SrcSH3 binding protein); (L) 
clone #126 calgizzarin; (M) clone #79 (fragile X mental retardation protein 1); (N) clone #45 caveolin; (0) 
clone #62 ezrin; (P) clone #85 cMET receptor; (R) clone #91 AHNAK; (S) clone #100 novel; (T) clone #71 
novel; (U) clone #67 novel. 
lt is clear that from the panel of northerns indicated in figure 1 0, there are clones whose relative 
abundance approaches the order of "rare" transcripts (e.g., panels C, G and S) as these 
clones require a few days exposure before a signal is observed. Others clones such as 
caveolin, HMG-1 and testin (panels N, J, and F respectively) are all highly abundant in the 
metastatic cellline. Panel (L) demonstrates a clone whose expression is upregulated some 3-
fold from basal Ievel, indicating genes of moderate differential expression can also be isolated. 
That is the protocol of SSH is not biased for the isolation of differential transcripts that differ 
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dramatically between to populations, but rather allows the identification of transcripts that 
cover the whole spectrum of different initial abundances. ln conclusion, the differential 
expression profile seen with the reverse northern screening analysis reflects true differences 
as confirmed in straight northerns. A total of 70 clones were monitored for differential expression 
with respect to the metastasizing cell line ASML, four of which appeared to be false positives. 
This equates to a true positive rate from the reverse northern screening to standard northern 
analysis of over 90 %. This value also indicated that positive signals as seen through reverse 
northern analysis used to screen the library, obviously reflected to a very high percentage the 
true expression status of the clones when analysed by standard northern analysis. This 
would equate to the fact that it is probably not neceassary to screen each identified clone for 
differential expression via standard northern blots, as a differential signal with reverse northern 
screening can be considered as being truely differential. 
3.4.3 Sequence ldentity of lsolated Differentially Expressed 
Clones 
From all clones identified as being potential differentially expressed, plasmid DNA was 
isolated and the inserts sequenced. A !arge proportion of sequencing was done commercially 
(4 base Iabs GmbH Reutlingen), and the obtained sequences edited to remove flanking vector 
sequences before blasting them through a number of public sequence data bases via the 
internet (Ebeling & Suhai, 1997; Altschul et al., 1997). Retrieved matches were analysed on 
the strength of homology and a table constructed that depicts either the true identity (homology 
> 94 % to known rat sequences), putative human homologous (homology;::: 56% to known 
human genes) or novel sequences (homology s 56 % to any call). Sequencing analysis 
indicated that the initial 625 cloned cDNAs represented 126 individual cDNA fragments. Their 
identity, strength of match, redundancy and size in bp is given in table 1. 
The accession number listed for most clones represents the data base identifier for the 
sequence that exhibited highest homology to the query sequence. Homology is given as a 
percentage identical match over the entire length of the query sequence. lt should however be 
noted that the highest match does not mean closest identity as all searches were performed 
initially using the nucleotide sequence and not the translated protein sequence, which is 
generally more sensitive (Henikoff & Henikoff, 1994; Henikoff et al., 1998). Therefore those 
matches were the homology is questionable, the suggested identity should be only regarded 
as an indication. ln cases were the matched homology is high > 90 % then the identity is 
probable (matched to rat), relatively high to high homology to a mouse or human sequence 
may indicate a rat homologue, but not necessarily. Lower homology 60-80 % might indicate a 
new family member. lf the returned matches are low the clone could be novel. Additionally, 
some of the clones identified are too short to allow a match of any certainty possible, moreover 
clones that lie in the untranslated regions may be mistaken for novel. 
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The redundancy for each clones is listed and provides an indication to relative abundance in 
the initial subtracted library. For example, caveolin (clone# 45) was represented by 47 clones 
from an initial 5000 screened. This equates to a redundancy of 0.9 % in the original library. 
However, from all clones identified as being potential differentially expressed (625) caveolin 
represents a redundancy of 7.5 %. So there is a small degree of redundancy for a number of 
clones but it is marginal and indicates respectively that the normalization step in SSH (e.g., the 
first hybridization) had worked with high efficiency (Gurskaya et al., 1996; Bonaldo et al., 
1996). 
Table 1 
Clone Accession.# Size % ID over bp Red Identity/ 
(bp) highest homology 
001 121 no EST 2 novel 
002 gb:M33534/gb:M590 193 95%, 183bp 2 5' I 3' LTR, NICER 
element (R) 
003 123 no EST 2 novel 
004 gb:X82180 161 78.3%, 143bp 1 ribosomal protein L4 (R) 
006 131 no EST 1 novel 
007 gb:U16741 201 95.9%, 172bp 3 capping protein, alpha 2 
subunit (M) 
008 gb:U72141 204 83.8%, 142bp multiple exostoses 2 gene 
EXT2(M) 
009 102 no EST 1 novel 
010 EST (M) gb:AA168416 124 88.1 %, 118bp 1 novel 
Oll 126 no EST 1 novel 
013 gb:L10377 294 88%, 283bp 2 clone CTG-B37 (H) 
014 270 no EST 4 novel 
015 92 no EST 1 novel 
018 gb:U92478 259 92.7%, 259bp 22 SrcSH3 binding protein (M) 
(2 separate clusters) 
021 84 noEST 1 novel 
022 EST (H) gb:W01116 251 77.6%, 161bp 6 novel 
023 EST (H) gb:AA304806 447 91 %, 276bp 2 novel 
024 122 noEST 1 novel 
025 emb:X59993 192 93.8%, 113bp 1 probable Zinc finger protein (R) 
026 EST (M) gb:AA09131 44 86%, 44bp 2 novel 
029 EST (M) gb:AA62735 161 83.1%, 169bp 8 novel 
031 102 noEST 1 novel 
032 EST (M) gb:AA124683 541 83.4%, 381bp 2 novel 
033 242 noEST 7 novel 
034 dbj:AB001349 210 98%, 210bp 3' UTR 3 steroidogenic acute regulatory 
protein (R) 
035 dbj:D63477 174 65.4%, 174bp 13 KIAA0143 (H) 
036 105 noEST 1 novel 
037 gb:U83411 155 83.9%, 155bp 1 carboxypeptidase Z (H) 
038 gb:L13039/X66871 50 100%, 50bp 1 annexinii/calpactin I heavy 
chain (R) 
040 91 noEST novel 
041 emb:Y00345 223 97%, 223bp 1 polyA binding protein (H) 
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Clone Accession.# Size % ID over bp Red Identity/ 
(bp) highest homology 
042 EST (M) gb:AA409131 498 86.7%, 330bp 3 novel 
043 emb:X62875 66 100%, 66bp 3' UTR 42 high mobility protein I (R) 
044 emb:Xl3835 181 99%, 174bp 1 calmodulin II (R) 
045 gb:U32114 454 85%, 426bp 47 caveolin-2 (H) 
046 EST (R) gb: H32003 197 97%, 153bp 1 transcript diff. expressed after 
nerve growth factor treatment 
048 gb:Z19552 256 97%, 253bp Topoisomerase II (R) 
049 247 noEST 1 novel 
051 EST (H) gb:T91167 221 79.8%, 198bp 1 novel 
052 104 noEST 12 novel 
054 dbj:D88313 148 96.6%, 148bp raplB (R) 
gb:X08004 92.6%, 148bp rap1B (H) 
ras-like GTP exchange 
factor 
056 gb:X81059 65 98.5%, 65bp 1 TEX-271, protein phosphatase 
gb:L76702 89.2%,65bp 2A (M) 
B56 delta (H) 
057 EST gb:AA161810 (M) 255 90.7%, 108bp 1 novel 
gb:T10577 (H) 78.8%, 156bp 
058 gb:X03212 46 82.6%, 46bp 1 keratin-7 Type li (H) 
059 gb:M86564 159 91.3%, 161bp 1 alpha-prothymosin (R) 
gb:M14630 87.6%, 16lbp alpha-prothymosin (H) 
060 gb:D14695 115 87.9%, 99bp 1 KIAA0025 gene (H) 
061 gb:M76124 242 76.8%, 142bp 3 EPG314 precursor (M) 
gb:M26481 67.4%, 141bp KS 114 antigen (H) 
062 gb:X60671 135 92.6%, 135bp 2 ezrin (M)/ (2 separate clusters) 
063 EST (H) gb:AA186686 228 76%, 91bp novel 
065 gb:S72008 256 89%, 264bp 1 CDClO homolog (H) 
gb:U08103 74%, 171bp D. melanogaster peanut 
066 137 noEST 1 novel 
067 265 noEST 6 novel 
068 gb:M92340 84 82.9%, 82bp 1 gp 130/IL-6 signal transducer 
protein (R) 
069 gb:D84068 309 95.9%, 293bp 2 0-Acetyl GD3 ganglioside 
gb:U58516 73.4%, 293bp synthase (R) 
breast epithelial Ag B46 (H) 
070 96 no EST 1 novel 
071 165 noEST 2 novel 
072 EST (M) gb:AA426984 129 91%, 61bp 6 novel 
073 EST (H) gb:R13346 64 87%, 64bp 1 novel 
075 emb:Xl2510 316 69.4%, 186bp 3 melanoma growth stimulatory 
gb:M57731 activity (H) 3'UTR 
076 emb:X74215 90 81%, 90bp Lon-like protease (H) 
077 EST (H) dbj:D62588 228 90.4%, 228bp 1 novel 
078 gb:M10068 83 100%, 83bp 1 NADPH cytochrome P450 
reductase (R) 
079 emb:X90875 217 96.3%, 217bp 1 fragile X mental retardation 
protein 1 (M) 
080 EST (M) gb:AA162657 172 97%, 172bp 1 novel 
081 EST (M) gb:AA033067 95 92.3%, 91bp novel 
082 EST (M) gb:AA174699 243 95%, 243bp 2 novel 
62 
Results 
Clone Accession.# Size % ID over bp Red Identity/ 
(bp) highest homology 
083 emb:Z63378 125 77.1%, 83bp 1 cpG island DNA fragment (H) 
64.5% amino acid id.with 
unknown ORF 
084 gb:U00594 193 75.9%, 195bp 41 TGF-beta regulated transcript 1 
(TRTl), 
gb:T84080 66.2%, 183bp Mustela vison human EST 
(3 separate clusters) 
085 gb:U65007 269 97.4%, 269bp 5 hepatocyte growth factor (R) 
(2 separate clusters) 
086 EST (H) gb:AA075872 233 67 .3%, 220bp 12 novel 
087 gb:U30877 148 71%, 141 Urechis caupo cathepsin B-like 
protease 
088 EST (M) gb:AA032965 179 72.7%, 154bp novel 
091 gb:M80899 221 86.9%, 221bp 1 AHNAK, desmoyokin (H) 
093 gb:X95082 88 92.1%, 89bp 2 parathyroid hormone regulated 
sequence (R) 
094 gb:x78989 240 90.6%, 234bp 25 testin 2 (M) (3 separatre clusters) 
095 252 no EST 2 novel 
096 286 no EST 1 novel 
097 gb:M74067 131 96.2%, 131bp 1 RAT ORF induced by androgen 
withdraw1 and apoptotic cell 
death (R) 
098 gb:X65651 131 99.2%, 131bp 1 uPA (R) 
099 109 noEST novel 
100 EST (M) gb:W11916 272 81.8%, 279bp 3 novel 
101 81 noEST 1 novel 
102 emb:X51538 96 95%, 96bp 1 ribosemal protein S24 (R) 
103 gb:U31867 108 92%, 88bp 3 Tclone 15, calcycline (R) 
gb:X52278 84%, 100bp calcycline (M) 
104 60 no EST 1 novel 
106 60 no EST 1 novel 
107 emb:V00680 60 96.7%, 60bp 1 mitochondrion 16S ribosemal 
RNA (R) 
108 gb:M69055 55 92.6&, 54bp 3' 1 Insulin-like growth factor 
UTR binding protein (R) 
109 gb:M19967 228 99%, 228bp 19 calpactinii!lipocortini 
emb:X05908 85%, 228bp 
110 gb:M63482 118 96%, 116bp 2 cytokeratin 8 (R) 
111 81 noEST novel 
112 gb:U05341 153 97.7%, 131bp 2 p55CDC (R) 
113 101 no EST 1 novel 
114 gb:D85904 234 90.3%, 237bp apg-2 (rel. to HSP 110) (M) 
gb:L12723 85.8%, 232bp hest shock protein 70 (H) 
115 gb:L76150 149 88.6%, 146bp CDK4/6 inhibitor p16ink4a (M) 
116 gb:M19635 78 96.4%, 56bp 1 large subunit ribosemal protein 
L36a(R) 
117 gb:X97443 216 97.7%, 216bp 2 Tmp-21 (R) 
gb:X97442 87.9%, 215bp Tmp-21 (H) /transmembrane 
protein 
119 EST (H) gb:AA374085 211 80.5%, 149bp 1 novel 
121 gb:X14671 270 98.1 %, 258bp 2 ribosemal protein L26 (R) 
122 81 no EST 3 novel 
125 EST (M) gb:AA214794 167 81%' 82bp 3' 1 novel 
63 
Results 
Clone Accession.# Size % ID over bp Red ldentity/ 
(bp) highest homology 
126 gb:U41341 106 94%, 55bp endothelial monocyte-activating 
gb:D38583 75.2%, 105bp polypep.I (M) calgizzarin (H) 
127 EST (M) gb:AA254302 218 90.8%, 142bp novel 
EST (R) gb:H32315 204 97%, 195 bp transcript diff. expressed 
after nerve growth factor 
treatment 
129 EST 245 novel 
gb:W55478 (M) 100%, 104bp 
gb:R71504 (H) 90%, 105bp 
130 EST (M) gb:W89336 290 94%, 152bp 1 novel, Zn-finger motif (partial)? 
131 EST (M) gb:AA143958 109 81.5%, 86bp 1 novel 
132 EST (M) gb:AA102862 164 80.2%, 164bp novel 
133 gb:D10729 106 95.3%, 106bp proteasome subunit RCI (R) 
134 76 noEST novel 
135 290 no EST 2 novel 
136 49 no EST novel 
137 288 noEST 1 novel 
138 gb:W89336 243 40% aa id. 1 Protein motif found in yeast 
50% aa id. with GCS1, GL03, human 
KIAA0041 KIAA0041 and KIAA0167 
139 gb:M24361 100 98.0%, 100bp 1 pyruvate Ieinase (R) 
140 131 noEST I novel 
141 gb:L38644 183 98.4%, 183bp karyopherin beta (R) 
142 107 noEST novel 
144 131 noEST 2 novel 
145 gb:M84340 268 87.1%, 272bp IL-10 (within intron sequence) 
(M) 
147 175 no EST 1 novel 
148 gb:U59289 33 81.5%, 27bp 1 h-Cadherin (H) 
60%, 10 aa 
151 EST (H) gb:AA354227 106 79.2%, 125bp novel 
152 EST (R) gb:H34895 145 93.7%, 127bp 3 novel 
Table 1. Key: (R) Rat, (M) mouse, (H) human, EST expressed sequence tag. 
The number of each respective clone is listed in the left-most coloumn. Accesion numbers are coded identifiers 
for a particular sequence that allow these sequences to be addressed dirctly from the public data bases. The 
percentage identity is given tagether with length of nucleotide match of the clone. Redundancy (Red) indicates 
how many times an identical cDNA fragment was isolated from the subtracted library and clones identified 
numerous times reflect those that were highly overexpressed as seen on direct northem analysis (for exarnple, 
clone # 43 and 45). The identity of each clone is given as the mostprobable identity and in some cases it is not 
possible to know whether a particular clone is novel or not, just based low homology, particularly across 
species. Note: the table depicts 152 gene fragments or clones when the stated number is 126. This is because 
some clones upon closer inspection represented the same target gene and were removed. The result is a Iist of 
clones numbered 1-152, with numbers missing, representing those clones removed (e.g., there is no clones with 
numbers 5,12,16,17 etc) 
Had the normalization procedure not been included then the proportion of abundant 
differentially expressed transcripts would have been over-represented in the library and may 
have masked those transcripts of low abundance. 
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ln table 2 are the overall statistics of the library as determined by sequence homology to 
known genes deposited in public data bases. Sequences that exhibited homology greater 
than 94% were classified as being identical (as a 6% difference is araund the expected Iimit 
of of errors generated by automated sequencing). Those sequences were the homology has 
been ranged between 56-86 % are classified as homologues. This range is arbitary as the 
border-line of homology, between a homologue or new family gene member to a novel 
sequence cannot be known. Therefore sequences that have homologiss less than 50 % have 
been catagorized as novel. lt is also of importance how the homology is desplayed and how 
many nucleotides are involved. 
Table 2 
Subtractive Library Analysis 
A 625 clones representing a total of 126 genes 
Periectlnear periect Homologues to known 
match > 94 % id h/m genes 56-86 % id No match. Novel 
Individual 23 genes 69 59 
Total Nr of 
cDNA clones 
92 281 253 
Total% of 
clones 15 44 40 
Total% of 
genes 15 46 39 
Number of genes represented 
B by 'X' number of clones 
'X' 2 3-5 6-1 0 11-20 21-40 41+ 
genes 44 22 18 13 7 2 3 
Table 2. (a) Statistical sequence analysis of 625 cloned cDNAs identified in the Bsp73-
1AS/ ASML subtracted library. Clones were grouped according to their degree of homology to matched 
target sequences from the data bases. (b) The identified genes are group according to the number of times picked. 
For example, 44 genes were isolated each as a single clone, 22 genes were pick twice only etc. Key h (human), 
m (murine). 
A high match consisting of a block of nucleotides with no homology on either side might indicate 
the presence of a homologaus domain, but is otherwise novel. Conversely, a reasonable (50-
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60 %) match over the entire length of the sequence in question to a human sequence may 
indicate the homologue or might be indeed novel. So the distinction between known and novel 
is often a very fine line and should be regarded as so. 
What is apparant from table 2 (A) is that the !arge. majority of clones, being 44 % and 40 % 
represented homologues and novel sequences respectively, with only a small proportion 
exhibiting perfect of near perfect match. (B) Many individual genes were identified by one 
clone only (being 44 genes, see figure 11) and therefore may indicate that the screening of 
5000 clones maybe under-representative of the complexity of the library. That is, the point at 
which no further addition of new genes (identified by picking more clones) had not been 
reached. As most genes were represented by one clone suggests the presence of more 
potential differentially expressed genes. Had all genes been picked more than 2-3 times each 
would indicate saturation and that the number of clones analysed exceeded the number of 
differentially expressed genes present in the library. Nevertheless, the analysis of 5,000 
clones would approach the upper Iimit of such a library and that doubling the number to 10,000 
may only bring a few additional clones. 
Figure 11 
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Figure 11. The above graph indicates the relative number of individual cDNAs against a given number of times 
picked (e.g., how many times each genewas picked), from the library. 
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Figure 12. Majority of clones were picked in the range from >2 times to <40 times as depicted in the graph 
above 
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On the other end of the scale are those genes which were picked more than 40 times, such as 
clone# 45 (caveolin). ln the library were a total of 3 such genes (see table 1) and this over-
representation reflected their high abundant status as seen by northern analysis (see panel N, 
figure 1 0). A large proportion of genes were picked once only ( see figure 11) and the number 
of inidividual genes represented by two of more picked clones progressively decreased until a 
pointwas reached were 40 or more clones represented only one gene. Conversely, most 
clones were picked in the order of more than twice but less than 30 times as depicted in figure 
12. The positive control for subtraction was as mentioned the uPA gene. This in the library 
was represented by one clone only but nevertheless was identified despite it's low 
abundance in the ASML line. By logical inference, genes of relatively high initial abundance in 
the ASML line will be represented by more than one clone as appose to those of lower 
abundance (e.g., uPA). However the finding that the positive control gene uPA was identified 
by one clone speaks for the fact that the reverse northern screening is sensitive enough to 
detect genes of low differential expression. 
3.4.4 cDNA Subtraction of Bsp73 AS versus ASML ldentifies 
Known Tumor Progression Genes 
Despite the fact that nearly half of the genes isolated were novel (based on the 
assumptions previously stated) or exist as ESTs, many genes identified through subtraction 
were reported tobe associated with or even play a functional role in tumor progression. This in 
itself stands as proof of concept in that as a metastatic cell line was subtracted against a non-
metastatic line, then it stands to reason that the differences must at least to some degree 
dictate the phenotype. Over 20 genes identified from the subtracted library are documented to 
be directly or indirectly involved in tumor progression. Some weil known examples are given in 
table 3. Hepatocyte growth factor receptor (c-MetR) as been documented to be expressed in 
human prostatic cancers (Kurimoto et al., 1998) and in addition has been shown to induce an 
motogenic-invasive phenotype (Giordano et al., 1993). The urokinase type plasminogen 
activator (uPA) gene is overexpressed in a number of human tumors (reviewed by Duffy et al, 
1990) and together with its inhibitor PAI has become a prognostic indicator in a number of 
malignancies, including breast (Jänicke et al., 1993). Table 3 above depicts some of the 
identified genes obtained from the subtracted library that are (A) functionally described in tumor 
progression and (B) only associated in the development of certain tumors but the functional 
role remains largely unknown. Nevertheless it indicates without any doubt that this subtractive 
approach produces an inventory of known genes involved in tumor progression and novel 
genesthat are possibiy invoived, and that potentially reflect the the genetic program mediating 
malignant properties of Bsp73-ASML cells. 
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(A) 
Clone# 
38 
85 
98 
108 
115 
126 
(8) 
Clone# 
08 
43 
50 
69 
79 
94 
103 
Table 3 
ldentity 
Annexin II 
c-Met receptor 
uPA 
IGF-binding protein 
CDK4/6 ink4a 
Calgizzerin 
ldentity 
EXT2 
High mobil prot I 
IAP 
alpha Prothymosin 
FRX prot I 
Testin 
Calcyclin 
Reference 
Nygaard et al., 1998 
Di Renzo et al., 1995 
Ferno et al., 1995 
Gill et al., 1997 
Pomerantz et al., 1998 
Tanaka et al., 1995 
Reference 
Hecht et al., 1997 
Xiang et al., 1997 
Wang et al., 1997 
Wu et al., 1997 
Fulchlgnoni-Lataudt 
et al., 1997 
Kondoh et al., 1997 
Berta et al., 1997 
Results 
ln other words, using SSH, known genes of clear documented function in cancer progression 
have been isolated as one might expect, however in addition, novel genesthat may represent 
putative new tumor progression markers have also been identified. This in itself stands as 
proof of concept in that SSH as a tabulated method is able to isolate from a specific tumor cell 
system (or indeed any system) a defined set of genes of known relevance in tumor 
progression. 
3.4.5 Functional Classification of ldentified Genes 
From the sequence identity of the known clones (see table 1) one can group them 
according to their functional roles in eucaryotic cells. This provides an overview concerning the 
dysregulation of certain functional classes of genes that accompanies a metastatic phenotype 
as depicted in figure 13. For every group listed in the pia chart, exists molecules that fall into 
these catagories which are also functionally involved in tumor progression. The functional 
groups are however not absolute as there is considerable overlap and many proteins have 
multiple functions. However it serves as a guide and a number of examples of isolated genes 
from the subtracted library that fall into these groups are given. Without question most of the 
cDNA clones from the subtracted library fall into the first three catagories, namely novel, 
existing as ESTs, or genes with ill defined functions (segments 1,2 and 3 respectively). The 
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next largest group (group 4) covers those molecules involved in cytoskeletal organization and 
transduction of signals from cell surface receptors to various cytoskeletal components. Such 
cellular components would be required for cell motility. For example, cytokeratin 8 (clone# 11 0), 
identified as being overexpressed in the metastasizing line, is reported in transfection studies 
to increase the invasive potential and migratory behavior of recipiant human melanoma cells as 
determined in vitro gelatin migration assays (Chu et al., 1996). Group 5 covering growth factor 
receptors relates to a !arge group of molecules, many of which have been implicated in tumor 
progression. For example hepatocyte growth factor receptor (c-MetR) has been associated 
with tumor progression in different human carcinomas. lt is overexpressed in osteosarcomas 
suggesting a role for the met proto-oncogene in the pathogenesis of this tumortype (Scotlandi, 
et al., 1997). ln human gastric carcinomas c-Met overexpression is also observed (Kuniyasu 
et al., 1993}. lncreased Ieveis of annexin II are observed in various cancer cells and tissues, 
and the molecule has been proposedas a marker of malignancy in vivo (Nygaard et al., 1998). 
Figure 13. Categoric 
grouping of clones. The pia 
chart indicates the functional 
grouping of all 126 individual 
cDNAs identified as being 
upgerulated with respect to the 
metastasizing cell line Bsp73-
ASML and have been grouped 
according to their documented 
function. Values depict percetages 
of clones that fall into the 14 
functional catagories listed. The 
groups are as follows: (1) Novel; 
(2) ESTs; (3) Known identity 
but function not clear; ( 4) 
Cytoskeletal associated molecules 
and intermediate filaments; ( 5) 
Growth factor receptors/growth 
factors; ( 6) Intracellular 
signaHing molecules; (7) 
Proteins of metabolic function; 
(8) Ribosomal proteins; (9) 
Cell cycle regulatory proteins; 
( 10) Transcription factors/ 
modulators; (11) Proteases; 
(12) Adhesion molecules; ( 13) 
Proteins involved in DNA 
replication/ stability and 
topology; and (14) Transposahle 
elements. 
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Annexin, a calcium-dependent, phospholipid binding protein 
involved in calcium signalling belongs to group 6 depicted in 
the pia-chart and was also isolated from the subtracted 
library. Proteins involved in cell cycle regulation (group 9) 
such as the cyclins have been weil documented in 
tumorigenesis. The cyclin 01 protein is found tobe amplified 
and is a reliable prognostic factor and post-translational 
modification of this gene may play a functionally important role in development of primary 
esophageal cancer (lnomata et al., 1998). Ovarexpression of cyclin E protein has been 
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reporied in several solid tu mors (Porter et ai., 1997) and in acute myelogenous leukemia (AML; 
lida et al., 1997). Clone # 65, a rat homologue of the yeast protein CDC1 0 encodes a 
component of the DSC1 Sp/MBF transcription complex, which is required for cell-cycle 
regulated expression at G1-S of several genes via cis-acting MCB (Miul cell cycle box) 
elements (Mclnerny et al., 1995). This clone is overexpressed in the metastasizing line and 
might therefore be responsible for the activation of certain genes which might of otherwise 
remained at a basel Ievei and consequently affect cell cycle. An interesting finding is clone # 
115, identified as p161NK4a (inhibitor of CDK4). This tumor suppressor protein represents one 
of the most direct links between cell-cycle control and cancer. The p161NK4a gene is frequently 
inactivated in human tumors, and inheritance of mutant alleles results in susceptibility to 
several types of cancer (reviewed by Serrano, 1997). lnactivation of p161NK4A in tumors 
expressing wild-type Rb is thought to be required in order for many malignant cell types to 
enter S phase efficiently or to escape senescence (Shapiro et al., 1998). This gene is 
inactivated by intragenic mutation or by homozygous deletion in almest 1 00 % of all pancreatic 
cancers (Schutte et al., 1997) but is overexpressed in the Bsp73-ASML pancreatic metastatic 
cellline. This might suggest that the overexpression of p16 might be the result of a dominant 
negative mutant that inadvertantly confers growth advantages to the ASML cells. Lastly, 
group 14 that covers transposable elements is also of interest. Intraeistemal A-Particle (IAP) 
sequences are endogenaus retrovirus-like mobile elements, present in the mouse genome. 
These elements transpese in a replicative manner via an RNA intermediate and its reverse 
transcription. Blumenstein et al. (1998) found that FDC-P1 cells undergo leukemic 
transformation when injected into sublethally irradiated DBA/2 mice. Transformation was related 
to Intraeistemal A-type particles (IAP) aberrant activation of growth-regulatory genes b y 
insertion of IAP genomes. ln c-myc transgensie mice IAPs are upregulated (Dupressoir & 
Heidmann, 1997) indicating that c-myc might regulate transcriptional status of IAPs which inturn 
could activate other downstream genes depending on their intergration site. So it is evident that 
many of the genes isolated do possess functions that may contribute to the manifestation of 
tumorigenesis or tumor progression. 
3.5 ldentification of subtracted genes in other cell systems 
Now that a Iist comprising of 126 individual differentially expressed genes that 
accompanies the metastatic phenotype of the Bsp73-ASML cellline had been defined, came 
the inherent problern that the shear number of clones prohibited functional analysis. That is, to 
functionally elude the role of each gene in the context of a metastatic phenotype by either 
overexpression or antisense studies would be an astronomical task and is not feasable. That 
some of the isolated genes play a significant role in the tumorigenic process is highly likely, 
however there exists no suitable experimental setting that allows the independent functional 
analysis of so many genes, such that the important players can be rapidly identified. What 
remains is correlation as the coordinated action of more than one gene might be required and 
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this is difficult to address in single cDNA transfection experiments. ln this context, correlation is 
the expression of certain sets of genes that accompanies a given characteristic trait in a 
defined system or in more than one system. The identified genes from the subtracted library 
correlate to the expression differences between a non-metastatic cell line and one that is able 
to metastasize, yet are these differences also typical in other cell line systems that comprise of 
celllines of differing metastatic potencies? 
ln other words, does the correlation extend to metastatic cell lines of different tumor progression 
models? This question is based on the asumption that general expression programs underly 
metastasis or, at least a limited number of such metastatic expression programs exist. To 
answer this question would identify those genes whose overexpression is seen in other cell 
line systems and therefore the likelihood of that particular gene, being of any functional 
relavance, would increase. These genes would represent promising candidates in this respect 
because their overexpression is not limited to just the one cellline system from were they were 
originally identified, but was rather more general concerning the metastatic potential in other 
tumor progression model system. 
3.5.1 Reverse Northern Screeing ldentifies Common Genes in 
other Tumor Progression Cell Systems 
ln order to reduce the large initial number of genes to a smaller number of more 
potentially valuable genes, required the analysis of correlation in other systems. Three other 
rat tumor progression models were chosen for this purpose, two originating from the mammary 
gland and the third from the prostate. ln addition, cross hybridization to human cDNAs was 
also addressed by generating cDNA probes from three human pancreatic adenocarcinoma cell 
lines PATU-8902 (Elsässer et al., 1993), PATU-8988s (Elsässer et al., 1992), and CAPAN-1 
(Kyriazis et al., 1986) and two human pancreatic carcinoma lines HUP-T3 and HUP-T4 
(Nishimura et al., 1993). Their tumorigenicity in nude mice has only been reported for PATU-
8902 (Elsässer et al., 1993) and for CAPAN-1 (Kyriazis et al., 1986). 
All differentially expressed clones from the Bsp73-1AS/ASML library were re-isolated, 
amplified by colony PCR and membranes constructed each containing a complete set. These 
membranes were subsequently screened in reverse northern fashion against three rat 
tumorigenic celllines systems originating from the protate and mammary as mentioned above. 
By screening in this manner it was possible to analyses the expression profiles of all clones 
simultaneously in each cellline used. The prostatic cell system (lsaacs et al., 1986) comprises 
of four tumorigenic celllines of differeing in vivo metatstatic potencies. The AT.1 line produces 
no metastases upon inoculation into Fisher F344 rats; whereas the AT.3 subline is moderately 
metastatic. Matlu and Matlylu both metastasize preferencially to the lymph and lung/lymph 
respectively. Concerning one mammary cell line system (Nicolson et al., 1988b; Nicoloson et 
al., 1988c) the parental line MTPa was reported not to metastasize in vivo whereas MTC 
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exhibts none to low metastatic potential. The lines MTLN-2, MTLN-3 and MTL Y were all 
demonstrated to produce metastases to varying degrees (Nicoloson et al., 1988b). 
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Figure 14a. Expression profile of clones indentified as novel, having ESTs or whose 
function is ill-defined. 
From each cellline indicated, poly (At RNA was isolated, ds cDNA synthesized and the cDNA restricted with 
Rsa I before labelling with 32P-dCTP. For probes obtained from rat celllines, hybridization conditions were as 
described for standard reverse northem screening. Conceming cDNAs derived from human lines the hybridization 
stringency was reduced (hybridization performed at 52 °C in Church buffer with subsequent washing steps of 
twice in 2 X SSC, 0.1 % SDS and once in 1 X SSC, 0.1 % SDS at 54 °C) in order to detect clones of 
homology. The colour intensity indicates expression level ofthat particular clone seen in the different cell lines. 
Dark red depicts highest expression, light red lowest and absence of colour no expression. The respective clone 
numbers are listed on the left. Cell Iines are Iisted on top. (-), (-/+ ), ( ++ ), and ( +++) indicates the metastatic 
potential of the cell lines, being non-metastatic, non-to-low metastatic, moderately metastatic, and highly 
metastatic respectively. 
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Figure 14b. The three blocks blue, green and brown shows expression profiles of the listed 
clones (see numbers left of figure) in all cell lines. 
The large blue block covers clones in the following functional groups: Cytoskeletal associated molecules, growth 
factor receptors/growth factors, intracellular signalling molecules, and transcription factors/modulators. The green 
block covers clones of metabolic function, ribosemal proteins, cell cycle regulatory proteins, and protases. The 
brown coloured block indicates clones of adhesion molecules, proteins involved in DNA 
replication/stability/topology, and transposable elements. Again, darkest colour indicates strengest expression, 
lightest colour lowest expression and no colour no detectable expression at the reverse norther Ievel. The 
respective clone numbers are listed on the left. Cell lines are listed on top. (-), ( -1+ ), ( ++ ), and ( +++) indicates 
the metastatic potential of the cell lines, being non-metastatic, non-to-low metastatic, moderately metastatic, and 
highly metastatic respectively. 
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The other mammary cellline system composed of just two lines MTW9B (non-metastatic) and 
MT450 (metastatic) were a kind gift from Prof. U. Kim (Kim & Depowski, 1975). Reverse 
northerns were performed with all cell lines and the intensity of positive signals graded 
according to the signal strength. The signal intensity gives an indication as to the relative 
abundance of that clone in a population of complex cDNAs against other positive clones that 
show significantly weaker signals. The results of such a screening are shown in figures 14a/b. 
From the reverse northern screening of all celllines depicted in figures 14a/b (see top of figure), 
clones that were identified as positive were noted and are shown as the numbers on the left of 
the figures. The colour intensity serves as a indication of expression Ievei of that particular 
clone with respect to others, that is the strongest signal was taken as 1 00 % and correlates to 
the strongest colour. Weak colouring is indicative of weak expression and those boxes that are 
white represent no detectable expression. 
From figures 14a/b there are a number of clones that on the reverse northern Ievei appear to 
be cerrelative in that their expression was also seen in other cell lines of differing tissue origin 
and metastatic competence. About 13 clones were positive for differential expression in the 
two rat tumor progression models and are listed in table 4 (their identity is given in table 1 ). 
Concerning the human cDNAs, reverse northern analysis (see figures 14a/b) showed that a 
large proportion of clones cross-hybridized to the human cDNAs. Moreover, many clones 
demonstrated differential expression across the five human pancreatic cell lines, that is some 
clones were only expressed in some of the human celllines and not in others (see figure 14a, 
clones 10, 119 and 122), however only three of the 13 rat clones, defined as differentially 
expressed in both a rat mammary and a rat prostatic tumor progression model, cross-
hybridized to the human cDNAs. 
So by simply addressing the question of correlation in other cell line systems through reverse 
northern screening, the original number of differentially expressed clones identified from the 
subtraction between Bsp73-1AS and Bsp73-ASML, being 126, has now been reduced to 
approximately 13. That is, 13 clones exhibit differential expression in two independent cell line 
systems. One could therefore speculate that these clones represent potential candidates 
concerning tumor progression markers as their dysregulation is not limited to the pancreatic 
system from which they were derived. ln addition, three of these clones (clones 25, 62 and 
11 0) could be of potential value as they also cross-hybridized to human cDNAs indicating the 
possible presence of a human homologue for clone 25 (novel with putative homology to a 
zinc-finger protein). Clones 62, and 110 are ezrin and cytokeratin 8 respectively. 
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Table 4 
Clone Differential Expression Differential Expression Cross-Hybridization 
Number Prostatic system Mammary system to Human Gell Lines 
23 yes slightly no 
25 yes yes yes (in alllines) 
38 yes no no 
43 yes yes no 
46 yes yes no 
62* · yes yes yes (in PATU-8988s) 
75 yes (weakly) yes no 
82 yes no no 
85* yes yes (weakly) no 
100 yes slightly no 
110 yes yes yes (not in HUP-T 4) 
147* yes no no 
148 veryweak no no 
Table 4. Expression of Bsp73-1AS/ASML subtracted clones in other progression models 
and cross hybridization to human tumor cell lines. The list of clones in the table above depicts those 
that demoostrate differential expression at the reverse northern level in the two rat tumor progression model 
systems. In addition, cross-hybridization of these particular clones to human tumorigenic celllines is shown. The 
asterics (*) indicates that differentialexpressionwas seen with direct northern analysis only. 
3.5.2 Direct Northern Analysis Prooves Cerrelative Expression of 
Subtracted Clones 
As these 13 clones were identified again by reverse northern screening it was 
nevertheless important to determine their expression directly at the rnRNA Ievei as gradual 
differential expression Ieveis between cell lines is hard to determine in reverse northern 
analysis. Direct northern analysis is moresensitive and provides additional information (e.g., 
transcript size). For this purpese the clones were hybridized to membranes containing 
poly(At RNA isolated from all celllines present in the three cell systems as is shown in figures 
15-17.From figure 15, the differential status of all clones is clearly visable with respect to the 
three cell line systems used to determine the extent of correlation. For additional comparison 
three genes that have been described as tumor markers or tumor progression markers, 
respective!y, were also analysed. Firstly, c-Met (identified in the subtracted library) was 
analysed for cerrelative expression is a classical receptor tyrosine kinase involved in cellular 
motility and invasiveness (Giordano et al., 1993) and can even confer invasive properties to 
recipient normal cells (Rong et al., 1994). 
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Figure 15. Comparison of expression profiles of novel genes and known tumor associated 
molecules in cell line systems of differing metastatic potential. The lAS and ASML lines 
represent the celllines from which the subtraction was made. From the prostatic cell lines, AT.l does not 
metastasize in vivo, whereas AT.3, MatLu and MatLyLu are all capable of producing metastases in vivo, 
MatLyLu being the most potent. In the mammary celllines, MTPa also shows no metastatic phenotype in vivo, 
MTC exhibits non-to-low metastatic potency, whereas MTLY is highly metastatic. MTLN-2 and MTLN-3 are 
both metastatic, the latter having a somewhat greater potential. For northern analysis, 3 J..lg of poly (At RNA 
was taken per cell line and run on 1.2 % agarose/formaldehyde gels in multiples such that all clones could be 
hybridized each to a seperate membrane. Clone fragments were amplified by PCR. Conditions of cycling were 94 
°C, 1 minute, then 30 cycles of: 94 °C, 20 sec; 68 °C, 12 sec; 72 °C 30 sec. Products were gel purified before 
extraction from the gel using DNAeasy (Biozyme). Approximalely, 25-50 ng was used for labeHing and 
hybridization was carried out under stringent conditions at 64 °C in Church buffer. Membranes were washed once 
in 2 X SSC, 0.1 % SCS and twice in 0.1 X SSC, 0.1 % SDS at 65 °C. 
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Secondly, uPAR genewas also analysed for correlation as its overexpression is an important 
factor in tumor progression (see introduction, section 1.3.5 part (B)) and as it also represents a 
gene not identified through the subtracted library. Lastly, the gene HMG-1 was analysed for 
cerrelative expression. lt has only been demonstrated to be associated with tumors 
(Chiappetta, et Ia., 1995) but was identified many times in the library. While it is clear that c-
Met shows pronounced differential expression in the pancreatic lines, it is only weakly 
detected in the prostatic line Matlu. Likewise there is only weak expression in the MTL Y and 
MTLN-31ines both of which are very metastatic. For uPAR there is clear expression in both the 
ASML and MTL Y (both highly metastatic) lines, however, in the prostatic system there is even 
a reduction of expression from the transition of non-metastatic (AT .1) to a metastatic line 
(AT.3). This for a gene of classical tumor progression status is somewhat surprising. HMG1 
{clone # 43) by centrast shows clearly differential expression in all systems conerning 
metastatic potentialandin this respect shows a better profile. The case for cytokeratin 8 (clone 
# 11 0) is the same were again there is very pronounced differential expression in both the 
pancreatic and mammary systems. ln the prostatic lines there is an obvious increase of some 
2-3 fold between AT.1 and AT.3. With respect to the novel clones shown (clones 23, 82 and 
100), their differential status is extremely streng for the ASML line and for clones 23 and 100 
there is clear differetial expression in both mammary and prostatic cell lines of metastatic 
capacity. This classifies them with respect to expression profile equivalent to c-Met and even 
better than uPAR (which does not exhibit increased expression in the prostatic cell lines 
capable of metastasizing). The expression picture of uPAR is more similar tothat of clone# 82, 
being only cerrelative in two systems. 
The northern analysis of a further four novel clones is shown in figure 16. Here again there is a 
perfect correlation of expression with metastatic capacity as is seen clearly with novel clone 
(clone# 46). ls clearly not expressed in the two non-malignant lines AT.1 and MTPa, but is 
present in those lines highly capable of producing metastases namely AT.3 Matlylu and 
MTL Y. The signal is not as defined as those seen with other clones but the expression pattern 
is obvious and represents a possible candidate gene in tumor progression. 
So already it is becoming evident that the subtraction between a non-metastatic cell line and 
its metastatic counterpart identifies clones like for example clones 23 , 100 and 46 (see figures 
15 and 16 respectively) that under the criteria of differential expression in other metastatic cell 
line systems, are as good if not better than the known tumor progression genes, as for 
example c-Met and uPAR. 
Clones 75 and 148 both exhibit differential expression (as might be expected) in the 
pancreatic ASML line and additionally in the prostatic AT.3 and Matlu lines (both metastatic), 
with no detectable expression in the corresponding non-metastatic lines. Both clone 75 and 
148 exhibit very weak expression in MTC and MTC/MTL Y respectively. Clone 147 apart 
from being expressed in the ASML line is also upregulated in MTL Y by some 5-6 fold but 
shows no change in mRNA Ieveis in the prostatic cell system. ln general these four clones 
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have an all tagether weaker expression status in any of the rat tumor progression cell line 
systems, as compared to those clones depicted in figure 15, whereby all showed significantly 
strenger expression. They therefore represented a class of abundant differentially expressed 
clones, and those seen in figure indicate a class of clones of lower differential abundance. 
Figure 16 
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Figure 16. Direct northern analysis of four clones identified as being differentially 
expressed at the reverse northern Ievel. The four listed clones previously identified as being 
differentially expressed detennined through reverse northem analysis, were checked for differential expression 
against the celllines listed on top of the figure. For northem analysis, 3 J.!g of poly (At RNA was taken per cell 
line and run on 1.2 % agarose/formaldehyde gels in multiples such that all clones could be hybridized each to a 
seperate membrane. Clone fragments were amplified by PCR. Conditions of cycling were 94 °C, 1 minute, then 
30 cycles of: 94 °C, 20 sec; 68 °C, 12 sec; 72 °C 30 sec. Products were gel purified before extraction from the 
gel using DNAeasy (Biozyme). Approximalely, 25-50 ng of PCR amplified probe was used for labeHing and 
hybridization was carried out under stringent conditions at 64 °C in Church buffer. Membranes were washed once 
in 2 X SSC, 0.1 % SCS and twice in 0.1 X SSC, 0.1 % SDS at 65 °C. 
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Figure 17 shows the results for the last two clones that were identified by reverse northern 
analysis as being upregulated in the metastasizing lines in more than one cell system. The 
novel clone 25 (see figure 17) depicts a differential expression pattern that would reflect a 
putative gene believed to be involved in tumor progression. lt shows expression in every cell 
line in all three cell systems that is capable of producing metastases in vivo and is not 
detectable in the corresponding benign tumor lines. ln this regard it represents a model clone 
candidate that potentially might be involved in tumor progression and would certainly warrent 
further investigation. 
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Figure 17. Northern analysis of two clones in three indipendent cell line systems. Clone # 
25 and 38 were monitared for their expression pattern in the celllines indicated. For northern analysis, 3 IJg of 
poly (At RNA was taken per cell line and run on 1.2 % agarose/formaldehyde gels in multiples such that all 
clones could be hybridized each to a seperate membrane. Clonefragments were amplified by PCR. Conditions of 
cycling were 94 °C, 1 minute, then 30 cycles of: 94 °C, 20 sec; 68 °C, 12 sec; 72 °C 30 sec. Products were gel 
purified before extraction from the gel using DNAeasy (Biozyme). Approximalely, 25-50 ng of probe was used 
for labelling and hybridization was carried out under stringent conditions at 64 °C in Church buffer. Membranes 
were washed once in 2 X SSC, 0.1 % SCS and twice in 0.1 X SSC, 0.1 % SDS at 65 °C. 
Annexin II, clone 38 showsalso to a convincing degree differential expression in two from three 
cell systems being the pancreatic and mammary. ln the prostatic cell lines, there is a noted 
reduction from the transition of the non-metastatic line (AT.1) to the metastatic line (AT.3), 
however it's expression is seen also in the two metastatic lines Matlu and Matlylu. ln the 
five cell lines from the mammary system there is a steady increase in expression from a basel 
Ievei (MTPa) to a 5-6 fold induction (MTL Y) that correlates with the transition from a non-
meatstatic line to one of high metastatic potency. 
in regard of the results frorn the northern analysis of the 13 target clones, it is clear that many of 
them share an expression pattern equal in match and in a number of cases better than known 
tumour progression markers such as the two included. lt would therefore seem reasonable to 
assume that some of these clones may indeed represent possible novel markers or be of 
significant importance in the progression of cancer. Moreover, these northern data also indicate 
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that not only those genes that have a high initial differential abundance are isolated but indeed 
also those of low differential abundance (compare figures 15 and 16). 
After the obvious success of identifing which clones from the original Bsp73-1AS/ASML 
subtraction fullfilled the criteria of cerrelative expression in two indipendent rat cellline systems, 
and therefore might be of potential importance, the question was extended further to consider 
which of the 126 clones originally defined in the subtraction are also differentially expressed in 
human tumor material. That is, while correlation in the rat systems allows identification of the 
best clones for functional analysis, cross-hybridization to human cDNAs aims at rapidly 
identifying clones that may potentially act as markers for clinical use. 
3.5.3 ldentification of Subtracted Clones Expressed in Human 
Tumors 
ln an identical manner to that used in the reverse northern screening with the different 
cell lines, human adenocarcinomas of stomach and colon origin were taken together with their 
corresponding matched normal tissue and screened in reverse northern fashion against all 
clones. Under these conditions it was necessary to reduce the stringency of hybridization and 
subsequent washing steps such that human sequences representing possible homologs of 
the metastases associated rat clones are not lost. After suitable exposure, positive clones 
were identified as those clones that were positive only to the human tumor cDNAs. The results 
of such a reverse northern are shown in figure 18. What is obvious is that filters that received 
probes derived from normal tissues (those marked N) show to a high degree the same positive 
clones, in particular the three most prominent ones, indeed these clones are expressed in all 
cDNA populations and therefore are suitable as internal contols This sort of mimicy is seen 
also with both tumor probes in that there is a high degree of overlap between positive clones, 
regardless of the fact that the tissue origin of the tumors is different. This is perhaps not 
surprising if one consideres that the subtracted library represents by definition enriched genes 
that are indicative of a metastatic phenotype in a rat cellline system. ln other words, clones 
that are positive for the tumor probes might reflect Subpopulations of cells in the human tumor 
that are "on their way" to metastasize. The identity of positive clones as seen with the tumor 
specific cDNAs only is given in table 5. For the majority of those clones listed of known 
identity, there exists documented evidence of an associated role in human tumor progression, 
and a number have been directly linked to tumor progression. Moreover, many clones seen 
positive with human tumor specific cDNAs were also identified as being expressen in many rat 
tumorigenic cellline systems (e.g., clone 38, (annexin II); clone 43, (HMG-1), clone 25 and 46, 
(novels) see figures 15-17). lnterestingly clone 85 identified as c-Met receptor from the original 
library was not detected in the reverse northern screenings of the tumor samples despite its 
documented role in tumor progression (Di Renzo et al., 1995; Schmidt et al., 1997). 
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Figure 18. Reverse Northern 
Screening of Human Tumors. 
Approximately 0.5 J.Lg of poly (At 
RNA, isolated from a human colon 
and stomach adenocarcinoma (TU) 
and their corresponding matched 
normal tissue (N), was reverse 
transcribed to ds cDNA and rescricted 
with Rsa I. Some 50 ng of the cut 
cDNA was 32P-dCTP labeled and 
used to probe two identical sets of 
differential clones previously 
identified from the subtracted library. 
Arrows on the tumor (Tu) 
membranes indicate clones habouring 
inserts that are only expressed in the 
tumor samples. The three strong 
signals seen with both normal tissue 
probes act as internal controls as 
they are also expressed in the tumor 
samples. Equal intensity of these 
clones indicates equal conditions. 
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The bar shown in "35743 Tu-
Colon" highlights a sequence of 
clones (Nrs.125-144) that are not 
detected in normal colon tissue, 
(the two arrows) show the two 
most prominant signals. 
Hybridizations were performed in 
Church buffer at a reduced 
temperature of 52 °C and 
membranes were washed once in 2 
X SSC, 0.1 % SDS, and twice in 
0.1 X SSC, 0.1% SDS at 50 °C. 
The reduced stringency of 
hybridization and subsequent 
washing would allow for detection 
of clones that cross-hybridized 
with human cDNAs thus 
identifying possible homologs. 
Films were exposed for 3 days at -
80 °C before developing. 
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This could be due to its low abundance of expression as is seen in northern analysis of this 
gene in rat tumorigenic celllines (see figure 15), but a moreplausible explanation is the low 
degree of homology seen between human and that of rat (56 % at the nucleotide Ievei 
according to sequence alignments from the public data bases). This fact demonstrates the 
Iimitation of reverse northern screening concerning the identification of putative human 
homologues from a predefined panel of subtracted clones originating from a different species 
such as the rat. 
Colon adenocarcinoma 
Sampie 35743/97-Tu vs N 
Clone number Identity 
2 NICER element 
7 alpha capping-prot 
10 Novel 
14 Novel 
25 Novel 
38 Annexin li 
41 Poly (A) binding-prot 
43 HMG-1 
44 Calmodulin II 
46 Novel 
48 Topoisamerase 
51 Novel 
59 alpha-prothromyosin 
79 FRX-prot 
90 Topoelastin 
99 Novel 
101 Novel 
110 Cytokeatin 8 
115 p16ink4a 
117 Tmp-21 
119 Novel 
122 Novel 
128 Novel 
132 Novel 
146 Novel 
151 Novel 
Table 3 
Stomach adenocarcinoma 
Sampie 61664/96-Tu vs N 
Clone number Identity 
1 Novel 
2 NICER element 
14 Novel 
25 Novel 
27 Ganglioside synthase 
32 Novel 
44 Calmodulin 
45 Caveolin 
46 Novel 
51 Novel 
57 Novel 
59 alpha-prothromyosin 
65 CDClO 
87 Cathepsin B-like prot 
91 AHNAK 
97 Apop protein 
99 Novel 
110 Cytokeratin 8 
115 p16ink4a 
117 Tmp-21 
119 Novel 
121 Ribo protein L 26 
128 Novel 
132 Novel 
139 Pyruvate kinase 
141 Karyopherin-ß 
144 Novel 
146 Novel 
Tabel 5. Sequence identity of Bsp73-1AS/ASML subtracted clones that cross-hybridize 
with human tumor specific cDNAs. Two types of human adenocarcinomas were screened through reverse 
northern analysis against the defined set of subtracted clones to identify those that cross-hybridized. Clones that 
failed tobe detected with cDNA probes derived from the normal tissue, but were positive for the tumor specific 
cDNAs were regarded as positive. Clone numbers in bold-case indicate those that are seen in both tumor types. 
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ln light of all facts stated, it is clear that the isolation of known human tumor progression or 
associated genes and indeed even novel genes that hold potential as being putative new 
markers, can be readily identified from a subtracted library that is generated not from human 
tissue material but rather from a rat cell line system. ln others words, the identification of novel 
human genes that are specifically expressed in human tumors identified through a rat 
subtracted library proves that such an approach is highly valid. 
Through reverse northern analysis the initial high number of differentially expressed clones 
was reduced to 13 concerning correlation in other rat tumor progression models, and to over 35 
when these genes were monitared for expression in human tumor samples only. To address 
the human functional relevance of these genes in the context of tumor progression is difficult, 
due to the shear number of potential clones. Rather studies should be directed to those clones 
that on the one hand exhibit differential expression in various rat tumor model systems, yet on 
the other hand are also expressed (upregulated or exclusively) in human tumor material. 
Through the large amount of information gained by reverse nothern screening of the original 
subtracted clones with cDNAs of rat and human origin, a number of clones did fit the criteria 
mentioned above. One such clone was chosen for functional analysis as it exhibited an 
expression profile typical to the model clone 25 (see figure 17), being expressed only in 
metastatic competent cells and in additionwas also expressed in human tumor material (see 
table 5). This clone (clone # 62) was identified as Ezrin and it's putative function concerning 
tumor progression was addressed and the results are given in part two. 
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PART TWO 
3.6 Functional Analysis of Rat Full Length Ezrin in the Bsp73 
Model System · 
Ezrin was first characterised as a minor component of intestinal brush border microvilli 
(Bratscher, 1983). Other related proteins were subsequently identified in various actin-based 
cytoskeletal structures. These included a 75 kD protein called cytovillin (Pakkanen et al., 1987}, 
and a p81 protein from A 431 human epidermoid carcinoma cells (Hunter & Cooper, 1981; 
Bratscher, 1989). Through numerous immunological studies and cDNA sequencing have now 
established that ezrin, cytovillin and p81 are the same protein. Ezrin belongs to the 
ezrin/radixin/moesin (ERM) protein family and homologues are found in various species. The 
sequence of their amino-terminal halves is highly conserved ( -80 % identity for any pair in 
mouse or for any pair in human). When the amino and carboxy-terminal halves of ezrin were 
transfected into cultured fibroblasts, they were targeted to the plasma membrane and actin-
filament bundles respectively (Arpin et al., 1994). This indicated that ERM proteins may 
function as plasma membrane actin filament cross-linkers. Depletion of individual ERM proteins 
by antisense oligonucleotides has provided direct evidence for their roles in vivo. (Takeuchi et 
al., 1994). Conversely, forced expression of ERM proteins has also profound effects. For 
example, transfection of ezrin cDNA into normal NIH3T3 firbroblasts resulted in lost of contact 
inhibition demonstrating its involvement in pathways that negatively regulate contact inhibition 
(Kaul et al., 1996}. Transfeetion into (NK)-resistant cells induces sensitivity to NK cells through 
the redistribution of ICAM-2 molecules (Helander et al., 1996}. 
Moreover, transfection of a truncated ezrin lacking the amino-terminal portion binds with high 
affinity to actin-filaments under physiological conditions (Turunen et al., 1994). The binding of 
native full length ezrin to actin filaments has not been established under physiological 
conditions. Conversely, at physiological ionic strength, full length ERM proteins have a very 
low affinity to the cytoplasmic domain of CD44 in vitro, whereas, the amino-terminal portions 
bind to CD44 with high affinity (Hirao et al., 1996). These findings led to the proposal of an 
intramolecular head-to-tail association model for ERM proteins, the amino- and carboxy-terminal 
portians may mutually suppress each other's function, namely membrane- and actin-binding 
respectively. This motion was supported by the observation that the effects of forced 
expression of the carboxy-terminal half of ezrin in CHO cells (namely the production of 
numerous thin processes) could be completely abolished by Co-expression of just the amino-
portion of ezrin (Martin et al., 1995}. 
Perhaps the most interesting observations concerning ezrin, certainly in the context of the work 
described in this thesis, is its putative role as a mediater of signal transduction events from 
certain receptor tyrosine kinases. Krieg and Hunter. (1992) reported the high and transient 
phosphorylation of ezrin in human epidermoid carcinoma cells upon epidermal growth factor 
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stimulation. They further mapped the phosphorylation sites to tyrosines 145 and 353. Some 
three years later, it was shown that hepatocyte growth factor/scatter factor (HGF/SF) a 
cytokine known to regulate motility, morphogenesis and growth of cells, stimulated the tyrosine 
phosphorylation of ezrin in human colon epithelial cells. Upon Stimulation, ezrin translocated to 
areas of ruffled membrane, an effect that was abolished by genistein, a tyrosine kinase 
inhibitor, suggesting that ezrin plays a key role in HGF/SF induced membrane ruffling (Jiang et 
al., 1995). Most recently, it was demonstrated that ezrin was crucial to HGF-induced 
morphogenesis in a polarized kidney-derived epithelial cell line. Forced expression of wild-type 
ezrin in these cells enhanced their motogenic and tubulogenesis formation upon HGF 
stimulation. Furthermore, a truncated form of ezrin (amino-terminal portion) when expressed 
impairs the effects of HGF on these cells, thus suggesting a dominant-negative mechanism of 
action. Site-directed mutagenesis of ezrin at codons Y145 and Y353 (known phosphorylation 
target sites) also perturbs the motogenic and morphogenic responses to HGF (Crepaldi et al., 
1997). 
Together these data implicates ezrin as a down-stream effector molecule of the c-Met receptor 
and that by removing endogenaus functional ezrin ablates both motogenic and morphogenic 
responses induced by HGF. 
3.6.1 Full Length Cloning of Rat Ezrin From the ASML Cell Line 
and the Generation of a Dominant Negative Mutant Form of Ezrin 
Through the subtraction analysis of the Bsp73-AS system, c-Met was found to b y 
highly upregulated in the metastasizing ASML line (see figure 10 panel P). This also proved to 
be the case for ezrin (see figure 10, panel 0). Based on the Observations made concerning 
ezrin as a possible mediater of both motogenic and morphogenic responses induced by HGF 
(Jiang et al., 1995; Crepaldi et al., 1997), and based on the fact that both these genes are 
highly differential expressed in the ASML line, the tentative assumption was draw that 
deliberate ablation of endogenaus ezrin function (by a dominate negative mechanism) in the 
ASML cellline could have functional consequences concerning the ability of ASML's in vivo 
metastatic potential. This seemed reasonable as c-Met is known to induce a motogenic-
invasive rather than a proliferative program (Giordano et al., 1993), and any interference of c-
Met function by targeting a known down-stream effector molecule, such as ezrin could affect 
the potential metastatic spread in vivo. Moreover it is a more simple task to ablate a signal 
transduction pathway by the selective inactivation of one particular component in that 
pathway, than it is to reconstruct a signal pathway where multiple components may be 
required. That is to say it is technically easier to block signal events from the c-Met receptor b y 
inactivation of ezrin in ASML cells and monitor a reduction of metastatic potential, than it is to 
reconstruct c-Met signalling in the 1 AS cells where multiple components would be required in 
order to increase the metastatic potential. As ezrin was identified as being differentially 
expressed in ASML through subtraction, the question addressing whether ezrin exhibited 
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differential expression in the two rat tumor progression model systems used in the analysis of 
correlation (see section 3.5.2} was raised. Forthis purpese direct northern analysed of ezrin 
expression in all the cell lines of the two model systems was performed as is shown in figure 
19. The northern data clearly shows that there is considerable overexpression of ezrin in those 
lines of metastatic capacity with little or no expression in the non-metastatic lines (1AS, MTPA 
and AT.1}. 
Figure 19 
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Figure 19. Direct northern analysis of ezrin in three rat tumor progression model systems. 
Approximately 3 J..Lg of poly(At RNA was isolated from alllines and size fractionated on an 1.2 % formaldehyde 
agarase gel before transfer to membrane. The membranes were then hybridized with a probe specific for ezrin. 
Hybridization of membranes were performed in Church bufferat 64 °C followed by washing once in 2 X SSC, 
0.1 % SDS and twice in 0.1 X SSC, 0.1 % SDS at 65 °C. Exposure to film was for 1 day at -80 °C. 
The degree of differential expression of ezrin in the Bsp37 -AS system seen at the northern 
Ievei was also reflected on the protein Ievei as is indicated in figure 20. 
Figure 20 
kDa ASML 10AS 1AS 1AS v4-v7 
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Figure 20. Ezrin protein expression in the Bsp73-AS system. Approximately 20 J..Lg of total 
cellular protein from the celllines indicated was run on a 12 % polyacrylarnide gel, transferred to membrane and 
probed with an anti ezrin antibody. For loading control, the bottom part of the gel was separately probed for Erk 
1 and 2 expression. ASML and lAS represent the lines used in the original subtraction, and 10 AS is a subline 
that exhibits low in vivo metastatic capacity. lAS v4-v7 represents a stable transfected Bsp73-1AS clone and is 
included as a neo control. 
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The degree of expression of ezrin in ASML is very high (see figure 20). and both the 10 AS 
and the 1AS exhibit very low endogenous ezrin expression, seenalso in the mRNA Ievei. The 
presence of a slightly smaller band (78 kDa) is cross-reactivity of the ezrin antibody to other 
ERM protein members, (as is described for the antibody, see Materials & Methods) radixin 
which has a molecular weight of areund 78 kDa. Radixin was not isolated from the subtracted 
library, despite its differential appearance on the protein Ievei. Reasons for this discrepancy 
might lie in fact that the true identity of this secend smaller band is not known (would require 
probing with an anti radixin antibody) and it might represent an entirely different protein that 
had been isolated in the library as a cDNA clone. Concerning ezrin's expression profile at both 
the protein and mRNA Ievei, there is a very close correlation to the metastatic potential in all 
model systems, indicating it is likely to have functional role in tumor progression. 
Before any functional studies could be addressed, it was necessary to obtain the fulllength rat 
ezrin cDNA sequence as the clone of ezrin derived from the subtracted library was only about 
140 bp long. Through sequence homology searches in public data bases (BLAST program. 
Internet) a partial 3'- rat ezrin clone was found containing the last 484 bp of the coding 
sequence of ezrin followed by 1.2 Kb of untranslated sequence (Accession Nr. X67788). This 
clone when aligned against the full length mouse ezrin cDNA (Accession Nr. X60671) exhibited 
a match of 94 % at the nucleotide Ievei indicating its authenticity. As only a partial rat ezrin 
clone existed, a 3-primer was designed from the 3 'end of the known partial rat ezrin clone and 
a 5'primer designed from the mouse sequence as is indicated in figure 21. 
Figure 21 
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Figure 21. Full length HA tagged cloning strategy of rat ezrin from ASML cells. Two 
primers were used for the RT-PCR cloning of fulllength rat ezrin. The 5'-primer sequence was obtained from the 
sequence of the fulllength murine ezrin, and the 3 '-primer sequence was designed from the partial rat cDNA clone 
of ezrin. The 3'-primer in addition carried aHA-tagthat ablated the internalstop codon to allow translation of the 
HA specific peptide sequence, required for detection. Both primers contain internal restriction sites to aid 
subcloning into a suitable eucaryotic expression vector. 
The 5'primer (5'- Erzin/Hind 111) covered the start codon (as determined form the mouse 
sequence) and contained an internal Hind 111 restriction site for the ease of subcloning into an 
appropriate eucaryotic expression vector. The 3'primer (3'- Ezrin/HA/EcoRI) carried, in addition 
to an EcoR I restriction site, the coding sequence for a human hemagglutinin protein tag (HA-
tag), derived from human influenza virus. This form of "epitope tagging", allows for the 
detection of an expressed protein against the background of the endogenous protein within 
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eucaryotic cells by using an antibody that specifically recognizes the tag (Wilson et al., 1984; 
Herscovics et al., 1994). The sequence of the primers is also given in Materials & Methods. As 
ezrin was overexpressed in ASML, it was the obvious source of template for the cloning of 
ezrin. Poly(Af RNA was isolated from subconfluent ASML cells and reverse transcribed to 
cDNA. The cDNA reaction after completion was diluted 1 0-fold and a 4 111 aliquot used for RT-
PCR using the 5' ezrin Hind 111 primer and the 3'ezrin EcoRI HA-tagged primer. 
After the RT-PCR reaction was completed, the products were analysed on an agarase gel 
(see figure 23 (A) lane A). The DNA band in lane A had the expected size of 1.8 Kb (murine, 
bovine and human ezrin sequences have all a length of 1. 75-1.8 Kb and an internal homology 
of areund 94 %. data base alignment, NCBI server, Internet) and was removed from the gel 
before direct cloning via the T/A overhands into the T/A cloning vector pCR2.1 kit. The 
authenticity of the cloned fragment was confirmed by sequenced analysis of both strands 
using automated fluorescent sequencing. The cloned fulllength rat ezrin cDNA matched 1 00 % 
to the sequence of the partial rat ezrin cDNA, with an overall match of 93 % to the full length 
murine sequence. 
Figure 22 
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Figure 22. Schematic representation of the functional domains of ezrin. The model structure of 
the predicted structural organisation of ezrin deduced from its primary structure (Gould et al., 1989). The amino-
terminal domain (black oval) is followed by an alpha-helical domain, and by a region rich in charged amino acids. 
The dominant negative mutant was constructed to include amino acids 1-309 as described by Algrain et al. 
(1993). 
As a truncated form of ezrin (amino-terminal portion) was reported to function in a dominant 
negative fashion when transfected into kidney derived epithelial cells by abolishing all 
stimulatory effects of HGF (Crepaldi et al., 1997), a HA-tagged truncated dominant negative 
mutantform of ezrin was constructed through RT-PCR as described by Algrain et al. (1993). 
Using the same 5'primer asthat used to clone fulllength ezrin with a 3'- HA-tagged primer that 
annealed to the end portion of the amino-terminal domain (nucleotide position 1-1019, spanning 
amino acids 1-309 see figure 22) RT-PCR was performed and the products analysed on an 
agarose gel (see figure 23 (A) lane 8). As with the fulllength clone, the band was excised, 
cloned and its authenticity confirmed by sequenced analysis of both strands using automated 
fluorescent sequencing. Now that the full length clone and the mutant clone had been 
generated, the two cDNAs were subsequently subcloned into pCDNA 3.1 (+) eucaryotic 
expression vector. 
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Figure 23. (A) The agarase gel 
depicts the RT-PCR products of full 
length and dominant negative mutant 
of ezrin. Lane (A) shows the expected 
cDNA size of the full length ezrin of 
approx 1.8 Kb (as determined from 
murirre and human sequence 
alignments). In lane (B) RT-PCR 
product of the dominant negative 
mutant form of ezrin and runs at the 
expected size of approx 1.0 Kb. 
Conditions of RT-PCR for the 
cloning of the fulllength ezrin. First-
strand cDNA synthesis was performed 
wiih 2 jlg of poly(At RNA isolated 
from ASML cells, according to the 
protocol outlined in Materials & 
Methods. After dilution, a 4 j.tl 
aliquot was removed and subjected to 
PCR in a total volume of 30 j.tl 
containing 10 pmole 5' Hind ID ezrin 
primer, 10 pmole 3' EcoRIIHA 
primer, MgC12 (f.c. 1.5mM), 1 x 
supplied PCR reaction buffer, dNTPs 
(10mM each), 2U Taq (Eurobio 
5U/j.tl) and bi-dest HzO to 30 j.tl. 
Cycling parameters were as follows. 
94 °C for 50 sec, then 26 cycles of 94 
°C, 20 sec; 66 °C, 30 sec; 72 °C , 
2 mins. The PCR generation of the 
dominant-negative mutant of ezrin, all 
PCR conditions were as described for 
the full length cloning of ezrin with 
the exception of substituting the 3' 
EcoRI'/HA-tagged primer for a 3' EcoRI!HA-tagged primer Both bands were cloned and confirmed by sequencing. 
(B) The fulllength ezrin and the mutant form were both subcloned into a eucaryotic expression vector (pcDNA 
3.1 ( + ), Invitrogen) and maxi-prep plasmid DNA isolated. Fulllength clone was then subjected to coupled [35S]-
methionine labeled transcription-translation as described in Materials & Methods and the products run on a 12.5 
% polyacrylamide gel before drying the gel and exposing to film. The positive control (PARP/HA) was an 
expression vector containing the coding sequence for the gene PARP, known to function in this assay. The 
translated product offulllength ezrin runs at the expected molecular mass of 81 kDa. 
(C) 293 cells (E1a/b transformed human fetal embyronic kidney cells) were transiently transfected with the full 
length construct containing ezrin cDNA (described under Materials & Methods). The cells were harvested 48 
hours after transfection, lysed and the proteins (20 j.tg per lane) separated on a 12.5 % SDS-PAGE gel. The gel 
was transferred to membrane and later probed for ezrin expression using an ezrin antiboby. As positive control 
protein lysate from ASML cells was taken. For negative control 293 cells were transiently transfected with an 
empty expression vector. Lanes markedas #25, #14, #1 represent three different fulllength clones that were each 
transiently transfected into 293 cells. Clone #25, contained aprematurestop codon (at position 483) which would 
result in no detection of protein as the antiboby epiotpe is at the extreme carboxy-terminal end. Clones #14 and 
#1 contain a fulllength reading frame and both upon transient transfection produce ezrin. In addition, clone #14 
was the clone used for the transcription-translation assay. The presence of Erk 1 and 2 serve as loading controls 
for protein amounts. 
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(lnvirtogen) using the two internal restriction sites (Hind 111/EcoRI) present in the primer 
sequences. Again clones were isolated and sequenced to confirm correct ligation and 
orientation. Maxi-prep DNA was prepared and the full length clone subjected to in vitro 
coupled [358]-methionine labeled transcription-translation as described in Materials & Methods. 
As a control, an expression vector containing the cDNA sequence for the gene PARP known to 
function in this assay was taken. The products of the reaction were run on a 12.5 % 
polyacrylamide gel together with middle range standard protein markers (Bio-Rad Labs. CA), 
before drying the gel and exposing to film (see figure 23 panel B). 
The full length HA-tagged ezrin runs at the expected size (as determined through sequence 
alignment data of murine and human ezrin) and additionally indicates that the clone represents 
a full length functional reading frame of ezrin. That is, the clone contains no premature stop 
codons or frame shifts, either of which would result in a change of size. ln order to be certain 
that the full length construct functioned in vivo, human fetal embryonie kidney cells, 293 cells 
were transiently transfected with three cloned constructs (see figure 23 panel C). Clone #25 
was found through sequencing analysis to contain an internal premature stop codon (at 
position 483) that would result in a truncated protein. This protein would not be detected as the 
ezrin antibody epitope resides in the carboxy-terminal. Clone #14 was the same clone shown 
to function in the coupled transcription-translation assay (see figure 23 panel B) and clone #1 
was another full length clone taken for conformation. Transfeetion of the empty expression 
vector in 293 cells functioned as a negative control and the positive control was ASML cell 
lysate. There is streng expression of ezrin in ASML cells as shown by the presence of a 81 
kD band. The secend slightly smaller band (approx 78 kDa) is cross-reactivity of the ezrin 
antibody to radixin (ezrin antibody known to cross-react with other ERM protein members, see 
Materials & Methods). There is very slight expression of ezrin in both the vector control and 
those cell which received clone # 25, being due to the presence of endogenaus ezrin in 293 
cells. Both clones #14 and #1 show increased ezrin expression when compared to the 
negative controls. The modest increase in expression is due to the fact that these clones were 
transiently transfected into 293 cells and only a small pool of cells would have taken up the 
construct and expressed ezrin. Erk 2 indicates that all lanes from the 293 transfectants were 
equally loaded, whereas there is an apparent reduction in the amount of Erk 1 in those cells 
transfected with clone# 25. So collectively, the data from figure 23 suggests that the full length 
rat ezrin clone represents the authentic rat ezrin sequence determined through western blot 
analysis of transfected clones. 
Under an similar experimental setting, the dominant negative clone of rat ezrin was also for 
protein expression . Using again the in vitro couple transcription-translation protocol, without 
the addition of [358]-methionine (cold reaction), the dominant negative HA-tagged mutantclone 
was translated and the product of the reaction used for immunoprecipitation using an anti-HA 
antibody. The immunoprecipitated was then subjected to western blot analysis and the 
membrane probed with an anti-HA antibody (see figure 24). Considering figure 24, lane 1 
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shows the direct products of the coupled reaction of the mutant from of ezrin having the 
expected size of approximately 40 kDa. ln lane 2 shows the translated mutant ezrin after 
precipitation with an anti HA antibody, and lane 3 indicates that there is still some translated 
ezrin product in the supernatant of the immunoprecipitation reaction. ln regard to these data, the 
mutant form of ezrin was shown to have a correct functioning HA-tag as demonstrated by the 
immunoprecipitation experiment and by the fact that the blot was probed with an anti HA 
antibody. ln addition, the mutantform demonstrated the approximate right molecular weight as 
expected from the length of the coding sequence (1.0 Kb). 
Figure 24 
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Figure 24. Confirmation of correct translation of the dominant-negative ezrin mutant. 
Immunoprecipitation was performed on the mutant ezrin clone and the products run on a 10 % polyacrylamide 
gel, before transfer to immobilon-P membrane (Millipore). The membranewas subsequently probed with an anti 
HA antibody. Lane 1 represents the initial coupled trascription-translation reaction product of mutant ezrin 
directly loaded. Lane 2 is the immunoprecipitant of the reaction after immunoprecipitation with an anti HA 
antibody. Lane 3 represents the supernatant of the immunopreciptation reaction. All reaction protocols are 
described in the Materials & Methods section. 
3.6.2 Generation of ASML Clones Expressing Dominant-Negative 
Ezrin 
Despite the fact that both a full length and muatnt form of ezrin had been constructed, 
the mutant form of ezrin would offer the most rapid analysis for endogenous function in the 
context of metastasis, rather than overexpression of the full length in the non-metastasizing 
Bsp73-1AS cells. lt is experimentally easier to abolish a pathway than to reconstruct one 
whereby multiple genes may be required. For this purpose, stable transfectants of ASML 
were generated by the transfection of the dominant negative ezrin mutant clone into ASML 
cells, followed by subsequent selection of putative positive clones under neomycin (G418, 
Sigma). Once growing clones had been expanded, cell lysates were prepared and subjected 
to western blot analysis using an anti HA antibody as can be seen in figure 25. From the nine 
neomycin resistant clones (1-9), three clones demonstrated expression of the HA-tagged 
dominant negative ezrin (see clones 3, 7, and 8). There was no detection of any 40 kDa band 
(corresponding to the mutant clone) in either ASML cells alone or in mock transfections with a 
vector control. This indicates that the detected band in the clones represents true endogenous 
expression of the transfected mutant ezrin cDNA. 
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Additionally, there was no change of phenotype of the transfected cells. Now that ASML 
clones stably expressing the dominant negative form of ezrin were generated, the obvious 
question was whether this forced expression of a mutant form of ezrin had any functional 
consequence concerning the tumorigenic potential of ASML cells when compared to ASML cells 
that had received only the empty vector (negative control). To address this question the three 
positively expressing clones (clones 3, 7 and 8) were further expanded and prepared for in 
vivo inoculation, together with a vector control, into syngienic male BDX-1 0 rats (as described 
under Materials & Methods). 
Figure 25 
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Figure 25. Identification of ASML clones stably expressing dominant negative ezrin. Stahle 
transfectauts were generated as described under Materials & Methods. A total of nine neomycin resistant clones 
were taken and cell lysates prepared and the proteins separated over a 10 % polyacrylamide gel hefore hlotting 
onto immohilon-P memhrane and prohing with an anti HA antihody. Stahle transfectants are indicated 1-9, M 
shows the lane used for protein standard markers, ASML indicates pure ASML cell lysate and ASML neo the 
vector control. 
3.6.3 Dominant-Negative Ezrin Reduces Tumor Formation 
Capacity of ASML Cells in vivo 
For each clone, and the vector control, eight animals were taken, each receiVIng 
approximately 5 X 1 05 cells in phosphate buffered saline (PBS) were subcutaneously injected 
into the left flank of each animal. This resulted in eight animals per clone and eight animals for 
the vector control. After a period of 14 days, the animals were inspected for signs of tumor 
growth on a twice weekly bases. Tumor growth was monitored for each tumor bearing animal 
until either the tumor had reach the permitted Iimit, or the animals showed obvious signs of 
moribund. Each sacrificed animal was autopsied and the internal ergans inspected for signs of 
metastases. The results were plotted as a survival curve (see figure 26). From figure 26 it is 
clear that those animals that received ASML cell expressing a dominant negative form of ezrin 
have an obvious prolonged life expectancy when compared to those animals that were 
inoculatad vvith vactor control. After a pariod of 8 \tVaaks, all control animals were sacrificed, at 
the same time point there were 6, 7 and 5 animals remaining corresponding to dominant 
negative clones #3, #8 and #7 respectively. After an addition 4 weeks the number of surviving 
animals was 6, 5 and 3 for dominant negative clones #3, #8 and #7 respectively. These 
animals that were sacrificed from the dominant negative groups did show, in addition to a 
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primary tumor at the site of injection, presence of metastases in both lung and lymph tissue, 
however 40-50 % of animals failed to develop even a primary tumor. These animals 
represented the majority of those that exhibit prolonged survival, as they failed to develop 
tumors.Others did show signs of tumor formation but at a prolonged rate. The conclusion is that 
the capacity of ASML cells under forced expression of dominant-negative ezrin to form primary 
tumors is drastically reduced. 
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Figure 26. Survival curves of male BDX-10 rats inoculated with ASML cells stably 
expressing dominant negative ezrin. The three coloured lines indicate the survival curves of animals that 
were inoculated with three independentdominant negative (dn) ASML clones. The vector control is shown by the 
black line. Eight animals were taken for each clone. 
Dominant negative ezrin in ASML does exhibit profound functional consequences in that 
inoculated animals either show a dramatic increase in survival or that the domninant clones 
failed to give rise to a primary tumor. This experiment clearly implicates the functional 
requirement of endogenaus ezrin in ASML cells for tumor development as functional ablation of 
ezrin perturbs tumor formation in vivo. The fact that under invitro conditions dominant-negative 
clones of ASML grow but in vivo their growth is drastically reduced suggests a number of 
things. Firstly, functional ezrin may not be required for in vitro growth in ASML cells but when in 
the context of an organism functional ezrin is required for growth of these cells. This requirement 
could be brought about by the presence of a specific factor that is only present in the in vivo 
situation, a factorthat requires ezrin to function such that the cells proliferate. ln other words, 
by abolishing ezrin function with the ectopic expression of a dominant-negative mutant, the 
growth factor dependency of ASML cells is altered. ln this respect further investigation should 
be focused on elucidating the functional role of ezrin in the context of tumor formation as it 
appears to be of significant importance 
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This work, the work on ezrin is just one example of a single chosen clone whose functional role 
in tumor progression has been succsessfully demonstarted. lt was the clone of choice as it 
demonstarted excellent correlation in two other rat tumor progression models, it cross-
hybridized to human tunor cNDA probes, and there existed some information concerning its 
function in eucaryotic cells, for example its dominant-negative effect with c-Met signalling. 
There is now reason to believe that other clones that also showed excellent cerrelative 
expression could also have profound effects on tumor progression like clone 25. However to 
investigate the function of a novel gene is vastly more work and would have involved the full 
length cloning of the gene to enable forced expression studies to be made and the generation 
of antibodies to detect endogenaus expression. ln the limited time frame left, this would not 
have been possible. Ezrin appeared a suitable alternative as its cerrelative expression data 
suggested general involvement in tumor progression, moreover, there existed antibodies for 
protein detection and a partial rat clone that aided the fulllength cloning. The work present here 
demonstrates the functional relavence of one clone identified from the subtracted library and 
shows without question that ezrin is functional significance in the context of tumor progression, 
and should be further investigated. 
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4 DISCUSSION 
4.1 Tumor progression: A Change of Paradigms 
At the cellular Ievei, it has long been appreciated that metastasis is an enormaus 
complex pathophysiological event and that this degree of complexity is reflected by an ever-
increasing Iist of molecular alterations which appear to be associated with the process. The 
powerful techniques of molecular biology are proving themselves able to be focused on a 
problern of such inherent difficulty as metastasis and tumor formation, however the limitations 
are obvious. This is most apparent if one considers the early reported attempts to understand 
metastasis. Such studies were either stuck at a descriptive Ievel (pathology), or (if a molecular 
genetic approach was persued) produced in the best case single molecules that were usually 
pleiotropic effectors (e.g. Ras or c-Met) and therefore affered little insight about other 
potentially involved downstream genes. 
The so called "functional" approaches aimed at identifying genes that are involved in 
metastasis failed mostly due to the inability of these methods (e.g. DNA-mediated gene 
transfer or retroviral insertional mutagenesis) to activate all the genes that contribute to the 
metastastic phenotype. Again, as in the case of Tiam-1 (retroviral insertional mutagenesis) or 
ras (Bernstein & Weinberg, 1985) researchers came up with rather pleitotropic effectors and 
the molecular mechanisms remained largely unclear. 
With the rapid advance of genomics, that is the simultaneaus analysis of huge numbers of 
genes at the nucleic acid Ievei, new methods became available that allowed efficient 
comparison of the transcriptional repertoire associated with a given phenotype. Despite the 
fact that these technologies are still in their infancy, they hold great promise as they are 
capable of analysing enormaus numbers of target genes in a single hybridization step. 
Moreover, which genes are analysed can be predetermined. 
4.2 Attempts to ldentify Genes lnvolved in Tumor Progression 
4.2.1 At the Genomic DNA Ievel (DNA-mediated gene transfer) 
The metastatic spread of cancer is an enormously complex phenomenon that remains 
largely unsolved, in part because it is difficult to model the entire process using experimental 
approaches in vitro. The ability to transfer DNA into a non-metastatic cells and to observe the 
induction of metastasis in vivo provides a means for identifying DNA sequences that are 
associated with the development of metastatic capacity. By transfection of human metastatic 
tumor DNA into Ha-ras transformed NIH 3T3 fibroblasts, resultant colanies produced lung 
metastasis after subcutaneous inoculation into immunocompetent NFS/NCr mice (Berstein & 
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Weinberg, 1985}. Similar experiments have been performed on rat mammary epithelial cells 
with fragments of DNA for human metastatic breast tumors and the same observations were 
made (Barraclough et al., 1998). These experiments demonstrated that the induction of a 
metastatic phenotype can be transferred via DNA from cell to cell and that the process is 
entirely DNA dependent. Such approaches can result in the isolation of putative genes but it is 
a vastly inefficient way as the isolation of the DNA fragment(s) responsible for the phenotype 
is difficult. ln addition, is fault-sensitive as Barraclough et al. (1998) isolated non-transcribed 
genomic DNA as the metastatsis inducing agent. 
4.2.2 At the Protein Level: Differential Antibody Screening. 
This approach focuses on identifying cell surface differences between two cell lines 
that differ in their metastatic capacity. One famous example was the isolation and identification 
of a variant form of a cell surface glycoprotein known as CD44 as a causative determinant in 
metastasis formation (Gunthert et al., 1991 ). Using a monoclonal antibody (MAb1.1 ASML) 
raised against a cell surface determinant of the metastasizing rat pancreatic carcinoma cell line 
BSp73-ASML, one cDNA clone was isolated that encoded an additional extracellular domain 
inserted into the rat CD44. This new variant was only expressed in the metastasizing cell lines 
of two rat tumors, and further more, overexpression of this variant in the non-metastasizing 
BSp73-AS cells sufficed to establish full metastatic behaviour. This variant form of CD44 was 
subsequently shown to be expressed in human tumors (Hofmann et al., 1991 ). So while the 
use of generating antibodies against metastasizing cells did identify what was later shown to 
be an important player in metastasis in the cell system used, the fact that only one difference 
was identified between two celllines (one capable of metastases, the other not) might suggest 
that what one is looking at is probably nothing more than "the tip of the iceberg". 
4.2.3 At the mRNA/cDNA Level: Subtractive cDNA Cloning 
Other investigators have tackled the problern from a different angle but essentially the 
same ends were met in that again only one gene was identified as being dysregulated. 
Ebralidze et al. (1989) examined the differences in gene expression in metastatic and non-
metastatic tumor lines. Using a subtractive cloning procedure coupled with differential colony 
screening Iead to the identification of one gene (mts-1) expressed specifically in the 
metastasizing line (Ebralidze et al., 1989}. At the same time another group using differential 
library screening with cDNAs derived from cell lines of varying metastatic potential isolated just 
one clonethat gave a strenger signal with cDNAs derived from low metastatic cells (Steeg et 
al., 1988a). This clone (NM23) was later shown to be an enzyme, a nucleoside diphosphate 
kinase (NDPK), whose function is to provide nucleoside triphosphate precursors for DNA and 
RNA synthesis (Lascu, 1996}. 8oth experimental settings again resulted in the isolation of a 
single candidate clone and not a inventory of differentially expression genes. 
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So in retrospect of the above facts there was an obvious problem, despite that these 
methods were nevertheless useful. The phenotype of tumor progression was very much 
restricted to the analyses of just single genes, whereas the inherent complexity of metastasis 
indicates that there are probably many more unidentified genetic alterations that were just 
"slipping through the net ". How is it then possible to identify more or if possible all the genetic 
dysregulations that underlie the metastatic phenotype? A simple answer would be just to 
improve or tighten the "nef', and over the last number of years this has been indeed the case. 
4.3 Technologies for Expression Profiling and Difference 
Analysis 
The last six years has seen the introduction of novel techniques that are collectively 
aimed at monitaring differential gene expression as their names suggest, such as differential 
display (Liang & Pardee, 1992; Sokolov & Prockop, 1994), and representational difference 
analysis (cDNA-RDA; O'Neil & Sinclaire, 1997). These techniques represent a means to 
improve the net, although there are still intrinsic drawbacks associated with each method. For 
example, differential display (00) restricts the analysis to differences of the 3'end of cDNAs, 
so that differences in the 5'portion of cDNAs (e.g. variants of alternatively spliced genes) are 
not detected. Additionally, variable reproducibility of the differential band patterns and the 
significant incidence of false-positives makes it difficult to isolate transcripts that are 
differentially expressed. Differential display does however allow muti-comparisons to be made 
on one gel and additionally, indicates both upregulated and down regulated transcripts. 
Another common feature of the methods mentioned above represents also an obstacle in the 
isolation of rare transcripts: the disproportion of concentrations of differentially expressed 
genes is maintained in the subtraction. cDNA-RDA requires multiple rounds of subtraction as 
the method fails to take into account the !arge differences in relative abundance of individual 
mRNA transcripts. Enzymatic degradation subtraction (EDS; Zeng et al., 1994) relies on 
discrimination of differential transcripts through a modified form of exonuclease digest followed 
by PCR amplification. However for efficient subtraction, extensive monitaring of the 
exonuclease digest is required. ln 1995, Vogelstein and collegues, published the tabulation of 
a new method called "serial analysis of gene expression" (SAGE; Velculescu et al., 1995) 
which is based on the use of specific sequence-tags (usually 13 bp lang), and has the 
potential to profile the transcriptional status of a given cell type to a sensitivity of single copy 
numbers. Although powerful, the method is not typically suited for the isolation of novel genes 
as the sequence-tags are just too small to allow for a confident comparison and subsequent full 
length cloning, 
From the perspective of my work, what was needed was a subtractive cloning procedure that 
would cater for high sensitivity and produce an inventory of differentially expressed genes 
(like SAGE), incorporate a normalization step to reduce over-representation of highly abundant 
genes (unlike that of cDNA-RDA) and not be proned for false positives or variable 
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reproducibility (as is often the case with DD). All of these requirements appeared to be met b y 
a another recently introduced technique subtraction suppressive hybridization (SSH) This 
method, unlike those mentioned, relies on the selective amplification and enrichment of 
differentially expressed sequences with a concomitant suppression of sequences not 
differentially expressed, by means of a suppression PCR reaction (Diatchenko et al, 1996). ln 
the course of my thesis, this method was adopted for the differential analysis of messenger 
RNA transcripts between a non-metastatic and its metastatic counterpart. The importance of 
the right choice of method, when differential gene expression is to be investigated, is 
highlighted by the fact that I lost a considerable amount of time trying unsuccessfully to 
implement another method, Enzymatic Degradation Subtraction (EDS; Zeng et al., 1994). 
4.4 Aim of the Work and Choice of the Model System 
Of equal importance is the choice of model system. As the aim of my work was to 
identify putative key players in metastasis it was crucial that a weil defined tissue culture cell 
system was used. One could argue that subtraction could be performed with rat tumor cells 
injected in vivo as appose to tissue culture cells, but this would increase the risk of 
contamination of other cell types. As a consequence, due to the sensitivity of SSH one might 
isolate transcripts that are not originally derived from the tumor cells, but rather from 
contaminating stromal cells present within the tumor mass. The advantages of using a defined 
rat cell system for the identification of novel molecules that are functionally involved in tumor 
progression are numerous. Firstly, there is no Iimitation of the amount of starting material. 
Secondly, a cellline is composed of a singleclone cell type and as such does not exhibit the 
heterogeneity or indeed the same high degree of complexity as is the case in solid tumors. The 
1 AS and ASML cells in this respect represents a genetically stable "frozen state" of 
expression. Lastly, the possibility of functional studies can easily accommodated by a cellline 
system, where potential function of tumor associated clones can readily be addressed. 
Therefore the rat pancreatic adenocarcinoma model system composing of two lines, Bsp73-
1AS a non-metastatic cell line and Bsp73-ASML a highly metastatic line was utilized. The 
ASML line had been reported to produce metastases in both lung and lymph tissue upon 
subcutaneous injection into BD 10 rats ((Matzku et al., 1983). This I was able to confirm and 
suggests that despite a period of 15 years, the cells still responded as originally observed as 
the phenotype was not change, that is the cells were genetically stable. Additionally, the same 
rat tumor model system had been used to isolate cell surface antigens specific to the 
metastasizing line, resulting in the identification of a variant form of CD44 (Gunthert et al., 
1991). lt was therefore reasonable to assume that this tumor model system would, other than a 
splice variant of CD44, have additional differences that might also contribute to the metastatic 
phenotype. Moreover, this cell system had been studied in detail and a differentially 
expressed gene (uPA) that would act as a positive control for the subtraction was already 
known. 
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ln the colorectal tumorigenic model proposed by Fearon & Vogelstein. (1996), they describe 
the transition of a locally growing carcimona to metastatses as "other genetic alterations". This 
statement typifies the present shortcomings of our knowledge concerning the genetic 
alterations that predisposes a tumorigenic cell to one capable of metastasis. The primary aim of 
my work was to cast some light into this "black box" by generating an inventory of genes 
associated the metastatic phenotype. 
4.5 Proof of Concept: Subtractive cDNA Cloning as a Rapid Way 
to ldentify Molecular Determinants of Metastasis 
A subtraction was performed between the non-metastatic Bsp73-1AS cellline and the 
highly metastatic Bsp73-ASML cell line. This resulted in the identification of 126 independent 
differentially expressed transcripts all of which were differentially expressed in the 
metastasizing Bsp73-ASML line, the majority of which, showed a very high degree of 
differential expression as confirrned by direct northern analysis. As expected one of the 126 
genes isolated was the positive control for the subtractive enrichment of differentially 
expressed genes (uPA). Upon the analysis of sequence data of all clones, it was obvious 
that nearly halve represented novel sequences or existed only as ESTs and many of the 
known clones identified had been already documented as relevant for tumor progression 
based on published studies. 
This Observation was taken as a "proof of concept" such that the experimental setting was 
(totally) valid, moreover, from published reports a large proportion of the known genes were 
described to be functionally involved with each other. This in turn allowed one to 
hypothetically construct small "mini-networks" of specific genes whose products functionally 
interact with each other in a direct manner. Although such a motive is, to a certain degree, 
speculative, it nevertheless serves as a realistic model and puts single observation into a 
molecular context. 
Consider briefly the mini motive depicted in figure 27. The activation of the c-Met receptor b y 
its Iigand HGF/SF is known to increase, through the transcription factor ETS1, the protein 
Ieveis of both uPAR and its Iigand uPA in specific cell types (Jeffers et al., 1996). The 
uPAR!uPA complex in turn can catalyse the conversion of a pro-HGF/SF single-chain molecule 
into an active two chain forrn by proteolysis (Mars et al., 1993). So there is a feed torward 
loop generated whereby uPAR!uPA activates the c-Met receptor by producing functional 
HGF/SF, and this in turn up-regulates the expression of both uPAR and uPA. These two 
molecules couples HGF/SF c-Met signalling to the activation of proteases that are important for 
the dissolution of the extracel!ular matrix such that metastatic competent cells can intravasate 
into the lymphatics or the vasculature. The c-Met receptor upon activation also 
phosphorylates ezrin (as do other receptor tyrosine kinases like EGF) thereby activating the 
molecule, which is then able to translocate to the cytoplasmic surface (Jiang et al., 1995) and 
interact with other surface receptors such as CD44 (Hirao et al., 1996). The function of ezrin is 
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not weil understood but it appears to act as a plasma membrane actin filament cross-linking 
molecule. However, more recently, it was demonstrated that ezrin was crucial to HGF-induced 
morphogenesis in a polarized kidney-derived epithelial cell line (Crepaldi et al., 1997). These 
data places ezrin as a transducer of extracellular signals and implicates it as crucial player in 
the motogenic and morphological response to HGF/SF. ln conclusion, this mini-motive has 
components necessary for the activation of proteases through c-Met signalling, tagether with 
the motogenic-invasive functions of c-Met that have been reported (Giordano et al., 1993) that 
appear to work through ezrin in some cell types. Although not proven, ezrin is shown in figure 
27 to influence protein synthesis, as a motogenic-invasive phenotype almest certainly 
requires de novo synthesis of certain molecules (e.g., proteases). A dominant-negative mutant 
form of ezrin can abolish this motogenic-invasive phenotype induced by HGF/SF it is 
assumed that ezrin must be directly involved. 
Bsp73-ASML 
Figure 27. An "expression motive" expressed exclusively in the metastasizing Bsp73-
ASML cells. The above diagram depicts a number of genes overexpressed in ASML cells whose products have 
been reported to functionally interact with each other in a manner that is of significance for tumor progression. 
An explanation of the motive is given in the text. 
Despite the fact that such a model leaves many questions unanswered, it was useful in 
identifying the central role of ezrin (see part two of results). 
Paradoxically the isolation and identification of such a large number of potential tumor 
progression related clones generated another problern that had in all respects not been 
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accounted for. Under what criteria are these clones to be segregated such that those of likely 
importance can be distinguished against those that are perhaps only indirectly involved or 
even the result of "bystander effecf'? This was of particular importance as a !arge proportion 
of the clones identified were novel or existed only as an EST. lt was clear that by attempting 
to answer this question on the bases of mass transfection studies (such as overexpression, 
antisense or dominant-negative experiments) is a task that exceeds the capacity of any 
individual. This would require the systematic full length cloning of many genes and the 
subsequent generation of antibodies to detect expression. What was required was a sort of 
''filter system" that would ascribe relevance to the clones and allow the isolation of those 
clones of higher probability of being potentially involved in tumor progression. This filter 
system was achieved through the analysis of cerrelative expression in other independent 
tumor progression models, and by cross-hybridization to human tumorigenic cell lines or b y 
hybridization experiments with human cDNAs derived form either a tumor or its matched normal 
tissue. So while reverse northern screening of the clones with other rat tumor cell lines would 
indicate clones of likely relevance in tumor progression that could be experimentally addressed, 
cross-hybridization to human cDNAs would identify clones of potential tumor marker status. 
A total of 13 clones were identified through such a screening and further analysed directly at 
the northern Ievei. All clones, including 6 novel ones (clones 23, 25, 46, 82, 100, and 147) 
demonstrated excellent cerrelative expression in the other tumor progression systems. The 
expression data of clone 25 appeared the clearest, showing expression in all line capable of 
producing metastases in vivo. For comparison, three other genes, uPAR, c-Met and HMG-1, 
of known involvement in tumor progression were also analysed, the latter two were also 
identified frorn the subtracted library. From these three genes HMG-1 showed excellent 
cerrelative expression in all systems, while c-Met was only weakly expressed in those lines 
of metastatic competence in the other two cell line systems. For uPAR, there was even a 
reduction of expression in the prostatic tumor cell system between the non-metastatic line 
(AT.1) and the highly metastatic sub-clone (AT.3). So despite their documented involvement in 
tumor progression, the expression profile of c-Met and uPAR in the three cell systems is not as 
striking as that of HMG-1. Both uPAR and c-Met represent strong candidates in tumor 
progression particular for uPAR (Ganesh et al., 1994; Rong et al., 1994, respectively), 
however HMG-1 that has only been associated with tumor progression (Chiappetta et al., 
1995) but exhibits the better profile in these systems. The expression data of the novel 
clones in comparison to uPAR, c-Met and HMG-1 would indicate that they are all of potential 
relevance as they follow an almost identical expression pattern and in some cases a more 
convincing one, in particular clone 25. 
By implementation of a suitable ''filter system" in the form of cerrelative expression the initial 
daunting number of 126 differential expressed clones had been reduced to werkable number of 
13 promising candidates. The large number of cross reacting clones to human cDNAs is again 
proof of validity of the experimental setting in that through subtraction of two rat oell lines, 
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homologues of human cDNAs can be identified that are specific to the tumor status. This 
means that a direct subtraction between human material may not be necessary and instead a 
weil defined rat tumor model may in fact offer the same potential as it also allows the capacity 
for functional studies with putative candidate genes. 
4.6 From Gene Expression to Protein Function 
The finding that several genes were transcriptional up-regulated and their proteins are 
likely to interact suggested that there should be the option to interfere with these complex 
networks. The appearance of phenotype-associated transcriptional networks suggests that it 
is simply nonsense to transcfect one gene (e.g. a protease) and to expect cells to change 
completely their phenotype. lnterference with the functional networks is by far more likely to 
give insight into the relevance of those networks for the establishment of the phenotype. (at 
least as lang as compensation for the blockage is limited). 
Through the identification of the (hypothetical) Ezrin I c-met I uPa I CD44 motive, a basis was 
provided for an experimental approach aimed at interfering with a crucial element in such a 
expression motive. Forthis purpose, a dominant-negative mutant form of ezrin was generated 
as described by Crepaldi et al. 1997. This mutantform of ezrin was subsequently transfected 
into ASML cells and stable clones selected. Upon inoculation into male BD 10 rats, it was clear 
that forced expression of a dominant-negative from of ezrin influences the tumor take rate and 
thus tumorigenicity of tumor cells and not only the metastatic potential when compared to those 
animals which had received vector control. As there was no change in in vitro growth 
characteristics of these clones we conclude that expression and function of Ezrin is absolutely 
necessary for the special conditions and requirements of in vivo growth. 
This functional approach demonstrates the relevance of interference strategies and marks the 
endpoint in an experimental system that started with differential analysis between a metastatic 
cell line and its non-metastatic counterpart and ended with the identification of a gene which 
was subsequently shown to be functionally involved in tumorigenesis. 
S.Resume' 
The work presented in this thesis clearly demonstrates the power of a subtractive 
approach when utilized in the context of identification of novel genes as tumor markers. lt also 
leaves scope for improvement that could take the form of automatization. That is, the complete 
screening of subtracted libraries could be performed through automatization, couplad with high 
through put sequencing with direct links to the public data bases to aid rapid identification of 
the clones. By adopting a "conveyer-belt" approach, to such an experimental setting, one 
could rapidly identify from vast numbers of tissue samples, dysregulated genes that 
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accompany or predispose to a certain disease conditions. This coupled with the human 
genome project will greatly speed-up the design of novel therapeutic interventions and 
strategies aimed at interfering with novel target molecules. As our understanding of a complex 
disease such as cancer improves, so too, will the tools that enable us to intervene such that 
the quality of life for affected individuals can be improved. 
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